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Type 1 Diabetes Mellitus (T1DM) affects millions of children worldwide and is
increasing in prevalence. Exogenous insulin therapy is currently the mainstay of
treatment but is unable to prevent the chronic complications of this disease. Islet
transplantation is a successful, minimally-invasive, potentially curable alternative
treatment, which has restored physiological euglycaemia in up to 85% of recipients in
recent clinical trials. However, worldwide human donor islet shortages limit the wider
application of this treatment. Pluripotent cells may provide alternative islet sources to
overcome this shortage. The human spleen may be one such source and is an excellent
candidate tissue for further investigation.
The main aims of this thesis were to investigate whether the developing spleen could
differentiate into insulin-producing cells and to investigate the molecular mechanisms
behind this. Using an avian model of pancreatic development, I characterise normal
avian foregut expression of the splenic mesenchymal transcription factor Tlx-1
between E4-E11 of development and report an optimised in situ hybridisation
protocol for this. I use a chick-quail chimaera model of pancreatic organogenesis to
show that the developing avian spleen is able to differentiate into insulin-producing
cells in vitro through islet Mesenchyme-to-Epithelial Transition (iMET). 1 show
evidence that, when recombined with differentiating pancreatic epithelium, splenic
mesenchyme is reprogrammed to express the pancreatic islet genes Pdx-1 and Isl-1.
Tlx-1 is dramatically down-regulated during this process, indicating that this tissue is
reprogrammed from a splenic to pancreatic endocrine fate. Finally, an attempt to
augment splenic iMET is made through the addition of a Wnt agonist.
These findings, together with the recent discovery that the mature human spleen
contains Tlx-1 positive cells, may be a useful target for future bench-to-bedside
translation strategies for this work. Therefore, the spleen may be an ideal future tissue
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1.1 The rationale for pancreatic islet transplantation
Diabetes Mellitus is the commonest human metabolic disorder, affecting over 200
million people worldwide and increasing in prevalence (King, Aubert et al. 1998;
Wild, Roglic et al. 2004). This condition is characterised by a critical reduction in the
functional beta-cell mass of the pancreas (Donath and Halban 2004; Maedler 2008),
resulting in hyperglycaemia and abnormal glucose homeostasis through reduced
insulin secretion. Around 10% of cases are due to Type 1 Diabetes Mellitus (T1DM),
also known as "Insulin-Dependent Diabetes Mellitus" or "Juvenile-Onset Diabetes
Mellitus". Incredibly, the incidence of childhood onset T1DM has doubled over the
past 10 years (Soltesz, Patterson et al. 2007). In T1DM, targeted autoimmune
destruction of beta-cells (Soeldner, Tuttleman et al. 1985; Atkinson and Maclaren
1994; Atkinson and Eisenbarth 2001) results in a 90% loss of functional beta-cell
mass (Kloppel, Drenck et al. 1984; Lohr and Kloppel 1987; Hanafusa, Miyazaki et al.
1990; Pipeleers and Ling 1992). The pathophysiology of Type 2 Diabetes Mellitus
(T2DM) is complex and multifactorial, involving a genetic predisposition, a reduced
functional beta-cell mass and an increase in insulin resistance (Gerich 1999; Bouwens
and Rooman 2005; Leahy 2005; Freeman and Cox 2006). However, in the later stages
of T2DM, beta-cell mass is reduced by around 50-65%. This lesser reduction is via a
ten-fold increase in beta-cell apoptosis instead of autoimmune destruction (Clark,
Wells et al. 1988; Butler, Janson et al. 2003; Kharroubi, Ladriere et al. 2004;
Marchetti, Del Guerra et al. 2004). Approximately 20-30% of patients with T2DM




The Nobel prize-winning discovery of insulin by Banting and Best in 1922 heralded a
new era in diabetes treatment (Banting and Best 1922; Banting, Best et al. 1922).
Prior to this, patients with T1DM would die from diabetic ketoacidosis and typically
at an early age. Patients could now survive by using exogenous insulin therapy.
However, it later became apparent that despite regular insulin therapy, an increasing
number of patients developed a range of long-term complications of the disease
(Kimmelstiel and Wilson 1936; Bell 1942; White and Waskow 1948). Diabetic
complications are now a leading cause of early mortality and severe morbidity
(Manuel and Schultz 2004). Hyperglycaemic diabetic complications (see Figure 1)
include macrovascular complications, such as coronary artery disease (with
subsequent ischaemic heart disease), cerebral vascular accidents and peripheral
vascular disease (with amputations), and microvascular complications, such as
retinopathy (and subsequent blindness), nephropathy (with end-stage renal failure)
and neuropathy. Hypoglycaemic complications, from insulin therapy and some oral
hypoglycaemic agents, include hypoglycaemic unawareness and subsequent loss of
consciousness, or even death. The complications of diabetes, combined with the
increase in incidence of types 1 and 2 (Passa 2002), pose an enormous health and
financial burden on society, prompting research into strategies to reduce this
morbidity and mortality. In particular, the relationship between glycaemic control and
the onset of diabetic complications has been extensively investigated.
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Figure 1 Examples of diabetic retinopathy and diabetic nephropathy
Fig 1(a)
Fig 1(a) Retinal photograph showing diabetic proliferative retinopathy (Yorston 2003)
Fig 1(b)
Fig 1(b) Example of glomerulosclerosis in diabetic nephropathy; original image x400
(Paueksakon, Revelo et al. 2002)
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The Diabetes Control and Complications Trial (DCCT) was a multicentre randomised
controlled trial designed to compare intensive with conventional diabetes therapy,
with regard to their effects on the development and progression of diabetic
complications in patients with T1DM (DCCTRG 1993). A total of 1441 patients were
recruited: 726 patients had no retinopathy at baseline (the primary-prevention cohort)
and 715 patients had mild retinopathy at baseline (secondary-intervention cohort).
Patients were randomly assigned to receive either intensive insulin therapy
(administered by three or more daily insulin injections, or by an insulin pump, and
guided by frequent blood glucose monitoring) or to conventional therapy (with one or
two daily insulin injections). The DCCT confirmed a relationship between T1DM
complications and both glycaemic control and duration of disease. Furthermore, it
showed that tight glycaemic control achieved by intensive insulin therapy can reduce
the incidence of chronic complications (see Figures 2 and 3). In patients with no
retinopathy at enrolment into the DCCT, intensive therapy reduced the adjusted mean
risk for the development of retinopathy by 76% (95 percent confidence interval, 62 to
85%), as compared with conventional therapy. In patients with mild retinopathy at
enrolment, intensive therapy slowed the progression of retinopathy by 54% (95
percent confidence interval, 39 to 66%) and reduced the development of proliferative
or severe nonproliferative retinopathy by 47% (95 percent confidence interval, 14 to
67%). In the two cohorts combined, intensive therapy reduced the occurrence of
microalbuminuria (urinary albumin excretion of >40 mg per 24 hours) by 39% (95
percent confidence interval, 21 to 52%), that of albuminuria (urinary albumin
excretion of >300 mg per 24 hours) by 54% (95 percent confidence interval, 19 to
74%), and that of clinical neuropathy by 60% (95 percent confidence interval, 38 to
74%). The DCCT was stopped prematurely after a mean follow-up time of 6.5 years,
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when the benefits of intensive treatment were deemed incontrovertible (EDICSG
2002). However, intensive insulin therapy did not restore true physiological
euglycaemia and the benefits of tight control came with the associated two-to-
threefold increased risk of potentially life-threatening severe hypoglycaemic episodes
(DCCTRG 1997; EDICSG 2002; EDICSG 2003; Nathan, Cleary et al. 2005).
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Fig 2 Cummulative incidence of a sustained change in retinopathy in patients with T1DM
receiving intensive or conventional therapy; Panel A = primary-prevention cohort, Panel B =
secondary-intervention cohort (DCCTRG 1993)















Year of Study Year of Study
Fig 3 Cumulative Incidence of Urinary Albumin Excretion >300 mg per 24 Hours (Dashed
Line) and >40 mg per 24 Hours (Solid Line) in Patients with IDDM Receiving Intensive or
Conventional Therapy; Panel A = primary—prevention cohort, Panel B = secondary-
intervention cohort (DCCTRG 1993)
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The DCCT provided clear evidence of the benefits of maintaining blood glucose
concentrations as close to the normal range as possible. Therefore, therapeutic
strategies have subsequently focussed on ways to improve glycaemic control, such as
the more widespread use of the mechanical insulin delivery pump. This device uses a
programmable pump and insulin storage reservoir to provide a continuous supply of
subcutaneous insulin, and the patient can trigger infusion pulses to cover meals
(Tamborlane 2006). Improvements in technology and the desire to achieve optimal
blood glucose control have resulted in a sharp increase in their use. However, such
mechanical devices require patient competency and motivation to use the device, and
carry the risk of pump malfunction (mechanical failure), prosthesis-related sepsis, and
concerns over non-physiological insulin pump delivery. The recent introduction of
continuous glucose monitoring systems (CGMSs) may offer the prospect of
improving insulin pump therapy to normalize HbAlC levels with minimal risk of
hypoglycaemia (Ellis, Naik et al. 2008). However, at present patients need to
regularly calibrate the subcutaneous CGMS devices with their blood glucose meter
measurements. Currently, they are therefore a useful adjunct for detecting blood
glucose fluctuations, but not yet a replacement for blood glucose meter measurements.
Biomedical engineering research continues into ways of safely and effectively
integrating the CGMS and insulin pump together to create an electronic "artificial
pancreas" (Gomez, Hernando Perez et al. 2008). Some of the concerns over insulin
pump therapy have been addressed through recent innovations, including a reduced
incidence of catheter obstructions through improved catheter design (Renard and
Schaepelynck-Belicar 2007). However, these pumps cannot yet achieve true
euglycaemia, and therefore an ideal treatment for T1DM is still sought. The ideal
treatment therapy for T1DM would restore tme physiological euglycaemia shortly
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after diagnosis (and so would need to be applicable for use in children) and would be
widely available, with low morbidity.
An alternative treatment strategy to intensive exogenous insulin therapy is
transplantation of glucose-responsive insulin-producing human pancreatic tissue. The
first transplant with pancreatic tissue was performed over a century ago (Williams
1894) but can now consist of either a whole pancreas transplant or isolated pancreatic
islets. The first whole pancreas transplant for T1DM was performed in 1966 (Kelly,
Lillehei et al. 1967) and is currently very successful, achieving >80% insulin
independence (defined as euglycaemia without insulin for 14 or more consecutive
days; (Close, Alejandro et al. 2007) one year post-transplant (Gruessner and
Sutherland 2005). The 2007 annual report of the Scientific Registry of Transplant
Recipients (SRTR) shows an 80% pancreas transplant graft survival at one year (for
pancreas transplant alone) and 27% at 10 years post-transplant (SRTR 2007).
Although pancreas transplantation is able to reverse diabetic complications (Navarro,
Sutherland et al. 1997; Fioretto, Steffes et al. 1998; Larsen, Colling et al. 2004), its
success comes with the morbidity of major surgery and a life-long requirement for
immunosuppression. Both these obstacles preclude its widespread application to many




Figure 4 Islet transplantation
Fig 4 (a) Fig 4(b)
Fig 4 Islet transplantation is a minimally-invasive treatment, as shown in the photographs
above. Fig 4 (a) shows the islet infusion being transplanted into a recipient. Fig 4 (b) shows
the percutaneous portal venous catheter, through which the islet transplant is infused into the
recipient. The infusion lasts approximately 10 to 15 minutes and is performed under antibiotic
and heparin cover. The portal venous pressure is monitored throughout. Fig 4 (c) shows the




Islet transplantation, on the over hand, is a minimally-invasive alternative with low
procedural morbidity (Frank, Barker et al. 2005). The technique involves isolating
islets from deceased donor pancreatic tissue, using collagenase digestion and density
gradient purification. These islets are then injected into the recipient liver, usually via
ultrasound-guided percutaneous cannulation of the portal vein (see Figure 4). Since
the introduction of the "Edmonton protocol" in 2000, this has achieved considerable
success in treating selected patients, with >80% independent of exogenous insulin at 1
year post-transplantation (Shapiro, Lakey et al. 2000; Nanji and Shapiro 2006).
Furthermore, successfully transplanted islets normalise serum HbAlC (Ryan, Lakey
et al. 2002; Ryan, Paty et al. 2005) and secrete insulin in their characteristic
physiological pulsatile manner (Porksen, Munn et al. 1994; Rorsman and Renstrom
2003) . The initial excitement of the 1 year follow-up data in Edmonton was tempered
by 5 year follow-up data showing that the majority of recipients required a second
islet transplant to achieve their insulin independence and only 10% remained insulin
independent at 5 years post-transplant (Ryan, Paty et al. 2005). The average duration
of insulin independence lasted only 15 months. Some noteworthy side effects of the
immunosuppression and transplant were also reported, such as mouth ulcers,
diarrhoea, anaemia, ovarian cysts, bleeding and branch portal vein thrombosis.
However, longitudinal studies do confirm that true restoration of euglycaemia can be
achieved, with reversal of diabetic hyperglycaemic complications (Fiorina, Folli et al.
2003; Lee, Barshes et al. 2005; Lee, Barshes et al. 2006). Islet transplantation also
improves glycaemic lability, particularly the prevention of severe hypoglycaemic
episodes requiring the assistance of another person and the sometimes very
debilitating "hypoglycaemic unawareness" phenomenon, where the patient loses their
ability to detect hypoglycaemia and may experience unexpected episodes of loss of
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consciousness in some cases (Close, Alejandro et al. 2007). Prevention against severe
hypoglycaemia and disease lability were enjoyed by the majority of recipients,
including those not achieving or maintaining insulin-independence. Such cellular
grafts also have the additional benefits of being suitable for tolerance induction and
immunomodulation (Purrello and Pipeleers 1995; Coulombe and Gill 2004).
However, islet transplantation does not completely restore the complex regulation of
in vivo insulin secretion, as denervation of the islet grafts affects gustatory cephalic-
phase insulin secretion (Berthoud, Trimble et al. 1980). In addition, beta-cell
regulation from other cells within the islet may be affected. Although somatostatin-
mediated beta-cell regulation is maintained, counter-regulation of hypoglycaemia by
glucagon is impaired (Gupta, Wahoff et al. 1997; Kendall, Teuscher et al. 1997; Paty,
Ryan et al. 2002; Rickels, Schutta et al. 2005; Rickels, Schutta et al. 2007).
The Collaborative Islet Transplant Registry (CITR) collects data from islet transplants
in North America, and selected centres in Europe and Australia. Each year, the CITR
provides a comprehensive overview of the cumulative data from 1999. In 2008, they
reported that 72% of islet transplant recipients achieved insulin independence overall,
whilst the insulin requirements of the remainder decreased substantially (CITR 2008).
However, insulin independence decreased over time (see Figure 5). 71% of those
achieving insulin independence remained so at 1 year post-transplant and 52% after 2
years. 11% received a further islet transplant 30 days after their first, and 65% within
a year of their first transplant. Importantly, hypoglycaemic unawareness was
markedly improved following transplantation and the only participants who
experienced a severe hypoglycaemic attack were on insulin at the time.
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Therefore, islet transplantation may be an excellent treatment for T1DM, as it is
efficacious (normalises HbAlC, has endogenous insulin secretion kinetics, reverses
diabetic complications) and safe (low procedural morbidity, has potential for use in
children, predicted to have low long-term complications).
Figure 5 CITR 2008 report: persistence of insulin independence and graft function
10 15 20 25 30 35 40
Months Post First Achieving Insulin Independence
Persistence of Insulin Independence
— Persistence of Graft Function
Fig 5 Persistence of insulin independence and graft function in islet alone recipients
achieving insulin independence (from the CITR 2008 annual report). Over time there is a
decrease in the sustainability of insulin independence. For islet alone recipients who ever
achieved insulin independence, 71% had retained this status one year after achieving it and
this decreases to 52% at two years. Similarly, graft function is lost over time but persists in a
higher percentage of recipients compared to insulin independence.
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1.2 Ongoing challenges for islet transplantation
Although intra-portal islet injection enjoys low procedural morbidity, its long-term
safety is still unknown. This is highlighted by reports of focal liver steatosis in
humans post-islet transplantation (Maffi, Angeli et al. 2005), with rat model studies
suggesting a risk of liver cell proliferation (De Paepe, Keymeulen et al. 1995) and a
potential for liver tumour formation (Dombrowski 2000). Furthermore, the potential
use of islet transplantation to treat children with T1DM is currently hindered by a
worldwide donor pancreas shortage and the risks associated with potential life-long
immunosuppression. The islet requirement for insulin independence is very high,
compounding the problem of donor pancreas shortages. Approximately 850,000 islets
(11,000 islet equivalents / kg body weight) are currently required for successful
outcomes with the Edmonton protocol. Interestingly, it is estimated that 70% of
patients receiving islet autotransplantation after total pancreatectomy can achieve
insulin independence with only 300,000 islets (Pyzdrowski, Kendall et al. 1992).
Although advances in islet isolation techniques and less toxic immunosuppression
may reduce the number of islets required to control glycaemia (Rood, Bottino et al.
2006), islet transplantation is currently restricted to a limited number of adult T1DM
patients, in whom the morbidity of the disease and its treatment outweigh the risks of
transplantation and lifelong immunosuppression. Since these risks currently outweigh
the benefits of islet transplantation in children, they are not routinely eligible to
receive islet allograft transplantation. In order to realise its full potential, however,
islet transplantation needs to be made widely available to all T1DM patients,
including children, prior to the onset of complications (Flathout, Lakey et al. 2003).
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At present, recipients of islet transplants receive generalised immunosuppression to
prevent allograft rejection and recurrent autoimmune islet destruction (Coulombe and
Gill 2004; Noguchi, Matsumoto et al. 2006). Prior to the Edmonton Protocol in 2000,
this would consist of protocols adapted from solid organ transplantation, consisting of
azathioprine, cyclosporine and corticosteroids. However, fewer than 10% of patients
were able to achieve insulin independence under these regimes. The Edmonton
Protocol dramatically transformed clinical outcomes in islet transplantation through
the introduction of a more potent, corticosteroid-free and less diabetogenic
immunosuppressive regimen consisting of sirolimus, low-dose tacrolimus, and
induction daclizumab (anti-interleukin-2 receptor antibody). In 2008, the CITR
reported that 59% of recipients overall had received this protocol with their first islet
transplant, but over two thirds of all islet cell transplants have involved different
immunosuppression regimens during 2006 and 2007 (CITR 2008). Therapies used in
recent years include Alemtuzumab, Anti-thymocyte globulin, Etanercept, Efalizumab,
and Methylprednisolone. Mycophenolate mofetil (MMF) has been used at times in
place of Sirolimus.
The limited long-term success of the Edmonton protocol may have been due to
homeostatic expansion of an autoreactive CD8+ T-cell population with that regimen
(Monti, Scirpoli et al. 2008). MMF is gaining popularity amongst islet transplant
immunosuppression protocols, following the discovery that it selectively inhibits T-
and B-cell proliferation by suppressing de novo purine synthesis (Van Belle and von
Herrath 2008). Therefore, expansion of the autoreactive T-cell population may be
reduced with MMF, which may have implications for graft survival.
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While insulin independence rates under modern immunosuppression protocols have
been highly successful, patients must be maintained on lifelong immunosuppression,
with its associated risks of toxicity, infertility, increased susceptibility to infection,
risks of malignancy and post-transplant lymphoma (Nanji and Shapiro 2004; Burra,
Buda et al. 2006).
Research continues into less toxic immunosuppression agents and future strategies for
immunosuppression-free anti-rejection therapy, such as immune tolerance induction
(Lohr, Knoechel et al. 2005; Delis, Burke et al. 2006) and immunoisolation devices
(Klomp, Ronel et al. 1979). Tolerance induction shows a great deal of promise
through techniques to block T-cell surface co-stimulatory molecules (Adams,
Shirasugi et al. 2002), or through T-cell depletion (Calne, Moffatt et al. 2000), or
possibly through donor-specific bone marrow transplantation (Delis, Burke et al.
2006). However, at present, these techniques are not yet efficacious or in widespread
use and require adjunctive non-specific immunosuppression. Immunoisolation devices
involve encapsulation of the donor islets to prevent interaction with host immune
cells, but have so far experienced limitations from material bioincompatibility, islet
hypoxia and failure to prevent all host immune pathways (Gray 2001; Kobayashi,
Harb et al. 2006). However, this strategy ought to reduce immunosuppression
requirements through prevention of the direct T-cell response. Following reports of
prolonged graft function and T1DM reversal following human allotransplantation
(Soon-Shiong, Heintz et al. 1994; Calafiore, Basta et al. 2006), phase I / II human
trials are currently underway to assess the safety of encapsulated islets (eg: AmCyte).
Research has also begun into macroencapsulation of donor islets with 3-D cell sheets
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to form an immunoisolated "Bioartificial Pancreas" (Kobayashi 2008; Lee, Nishimura
et al. 2008).
Even if the human cadaveric pancreatic donor shortage was overcome, it is estimated
that this will still only meet 0.5% of the T1DM need (Hirshberg, Rother et al. 2003).
Therefore, an alternative source of islets is still required. Xenogeneic pancreases offer
a potentially unlimited source of islet tissue for transplantation (Trucco, Casu et al.
2007). However, xenografts are more immunogenic than human allografts, through
complement-mediated hyperacute rejection, which results in marked early graft loss
(Badet, Titus et al. 2001). Methods are under investigation to try and modulate this
immune response, including co-transplantation with immunomodulatory cells such as
Sertoli cells (Valdes-Gonzalez, Dorantes et al. 2005), co-stimulation blockade to
prevent T-cell expansion and / or depletion (Hering, Wijkstrom et al. 2006), using
human peptide expressing xenogeneic cells (Omori, Nishida et al. 2006),
encapsulation techniques (Dufrane, Goebbels et al. 2006), or a combination of these
approaches. These methods have experienced initial success in animal-to-animal
models and initial animal-to-human transplantation experiments. However, they are
still under investigation and further research into concerns over possible zoonotic
infection transmission need to be addressed. For example, the infection risk to humans
from "porcine endogenous retrovirus" (PERV) associated to leukaemia has been
extensively debated and investigated, and until this issue is resolved it may be
questionable to promote the widespread xenotransplantation of porcine islets
(references within Limbert 2008). Although the concerns for disease potential from
PERVs are easing, there is a paucity of evidence over the safety of this approach in
humans and small-scale, well designed, carefully controlled clinical trials may allow a
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better appreciation of the risks (Louz, Bergmans et al. 2008). The University of
Minnesota (together with the Spring Point Project) plan to begin a clinical trial of
porcine islet xenotransplantation into humans in 2009.
This failure to adequately resolve the problem of donor tissue paucity for islet
transplantation has generated considerable worldwide interest in the potential that
human pluripotent cells may hold in resolving this problem. Such cells may also
avoid, or reduce, the need for immunosuppression currently required for allograft
transplantation, thus improving the prospect for use in children with T1DM (see
Chapter 1, section 1.4: Potentialpluripotent cell-based therapiesfor islet neogenesis).
In order to elucidate possible mechanisms of generating beta cells / islets from
pluripotent cells, it is important to first consider normal pancreatic endocrine
development.
1.3 Pancreatic organogenesis
Pancreatic organogenesis consists of three phases: primary, secondary and tertiary
transitions. These are summarised in the following sub-sections and, for consistency,
embryonic days are given in terms of murine gestation, which mirror the temporal
relationships of avian and human pancreatic organogenesis (Streeter 1942; Streeter
1948; Park, Chae et al. 1992; Kim, Hebrok et al. 1997):
Primary transition (E8.5-E13)
This phase is characterised by the following events: pancreas specification, bud
formation, "protodifferentiation" of pancreatic progenitors, epithelial branching and
ventral bud rotation. Pancreas specification (E8.5) occurs in the pre-pancreatic
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posterior foregut endoderm, through expression of both Pancreas duodenum
homeobox-1 (Pdx-1) and Pancreas transcription factor la (Ptfla) in all progenitor
cells contributing to lineages of both endocrine and exocrine pancreatic development
(Gu, Dubauskaite et al. 2002; Kawaguchi, Cooper et al. 2002). Both of these
transcription factors are required for pancreatic specification, whilst neither in
isolation is sufficient (Afelik, Chen et al. 2006). Pdx-1 expressing progenitors give
rise to all cells of the pancreas (Gu, Brown et al. 2003) and lack of Pdx-1 expression
results in pancreatic agenesis (Jonsson, Carlsson et al. 1994). Ptfla deficient mice
show no pancreatic acinar cells and abnormal endocrine cell differentiation (Krapp,
Knofler et al. 1998).
Upstream regulation of pancreatic specification is incompletely understood, but
intrinsic factors regulating Pdx-1 expression are likely to be involved. These include
forkhead box 2 (Foxa2), also known as hepatocyte nuclear factor 3/1 (Hnf3f>) (Ang,
Wierda et al. 1993; Cockell, Stolarczyk et al. 1995; Lee, Sund et al. 2005); (sex
determining region Y)-box 17 (Soxl7) (Kanai-Azuma, Kanai et al. 2002); one cut
domain 1 (Onecutl) (Jacquemin, Pierreux et al. 2003); T-cell specific transcription
factor 2 (Tcfl) (Haumaitre, Barbacci et al. 2005). Extrinsic inductive signalling
responsible for initiation and maintenance of the intrinsic system includes retinoic
acid (PA), fibroblast growth factors (FGFs), transforming growth factor-/! (TGF/1)
family proteins (such as bone morphogenetic proteins and nodal / activins). This
extrinsic signalling is provided by posterior mesoderm (Stafford, Hornbruch et al.
2004), lateral plate mesoderm (Kumar, Jordan et al. 2003), notochord (Hebrok, Kim et
al. 1998) and aortic endothelium (Jacquemin, Yoshitomi et al. 2006).
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Pancreatic bud formation follows the onset of specification, with thickening and
invagination of the specified endoderm into the surrounding mesenchyme, forming a
dorsal pancreatic bud (E9.5) and ventral pancreatic bud (El0.5). Concurrently,
glucagon-expressing cells (E9.5) and then insulin-expressing cells (El0.5) appear
(Beaupain and Dieterlen-Lievre 1974; Dieterlen-Lievre and Beaupain 1974; Gittes
and Rutter 1992; Kim, Hebrok et al. 1997). These protodifferentiated cells express
sub-physiological amounts of hormone and have a limited capacity for mitosis (Pictet,
Clark et al. 1972). These first hormone-expressing cells are not precursors of the
definitive alpha- and beta- cells, which instead are derived from neurogenin-3 (Ngn3)
expressing endocrine precursors during secondary transition (Gu, Dubauskaite et al.
2002). It is therefore important to consider this important phenotypic difference
between protodifferentiated hormone-expressing cells and definitive islet cell
precursors when investigating potential pluripotent cell differentiation strategies.
Pancreatic epithelial branching begins at El 1.5 and generates a primitive ductal
network. The extracellular proteins laminin (Crisera, Kadison et al. 2000) and
collagens (Hisaoka, Haratake et al. 1993) are required for pancreatic branching, which
is controlled through mesenchyme-epithelial extrinsic signalling via FGF10
(Bhushan, Itoh et al. 2001), Hepatocyte Growth Factor (Brinkmann, Foroutan et al.
1995), Epidermal Growth Factor (Miettinen, Huotari et al. 2000), Indian Hedgehog
(Hebrok, Kim et al. 2000), Activin and Follistatin (Ball and Risbridger 2001).
Ventral pancreatic bud rotation occurs from E12.5, rotating behind the duodenum to
reach a position adjacent to the dorsal bud (Slack 1995). The buds then fuse, possibly




This phase achieves specification and determination of the endocrine and exocrine
pancreatic cell lineages. Endocrine cell specification and differentiation is controlled
by neurogenin 3 (Ngn3), which is induced in epithelial cells from E9 by Tcfl {Hnfla),
Foxal (Hnf3ft) and Onecut (Hnf6) (Ang and Rossant 1994; Weinstein, Ruiz i Altaba
et al. 1994; Pontoglio, Sreenan et al. 1998; Jacquemin, Durviaux et al. 2000; Lee,
Smith et al. 2001). Interestingly, Ngn3 is considered the key endocrine specification
regulator, as it is both necessary and sufficient for all endocrine differentiation to
occur (Gradwohl, Dierich et al. 2000; Gasa, Mrejen et al. 2004). Its expression is
augmented during secondary transition, owing to a rapid endocrine precursor
expansion, but then declines from El7.5 onwards to be absent at birth (Gradwohl,
Dierich et al. 2000; Schwitzgebel, Scheel et al. 2000). Its expression is regulated
through Notch- mediated lateral inhibition (Apelqvist, Li et al. 1999). Pro-endocrine
Ngn3 actually induces expression of Notch ligands, which in turn inhibit endocrine
differentiation in adjacent precursors, leading to the initial scattered endocrine cell
arrangement (Fujikura, Hosoda et al. 2006). Furthermore, pancreatic mesenchyme
represses Ngn3 expression through Notch signalling, but also produces fibroblast
growth factor 10 (FGF10) to maintain the Notch activation, and induces hairy and
enhancer ofsplit 1 (Hesl), which favours precursor cell proliferation over endocrine
differentiation (Hart, Papadopoulou et al. 2003; Miralles, Lamotte et al. 2006).
Ngn3 induces expression of a programme of three known transcription factors that are
required for pancreatic endocrine differentiation; NeuroDl (Huang, Liu et al. 2000),
insulinoma-associated 1 {IAI) (Gierl, Karoulias et al. 2006; Mellitzer, Bonne et al.
2006), and islet 1 (Isl-l) (Ahlgren, Pfaff et al. 1997). Once committed to an endocrine
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fate, paired homeobox 4 (Pax4) and aristaless related homeobox (ARX) determine
islet cell lineages; Pax4 differentiating towards beta- and delta-cell fates and ARX to
alpha- and epsilon-cell fates (Collombat, Mansouri et al. 2003; Heller, Jenny et al.
2005). The individual islet cell lineages then proceed to terminal differentiation along
independent and distinct transcriptional pathways, summarised below and reviewed
(with references) within Bonal and Herrera 2007:
Beta cells'. Pax4, Pax6, NK homeobox 2.2 (Nkx2.2), Nkx6.1, v-maf
musculoaponeurotic fibrosarcoma oncogene A (MAFA), H2.0-like homeobox b9
(Hlxb9), Pdx-1
Alpha cells'. ARX, Pax6, Nkx2.2, MAFB, brain-specific homeobox 4 (Brn4), Foxa2
Delta cells: Pax4, Pax6 (Collombat et al. 2003; 2005)
Pancreatic Polypeptide cells: Nkx2.2 (Sussel, Kalamaras et al. 1998)
Epsilon cells', not yet described, but repressed by Pax4 and Nkx2.2 (Chao, Loomis et
al. 2007; Wang, Elghazi et al. 2008)
The scattered epithelial endocrine precursors also migrate during secondary transition
to form irregular islet cell clusters (isletogenesis). This occurs under FGF2 induction
(Hardikar, Marcus-Samuels et al. 2003), whilst cell migration is permitted via
degradation of the extracellular matrix (ECM) via TGFfi (Miralles, Battelino et al.
1998).
Exocrine differentiation of acinar and ductal tissue from Ptfla expressing precursors
occurs during secondary transition, under as yet unknown extrinsic mesenchymal
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signals. This is shown by absent exocrine differentiation in mice lacking dorsal
pancreatic mesenchyme (Ahlgren, Pfaff et al. 1997).
Tertiary transition (El 9 - 3 weeks after birth)
The existing primitive islet cell clusters now undergo extensive remodelling into adult
islet morphology, through coordinated proliferation, apoptosis and islet neogenesis.
The exocrine tissue undergoes extensive growth, leading to acinar cell condensation
into discrete adult pancreatic acinae (Jensen 2004). Both exocrine and endocrine cells
undergo final differentiation during early neonatal life into physiologically functional
adult pancreatic tissue. Until this final maturation step, islet cells are poorly
responsive to a glucose stimulus (Hughes 1994). This marks the final step of normal
pancreatic organogenesis.
1.4 Potential pluripotent cell-based therapies for islet neogenesis
When considering islet regeneration, it is interesting to consider why we should wish
to regenerate islets, rather than purely beta-cells? The benefits of islet replacement
over beta-cell replacement include: enhanced glucose-responsive insulin secretion
through autocrine stimulation between adherent beta-cells (Aspinwall, Lakey et al.
1999; Hauge-Evans, Squires et al. 1999); advantageous insulin, glucagon and
somatostatin secretion kinetics through paracrine signalling between beta- and non-
beta cells within the islet (Brunicardi, Kleinman et al. 1994; Kleinman, Ohning et al.
1994; Kanno, Gopel et al. 2002; Ishihara, Maechler et al. 2003; Hope, Tran et al.
2004; MacDonald and Rorsman 2006); superior graft function when beta-cells are co-
transplanted with non-beta cells (Keymeulen, Korbutt et al. 1996); islet regeneration
and insulin secretion are both supported through maintenance of the neural network
Chapter 1
Page 40
and vascular endothelium present with intact islets (Porksen, Munn et al. 1994; Hess,
Li et al. 2003; Mathews, Hanson et al. 2004). Therefore, there are distinct advantages
to achieving regeneration of whole islets rather than pure beta-cells. Most research in
the literature has so far primarily focussed on trying to achieve beta-cell regeneration,
although there has been a report of in vitro single cell precursor expansion into cell
clusters comprising several islet cell types, including alpha, beta and delta cells
(Seaberg, Smukler et al. 2004).
The search for a renewable and expandable islet source has produced considerable
interest in the "stem cell" field, which holds a great deal of promise for the future
treatment of Diabetes Mellitus (Shamblott and Clark 2004; Bonner-Weir and Weir
2005). Stem cells can be defined as undifferentiated cells with continued proliferative
capacity, yielding both undifferentiated daughter cells (self-renewal) and
differentiating daughter cells of more than one cell type (Shostak 2006). Three main
types of stem cells exist: embryonic stem cells (ES cells), foetal stem cells and adult
stem cells (Bonner-Weir and Weir 2005). A stem cell strategy would attempt to
produce new islets (islet neogenesis) through recapitulation of pancreatic
organogenesis, instructing pluripotent cells to differentiate into a safe and functional
islet phenotype via lineage-specific transcriptional signalling. However, many
questions still remain, including: Which is the optimal pluripotent stem cell type to
use for this purpose? How can we successfully produce fully functional islets (or beta-
cells) from such a source? What are the exact molecular mechanisms controlling
normal pancreatic organogenesis? Does a suitable adult stem cell (or an islet
progenitor) exist and where is it located (pancreatic or extra-pancreatic)?
1.4.1 Embryonic stem cells
Chapter 1
Page 41
Pancreatic islet stem cell research has so far largely focussed on embryonic stem (ES)
cell strategies to try and differentiate cells from the inner cell mass of pre-
implantation blastocyst embryos (Evans and Kaufman 1981; Martin 1981; Thomson,
Itskovitz-Eldor et al. 1998) down a pancreatic endocrine lineage. ES and ES-derived
cells express low levels of major histo-compatibility complex (MHC) class I and lack
MHC class II protein expression (Drukker, Katz et al. 2002), making these cells
"immune privileged", which may afford some protection against host-versus-graft
disease (HVGD) following allotransplantation (Fandrich, Lin et al. 2002; Hori, Ng et
al. 2003; Drukker 2004; Dmkker and Benvenisty 2004; Li, Baroja et al. 2004;
Drukker, Katchman et al. 2006). ES cells hold a great deal of natural potential to
undergo islet differentiation. Although a rare event (<0.1 %), spontaneous
differentiation into insulin-producing cells in vitro has been reported in mouse
(Houard, Rousseau et al. 2003) and human (Assady, Maor et al. 2001) ES cell lines.
Therefore, directed differentiation protocols have been developed trying to
recapitulate normal in vivo islet developmental cues. These include co-culturing ES
cells with differentiating foetal islet tissue (Brolen, Heins et al. 2005); nestin selection
of putative ES-derived islet precursor cells (Lumelsky, Blondel et al. 2001); targeted
differentiation of ES cells into endoderm (D'Amour, Agulnick et al. 2005) then islet
precursors (Hebrok, Kim et al. 1998) through culture manipulations; targeted
differentiation of ES cells through forced expression of key pancreatic genes, such as
Pdx-1 (Treff, Vincent et al. 2006); maturation of islet precursors into functional
surrogate beta-cells (Soria, Roche et al. 2000). However, ES cell studies have so far
failed to successfully achieve differentiation into adequate islet beta-cell tissue, which
is safe, fully-functional and sufficiently glucose-responsive (Heit and Kim 2004;
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Stainier 2006). Also, it is important to note that the use of human ES cells has
encountered ethical and religious controversies over the worth and moral right of
developing embryos (Oakley 2002; Copland 2004; McConnaha 2005). ES cell
research is therefore subject to strict governmental regulation and is even banned in
some countries (Gruss 2003; Halme and Kessler 2006). Novel techniques for ES cell
harvest, which do not impair the development of the embryo, have recently been
developed, such as single blastomere derivation (Chung, Klimanskaya et al. 2006;
Chung, Klimanskaya et al. 2008). These may reduce ethical barriers to the use of
human ES cells (Jaenisch and Meissner 2006; Taupin 2006). However, safety
concerns remain over the risk of in vivo teratoma formation in ES-derived tissue, from
uncontrolled differentiation into alternative phenotypes (Thomson, Itskovitz-Eldor et
al. 1998; Amit, Carpenter et al. 2000). Rapidly dividing undifferentiated ES cell
proliferation may predispose to genomic instability and neoplastic transformation. In
addition, ES-derived cells may exhibit phenotypic instability and dedifferentiate,
resulting in a loss of the desired phenotype, with a return to a more undifferentiated
and potentially pro-teratogenic state (Draper, Smith et al. 2004; Inzunza, Sahlen et al.
2004; Fujikawa, Oh et al. 2005). These safety concerns must first be resolved before
ES-derived cells become a suitable candidate tissue for cellular transplantation in
humans.
1.4.2 Foetal stem cells
Foetal stem cells refer to pluripotent cells derived from the foetus. Not only might
these cells provide a useful pluripotent cell source for islet transplantation, but the
study of foetal pancreatic pluripotent cells is also useful in understanding the process
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of islet differentiation. Foetal cells are a potentially attractive cell source, as they also
enjoy "immune privileged1" status, making them less susceptible to rejection (Bai,
Maedler et al. 2004). Furthermore, islet precursor proliferation and differentiation
occurring in vivo, following foetal tissue transplantation, reduces the minimum graft
volume needed to restore the beta-cell mass (Hammerman 2004). Foetal islets also
appear resistant to factors impairing engraftment, such as hypoxia-induced apoptosis
(Emamaullee, Shapiro et al. 2006). Foetal pluripotent cells capable of in vitro
differentiation into insulin-producing cells and capable of reversing diabetes in
experimental mouse models have been acquired from: the foetal pancreas itself (Wu,
Jagir et al. 2004), foetal gut (Suzuki, Nakauchi et al. 2003), foetal liver (Zalzman,
Gupta et al. 2003) and foetal bone-marrow (Ai, Todorov et al. 2007). Alternatively,
foetal beta-cell precursors themselves can be transplanted and then undergo in vivo
proliferation and differentiation into a functional beta-cell mass (Beattie, Lopez et al.
1999). Experimental transplantation of foetal pancreatic islets has also been attempted
in humans, using human (Dordevic, Lalic et al. 1995) or porcine (Valdes-Gonzalez,
Dorantes et al. 2005) foetal islet tissue. However, recipients rarely achieve insulin-
independence, although they show demonstrable improvements in glycaemic control
(Djordjevic, Lalic et al. 2004; Valdes-Gonzalez, Dorantes et al. 2005) and diabetic
complications (Farkas, Fulop et al. 1997). Widespread clinical application may be
hindered by limited availability and ethical constraints of using human foetal islet
tissue (Mandel 1999). The immunobiology of foetal islet tissue transplantation also
remains very complex, with incomplete immune tolerance of foetal tissue (Bennet,
Bjorkland et al. 2000; Solomon, Kuziel et al. 2004), and recurrence of autoimmunity
following foetal islet transplantation in humans (Brooks-Worrell, Peterson et al.
2000). If xenotransplantation was used to address the lack of foetal tissue availability,
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using foetal porcine tissue for example, then the immunological and safety concerns
of this would also need to be carefully considered (Mandel 1999).
1.4.3 Adult stem cells
These concerns have generated interest in the adult stem cell field, using pancreatic or
extra-pancreatic adult stem cells, or islet progenitors, located within differentiated
tissues of the foetus, child or adult to derive the islet tissue (Weissman 2000). Adult
stem cells have a more restricted developmental potential than ES cells and this may
limit the breadth of phenotypes they can adopt. Despite this, pluripotent cells can
adopt cell fates beyond their normal developmental potential under favourable
circumstances, such as bone-marrow mesenchymal stem cells adopting a nerve cell
fate, for example (Sugaya 2003). Furthermore, adult stem cells may be less
tumorigenic (and less likely to undergo teratoma formation) than ES cell-derived
tissue (Grompe 2002). This less contentious pluripotent cell type may also overcome
the ethical issues surrounding ES cell therapy and make such a cell-based therapy
more applicable for human use. Deriving the adult stem cells from the diabetic patient
may also reduce generalised immunosuppression needs currently required with
allografts (Noguchi, Matsumoto et al. 2006) with its associated risks, which currently
generally excludes children from receiving islet transplant therapy (Hathout, Lakey et
al. 2003). It is currently unknown whether the human diabetic patient's own immune
system would tolerate replacement autografted beta-cells derived from adult stem
cells (Burns, Persaud et al. 2004; Weir 2004), or whether the transplanted beta-cells
would undergo the same targeted autoimmune-mediated destruction as their
predecessors (Soeldner, Tuttleman et al. 1985; Atkinson and Maclaren 1994;
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Atkinson and Eisenbarth 2001). However, there has been a recent report that human
adult stem cells are capable of expressing high levels ofMHC class I proteins, and so
may be rejected on transplantation unless modified (Kim, Kim et al. 2005). Therefore,
a concomitant immunomodulatory strategy may be required to protect adult stem cell
derived islets from attack.
A naturally occurring adult islet stem / progenitor cell has remained elusive and even
its existence remains controversial in diabetes research. Beta-cell turnover does occur
naturally, although more slowly in humans than in mice (Bouwens and Pipeleers
1998; Butler, Janson et al. 2003; Bouwens and Rooman 2005; Dor 2006). Formation
of new beta-cells in vivo may occur via neogenesis through differentiation of a beta-
cell progenitor / pluripotent stem cell (Bonner-Weir, Toschi et al. 2004; Bonner-Weir
and Sharma 2006) and / or via replication of pre-existing fully differentiated beta-
cells (Dor, Brown et al. 2004; Dor and Melton 2004; Dor 2006). In vivo genetic
lineage tracing studies indicate that in healthy adult mice, the beta-cell population is
maintained during adult life through existing beta-cell replication rather than an adult
stem cell population (Dor, Brown et al. 2004). Detectable C-peptide levels and
residual beta-cells do exist in 11 to 40% of patients with longstanding T1DM (Rother
and Harlan 2004). Therefore, beta-cell mass regeneration through replication may
offer a potential future therapeutic strategy for some patients, if the autoimmune
process was ameliorated and the residual beta-cell mass could be expanded
sufficiently. The replication theory has recently been demonstrated in partially
pancreatectomised adult mice, where new beta-cells formed through replication of
existing beta-cells (Dor, Brown et al. 2004; Ackermann Misfeldt, Costa et al. 2008).
Another study reports partial recovery of endogenous islet beta-cell function in
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streptozotocin-induced diabetic mice, through a combination of beta-cell proliferation
and hypertrophy, following removal of an 120 day syngeneic islet transplant
(Yin, Tao et al. 2006). Pancreatic islet beta-cell regeneration (and transient liver cell
transdifferentiation into insulin-producing cells) has also been reported to restore
normoglycaemia when recombinant Pdx-1 intra-peritoneal injections are administered
to streptozotocin-induced diabetic mice (Koya, Lu et al. 2008). However, this
remarkable proof-of-principle report faces many obstacles to clinical translation
(including safety concerns, degradation of the protein by serum proteases, toxicity to
non-target organs etc.) and further studies are required. In addition, such a therapy
may not be widely applicable to those T1DM patients with no residual beta-cells left
to regenerate.
It is not known whether in vivo beta-cell mass regeneration may also occur through
neogenesis from progenitor cells, or an adult stem cell population. An adult islet
progenitor, or an adult pancreatic pluripotent cell, capable of deriving cells with
phenotypic similarities to beta-cells have been identified in the pancreas itself
(Cornelius, Tchernev et al. 1997; Linning, Tai et al. 2004; Lechner, Nolan et al.
2005), and within specific pancreatic tissues; such as exocrine / acinar tissue
(Baeyens, De Breuck et al. 2005; Todorov, Omori et al. 2006; Okuno, Minami et al.
2007; Jetton, Everill et al. 2008), ductal tissue (Bonner-Weir, Taneja et al. 2000;
Wang, Rosenberg et al. 2005; Xu, D'Hoker et al. 2008) or islet tissue (Zulewski,
Abraham et al. 2001; Abraham, Kodama et al. 2004; Gershengorn, Hardikar et al.
2004; Eberhardt, Salmon et al. 2006). The recent report of insulin-producing cell
production from facultative endocrine progenitors in the ductal lining of the adult
mouse pancreas upon injury is particularly noteworthy (Xu, D'Hoker et al. 2008).
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Taken together with Dor et aVs findings, this suggests that in the adult mouse the
beta-cell population may be maintained by self-duplication during health, but that islet
neogenesis via an islet progenitor or adult stem cell can be utilised at times of stress
(Dor, Brown et al. 2004; Xu, D'Hoker et al. 2008). Despite these findings, an adult
pluripotent cell within the pancreas which is capable of yielding tissue suitable for
diabetes reversal in humans has not yet been successfully realised. If a ductal lining
progenitor does exist in humans, it may be problematic expanding a sufficient number
for diabetes reversal, or safely and readily accessing these cells for autotransplantation
(but could theoretically be achievable through Endoscopic Retrograde Cholangio-
Pancreatography).
This has led to research into potential alternative sites of adult islet stem / progenitor
cells, or other differentiated cells which may be amenable to transdifferentiation or
dedifferentiation strategies. Transdifferentiation refers to pluripotent cell maturation
and differentiation which crosses the tissue-lineage boundaries of its normal
developmental potential, or even the switching of a fully differentiated cell into a new
phenotype (Slack and Tosh 2001; Tosh and Slack 2002). Dedifferentiation, on the
other hand, refers to reversion to an immature intermediate precursor, which may
precede the acquisition of a new phenotype. Interestingly, there have been recent
reports where both mouse and human differentiated adult somatic cells have been
induced into a pluripotent state by virus-mediated transfection with pluripotency
genes, including octamer 4 (Oct4), Sox2, cellular myelocytomatosis oncogene (c-myc)
and Kruppel-like factor 4 (Klf4) (Takahashi, Tanabe et al. 2007; Aoi, Yae et al. 2008;
Bru, Clarke et al. 2008; Huangfu, Maehr et al. 2008). Some of the specific somatic
cells used include human adult fibroblasts (Takahashi, Tanabe et al. 2007) and adult
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mouse liver cells, stomach cells and terminally differentiated pancreatic beta-cells
(Aoi, Yae et al. 2008; Stadtfeld, Brennand et al. 2008). Furthermore, these
dedifferentiated induced human pluripotent cells had similar properties to human ES
cells (in morphology, proliferation, surface antigens, telomerase activity, gene
expression and epigenetic status) and were capable of differentiating into cells of all
three germ layers (Takahashi, Tanabe et al. 2007; Stadtfeld, Brennand et al. 2008).
There has been a recent report of generating insulin-secreting islet-like cell clusters
from induced pluripotent cells derived from human skin fibroblasts (Tateishi, He et al.
2008). Again, these experiments used Oct4, Sox2, c-myc and Klf4 to induce the human
skin fibroblasts into pluripotency, before differentiating the cells down a
differentiation protocol previously used to produce insulin-secreting islet-like clusters
from human embryonic stem cells. The prospect of using differentiated adult somatic
cells for islet neogenesis is certainly very exciting, as these cells are readily available
from the patient and would overcome the ethical barriers to using ES cells. However,
these are early reports showing proof-of-principle, but at extremely low frequencies,
and little is still known about the mechanisms behind this process. Furthermore, the
stability and safety of these "induced" cells would also need to be firmly established,
in particular whether viral integration is associated with any genomic instability and
whether inducing these cells into a more immature rapidly proliferating phenotype
might predispose to neoplastic transformation?
Potential alternative sites of adult stem cells, progenitor cells, or cells which may be
capable of transdifferentiating into insulin-producing cells (and also functionally
tested, in the majority of cases, as capable of reversing chemically-induced diabetes)
include; pancreatic exocrine tissue (Zhou, Brown et al. 2008), the pancreatic duct
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(Bonner-Weir, Inada et al. 2008; Xu, D'Hoker et al. 2008), the gut (Cheung,
Dayanandan et al. 2000; Fujita, Cheung et al. 2004; Lear, Jayanthi et al. 2004), the
liver (Yang, Li et al. 2002; Nakajima-Nagata, Sakurai et al. 2004; Yamada, Terada et
al. 2005; Tang, Cao et al. 2006; Koya, Lu et al. 2008), the salivary gland (Matsumoto,
Okumura et al. 2007), the placenta (Battula, Bareiss et al. 2007), the amnion (Wei,
Zhang et al. 2003), umbilical cord blood (Zhao, Wang et al. 2006; Sun, Roh et al.
2007) , nervous tissue (Hori, Gu et al. 2005), bone marrow (Ianus, Holz et al. 2003;
Oh, Muzzonigro et al. 2004; Li, Zhang et al. 2007), peripheral blood (Ruhnke,
Ungefroren et al. 2005), adipose tissue (Timper, Seboek et al. 2006; Lee, Han et al.
2008) and the spleen (Kodama, Kuhtreiber et al. 2003).
The recent report of in vivo reprogramming of differentiated pancreatic exocrine cells
in adult mice into cells that closely resemble beta-cells has generated a great deal of
interest (Zhou, Brown et al. 2008). This transdifferentiation was achieved in vivo by
re-expressing a specific combination of three transcription factors (Ngn3, Pdx-1 and
Mafa) in the exocrine cells of the pancreas by adenoviral vector transfer. This
combination of transcription factors resulted in the conversion of >20% of infected
cells into insulin-expressing cells, which were first detected 3 days after injection.
These induced cells were indistinguishable from islet beta-cells and this
reprogramming effect appeared to be rather specific for pancreatic exocrine cells, as
infected skeletal muscle or fibroblasts did not express insulin. Streptozotocin-induced
diabetic mice also experienced a significant improvement in their hyperglycaemia
following infection of their pancreas with the adenovirus (and the virus did not appear
to spread to other organs).
Chapter 1
Page 50
Umbilical cord blood has also generated considerable interest as an accessible,
abundant and ethical pluripotent cell source for cell-based therapies (Koblas, Harman
et al. 2005; Greschat, Schira et al. 2008), which can be differentiated into insulin-
producing cells (Sun, Roh et al. 2007) capable of restoring normoglycaemia in
experimental models of diabetes (Zhao, Wang et al. 2006). However, the safety of
such cells for future therapies has yet to be determined (Koblas, Harman et al. 2005).
The potential role of the human spleen as a future source of adult stem cells for islet
transplantation is discussed and reviewed in the next chapter.
Chapter Two





Epithelium and mesenchyme are two phenotypically distinct tissue types. Epithelium
is characterised by tightly-packed sheets of cells adherent to one another (through
tight junctions, gap junctions and adherent junctions) and to the underlying
extracellular matrix (ECM) or basement membrane. Epithelium is typically non-
migratory and has a recognisable architecture. Contrastingly, mesenchyme is
comprised of loosely arranged cells, which rarely have cell-cell adhesions.
Mesenchyme is migratory, by way of its pseudopodia, and adopts no specific
recognisable architecture.
Despite these disparate phenotypes, cells do undergo transitions between epithelium
and mesenchyme during the requirements of development or the nature of disease. For
example, epithelial-to-mesenchyme transition (EMT) occurs during development in
the process of gastrulation, when the epiblast cells ingress to form mesoderm and
endoderm primary germ layers (Stern 2004). EMT is also seen in disease, where it is
an important determinant of malignant transformation and tumour invasion (Grille,
Bellacosa et al. 2003). Examples of mesenchyme-to-epithelial transition (MET) during
development include somite formation from paraxial mesoderm (Nakaya, Kuroda et
al. 2004) and kidney organogenesis (Davies and Fisher 2002). During kidney
development, signals from the ureteric bud induce epithelialisation of condensed
metanephric mesenchyme, leading to definitive nephron formation. It is interesting to
note that the kidney was originally thought to be derived exclusively from epithelium,
but now the role of MET in its organogenesis is firmly established (Davies and Fisher
2002; Denholm, Sudarsan et al. 2003).
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In the search for a pluripotent cell source of replacement islets to reverse Diabetes
Mellitus, it is important to understand the developmental origin of pancreatic islet
cells. Previous fate mapping studies have revealed that cells of the endocrine and
exocrine pancreas are derived exclusively from pancreatic endodermal epithelium (see
Chapter One, section 1.3; Pancreatic Organogenesis), under the influence of signals
from the lateral plate mesoderm (Percival and Slack 1999; Kumar, Jordan et al. 2003).
These studies showed that embryonic pancreatic epithelium was competent to derive
pancreatic islet, acinar and ductal tissue, finding no examples of a cellular
contribution from the mesenchyme. This finding is supported by expression of
regulatory genes required for pancreatic organogenesis by the foregut epithelium
(Jensen 2004). However, recent studies have demonstrated novel ways of
recapitulating beta-cell neogenesis, using alternative transcriptional networks (Servitja
and Ferrer 2004). Several groups have now elucidated a specific role for transitions
between mesenchymal and islet cell-types in the development and regeneration of
islet tissue (Kodama, Kuhtreiber et al. 2003; Gershengorn, Hardikar et al. 2004;
Atouf, Park et al. 2007; Chase, Ulloa-Montoya et al. 2007).
Previous findings from our own laboratory have shown that the developing foregut
mesenchyme (from the developing stomach mesenchyme or pancreatic mesenchyme)
is capable of differentiating into pancreatic endocrine and exocrine tissue when
combined with pancreatic epithelium in a model of developing avian pancreatogenesis
(Lear, Jayanthi et al. 2004; Teague, Jayanthi et al. 2005; Teague, Rowan-Hull et al.
2006; Teague, Rowan-Hull et al. 2007).
Chapter 2
Page 54
These findings of islet Mesenchyme-to-Epithelial Transition (iMET) are supported by
observations from other groups: Firstly, the reported reversal of diabetes in adult Non-
Obese Diabetic (NOD) mice when transplanted with adult donor mouse splenocytes
(with attenuation of autoimmunity) by in vivo transdifferentiation of mesenchyme-
derived splenocytes into epithelial beta-cells (Kodama, Kuhtreiber et al. 2003).
Secondly, cellular gene expression of endogenous insulin has been observed in
cultures of mesoderm and ectoderm of E7.5 gestation mice devoid of endoderm
(Wells and Melton 2000). Thirdly, epithelia of renal nephrons are now known to
differentiate via MET in the kidney, as previously mentioned (Davies, Perera et al.
1999; Denholm, Sudarsan et al. 2003), whilst epithelia of lymphatic vessels also
undergo MET (Wilting, Papoutsi et al. 2001). Finally, the important mediator of renal
MET, Wilms tumour suppressor gene 1 (Wtl), is also expressed at the onset of
pancreatogenesis by the presumptive dorsal pancreatic mesenchyme (Armstrong,
Pritchard-Jones et al. 1993).
We were therefore now interested in investigating whether the developing spleen,
itself a mesodermally-derived organ (Brendolan, Rosado et al. 2007), could also
undergo MET to produce islets.
2.2 The spleen
The vertebrate spleen is a lymphoid organ that plays important roles in
haematopoiesis, the generation of primary immune responses and filtration of blood
(to remove aged or abnormal blood cells and remove intraerythrocytic inclusions)
(van Rooijen, Claassen et al. 1989; Zapata and Cooper 1990; Chadbum 2000;
Brendolan, Rosado et al. 2007). The spleen also stores a small fraction of the body's
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red blood cells. These functions are performed by the red pulp of the spleen. The
white pulp, on the other hand, is the lymphoid compartment of the spleen. This tissue
releases neutrophils to counter infection and produces antibodies against invading
pathogens. It also stores upto one third of the body's platelets and releases these to
counter bleeding. Removal of the spleen can result in Overwhelming Post-
Splenectomy Infection (OPSI), as the body can subsequently struggle to fight certain
invading microorganisms (especially encapsulated bacteria) and it is usually necessary
for patients undergoing splenectomy to receive immunisations prior to the procedure
(currently Pneumococcus, Haemophilus Influenzae B and Neisseria Meningitidis
vaccinations are given in clinical practice) plus long-term prophylactic antibiotics
(Waldman, Rosenthal et al. 1977; Jirillo, Mastronardi et al. 2003; Okabayashi and
Hanazaki 2008).
2.3 Developmental anatomy of the spleen
The development of the spleen has previously been described in chick embryos from
E4 until after hatching using a number of cytological markers (Yassine, Fedecka-
Bruner et al. 1989). This organ undergoes dramatic functional changes during
ontogeny and switches from haematopoietic to immune function. The chick spleen
rudiment first becomes recognisable at E3 as a slight bulge of the dorsal mesentery
capping the dorsal pancreatic bud (Yassine, Fedecka-Bruner et al. 1989). The splenic
and pancreatic mesoderm remain continuous until E5. At E6, as the duodenal loop
grows out, the splenic bud separates from the pancreas and forms a loose network of
mesenchymal cells. From E3 to E9 this loose mesenchymal network becomes
progressively interspersed with basophilic cells. From E9 to El3, the basophilic cells
are very abundant and erythropoiesis begins. The first reticular fibres become visible
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in the chick embryonic spleen at Ell. By El 1.5, the splenic anlage is lined by a
mesothelial sheath, which will form the prospective splenic capsule. From El3 to
hatching, granulopoiesis is active, becoming the dominant process from El5, as
erythropoiesis decreases. The first T-lymphocytes are observed in the spleen on El6
and the first B-lymphocytes on El8 (Hoffmann-Fezer, Rodt et al. 1977). For
comparison, in the mouse embryo, free mononuclear cells are scattered throughout
the splenic anlage at El5 and the spleen is prehaematopoietic (Sasaki and Matsumura
1988). Immature erythroid cells and small lymphocytes first appear in the mouse
embryonic spleen at E16 and the spleen then becomes erythropoietic.
2.4 Gene expression during splenic development
The genetic control of splenic development is poorly understood, although recent
studies in mutant mice have shown several genes are important for the spleen to
develop normally. These include T-cell leukaemia homeobox 1 (Tlx-1; previously
known as Hox-11), pre-B-cell leukaemia homeobox 1 (Pbxl), podocyte-expressed 1
{Pod-1; also known as capsulin or epicardin), Wtl, Nkx2.3, bagpipe homeoboxfactor
1 (Bapxl; also known as Nkx3.2), Nkx2.5. However, the exact relationship between
these genes remains undetermined.
2.4.1 Tbc-l (Hox-11)
Tlx-1 (previously known as Hox-11) is a transcription factor encoded by a highly
conserved homeobox gene whose expression is critical for the specification of splenic
fate. It is expressed in various locations in the normally developing mouse embryo,
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including the branchial arches, pharynx, heart, hindbrain, pinna, external auditory
meatus and spleen (Raju, Tang et al. 1993; Roberts, Shutter et al. 1994; Dear,
Colledge et al. 1995; Logan, Wingate et al. 1998). It is initially expressed at E8.5 in
the developing muscle plates of branchial arches 1, 2 and 3 and subsequently in the
motor nuclei that innervate them, cranial nerves V, VII, and IX respectively. Hox-11
was also noted to be on in a single site within the abdomen (the splanchnic mesoderm)
beginning at El 1.5. Roberts et al first reported the role of this gene in splenic
development (Roberts, Shutter et al. 1994). They found that Hox-11 was expressed in
a highly localised portion of the splanchnic mesoderm destined to form the spleen,
beginning at El 1.5. This tissue condensed into a small mass on the dorso-lateral
margin of the future stomach and continued to express Hox-11 as it proliferated to
form the definitive spleen. It continued to be expressed in the developing spleen
through E13.5 but was down-regulated thereafter (weaker expression at E14.5).
Interestingly, they reported that expression of this gene was required for splenic
genesis, as their Hox-11 -/- mice had no spleen but otherwise appeared normal. In
addition, many of the erythrocytes in these mice contained Howell-Jolly bodies, a
finding consistent with asplenia.
However, Dear et al subsequently discovered that Hox-11 is not required to initiate
splenic development but is instead essential for the survival of splenic precursors
during development (Dear, Colledge et al. 1995). They similarly observed that
newborn Hox-11 -/- mice exhibit asplenia. They found that splenic formation begins
normally at El 1.5 in Hox-11 -/- mice mutant embryos, but the spleen anlage then
underwent rapid and complete resorption between E12.5 and El3.5, showing
molecular features of apoptosis, rather than inflammation or cell lysis. In Hox-11 +/-
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mice, sections of El8.5 spleen show Hox-11 expression in the outer capsule of the
spleen and the trabeculae, which together form the framework of the spleen. Hox-11
was not seen in the erythroid precursors within the spleen. They explain the splenic
atrophy observed in their Hox-11 -/- mice by the inability of this splenic framework to
survive. However, it was only splenic development that seemed affected by Hox-11
null mutants, possibly via functional redundancy of related genes. Interestingly,
Roberts et al also performed a Terminal Transferase Uridyl Nick End Labelling
(TUNEL) assay (Gavrieli, Sherman et al. 1992) on their Hox-11 -/- mice to see if the
spleen actually atrophied, but serial sections at multiple time points from embryos
revealed no increase in cell death within the dorsal mesogastrium at the site where the
spleen would normally develop (Roberts, Sonder et al. 1995). They observed instead
an increased stomach size, and possibly also the pancreas, in their Hox-11 -I- mice
suggesting that cells normally destined to form the spleen may adopt the fate of
surrounding cells in the absence ofHox-11, rather than undergoing apoptosis
Logan et al studied Tlx-1 {Hox-11) expression in the sensory nervous system of the
chick embryo (Logan, Wingate et al. 1998). Expression was noted in similar regions
to that previously reported in the mouse (hindbrain, heart, branchial arches etc) and
prominent expression from stage 20 onwards in mesenchymal cells of the dorsal
mesentery of the gut region, which corresponded to the splenic primordium.
Hox-11 expression is known to persist until birth in the mouse (Kanzler and Dear
2001) and there is evidence for continued expression of this early developmental
marker in CD45 -ve cells of the adult human spleen (Kodama, Davis et al. 2005;
Dieguez-Acuna, Gygi et al. 2007). However, to the best of our knowledge and
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following a thorough literature search, Tl.x-1 (Hox-11) expression in the embryonic
chick spleen has not yet been formally characterised during development (see Chapter
Five).
2.4.2 Pbx-1
Absence of Pbx-1 expression results in asplenia within mice embryos with 100%
penetrance (Selleri, Depew et al. 2001). Pbx-1 deficient mice died at El5 / El6
(Selleri, Depew et al. 2001; Brendolan, Ferretti et al. 2005) from severe hypoplasia or
aplasia ofmultiple organs, including asplenia but also pancreatic morphogenesis and
function (Kim, Selleri et al. 2002), amongst others. They additionally had widespread
skeletal patterning defects. The exact reason for the asplenia in these mice is unclear
but Pbx-1 has been reported to interact with the HOX-11 protein (Shen, Chang et al.
1996), suggesting that these may co-operate during splenic development. Brendolan et
al analysed asplenic mouse models lacking Pbx-1, Hox-11, Nkx3.2 or Pod-1 and
found a genetic hierarchy existed, with Pbx-1 itself playing a common crucial co-
regulator role in splenic development (Brendolan, Ferretti et al. 2005). Hox-11 and
Nkx2.5 were absent in the splenic mesenchyme in their Pbx-1 -/- embryos. Hox-11
was completely absent (rather than delayed) in the splenic mesenchyme {in situ
hybridisations performed from Ell-El 3.5 embryos) but was present elsewhere in the
other organ primordia within these embryos. However, Pbx-1 expression was not
altered in the splenic mesenchyme of Hox-11 -/- embryos, indicating that the onset
and continued expression ofHox-11 is Pbx-1 dependent, but not the other way round.
Interestingly, although two of the earliest known markers of splenic condensing
mesenchyme (Hox-11 and Nkx2.5) were absent, the other splenic mesenchymal
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markers Pod-1 and Nkx3.2 were maintained in these Pbx-1 -/- embryos, showing that
condensing splenic mesenchymal cells were still present and splenic gene expression
is not globally impaired by loss of Pbx-1. Interestingly, a TUNEL assay (Gavrieli,
Sherman et al. 1992) was performed on this Pbx-1 -/- mouse splenic mesenchyme and
no detectable increase in apoptosis was found, whilst Bromodeoxyuridine (BrdU) in
vivo labelling showed a marked reduction in the cell proliferation, and thus expansion,
of the splenic anlage by E13.5 (Brendolan, Ferretti et al. 2005).
Pbx-1 expression in the splenic mesenchyme is independent of Pod-1 or Nkx3.2 in
mice embryos, whilst Nkx3.2 and Pod-1 are both expressed independently of each
other at E12-12.5 (Lu, Chang et al. 2000; Brendolan, Ferretti et al. 2005).
Furthermore, Pbx-1 and Nkx3.2 both independently regulate Hox-11 expression, with
Hox-11 expression being dependent on both Pbx-1 (Brendolan, Ferretti et al. 2005)
and Nkx3.2 (Lettice, Purdie et al. 1999). Nkx2.5 is not expressed in the splenic
mesenchyme of Pod-1 -/- or Pbx-1 -/- mice embryos (Brendolan, Ferretti et al. 2005),
indicating that its splenic expression is dependent on the expression of these genes.
However, Nkx2.5 is still expressed in the splenic mesenchyme ofNkx3.2 -/- embryos
at E12-12.5 (Brendolan, Ferretti et al. 2005). Nkx2.5 expression is dependent on both
Pbx-1 and Pod-1 but not on Nkx3.2. Therefore, Pbx-1 functions upstream of Hox-11
and Nkx2.5 and so controls expression of Pod-1 and Nkx3.2, both essential for splenic
development (Brendolan, Ferretti et al. 2005).
In addition to genetically regulating downstream expression of key genes controlling
splenic expression (Nkx3.2 and Pod-1), Pbx-1 also genetically interacts with Hox-11
during splenic development (Brendolan, Ferretti et al. 2005). Pbx-1 was found to
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directly bind to the Hox-11 promoter, along with Hox-11 itself, in embryonic mouse
splenocytes. The simultaneous binding of Hox-11 to its own promoter suggests an
auto-regulatory role in splenic development.
2.4.3 Wtl
Wtl (Wilms tumour suppressor gene) is also required for normal splenic development,
as Wtl -/- mice embryos experience splenic anlage formation around El2 to El3
gestation but the spleen then involutes by El5, before haematopoietic cell invasion
(Herzer, Crocoll et al. 1999). Wtl is known to be expressed in the condensing splenic
mesenchyme (Rackley, Flenniken et al. 1993). Hox-11 mRNA is first expressed at
E10.5 followed by Wtl expression at El 1.5 (Koehler, Franz et al. 2000). During Ell,
Wtl expression overlaps with Hox-11 expression in the spleen (Herzer, Crocoll et al.
1999) but its expression is decreased in Hox-11 -/- embryos, indicating that Wtl
expression is regulated by Hox-11 during splenic ontogeny (Koehler, Franz et al.
2000). Wtl expression was also down-regulated in the condensing splenic
mesenchyme of Pbx-1 -/- embryos (Brendolan, Ferretti et al. 2005), but was
maintained in the outer mesothelial lining (which will give rise to the splenic capsule
(Sadler and Langman 1995). Taken together with the Pbx-1 -/- and Hox-11 data, a
genetic hierarchy has been suggested whereby Pbx-1 regulates Hox-11, which in turn
regulates Wtl in the condensing splenic mesenchyme (Brendolan, Ferretti et al. 2005).
Furthermore, a recent report has shown that absence of BarH-like homeobox 1 (Barx-
1) expression (a stomach mesenchymal transcription factor) in mice embryos results
in defective splenic positioning and expansion, with reduced splenic Wtl expression




Bapxl (also known as Nkx3.2) is known to be important for normal splenic
development. Bapxl null embryos die perinatally and, amongst other anomalies such
as skeletal dysplasia, are notably asplenic with an absence of splenic precursor cells
from an early stage of splenic anlage formation (Lettice, Purdie et al. 1999; Tribioli
and Lufkin 1999; Akazawa, Komuro et al. 2000). In the mouse, Bapxl is initially
expressed in the dorso-lateral mesenchyme flanking the developing pancreas and by
El2.5 it is restricted to the splenic anlage, with no expression in the gastrointestinal or
pancreatic endoderm (Hecksher-Sorensen, Watson et al. 2004).
2.4.5 Nkx2.5
The homeobox gene Nkx2.5 serves as a marker for splenic precursor tissue (Patterson,
Drysdale et al. 2000). Nkx2.5 is expressed in high levels in the adult heart and spleen
of the mouse (Lints, Parsons et al. 1993) and is known to be expressed in early stages
of splenic development in Xenopus (Patterson, Drysdale et al. 2000). Pre-splenic
tissue is initially located in symmetric domains on both sides of the embryo in stage
37 Xenopus embryos, but only the left side goes on to form the mature spleen (Nkx2.5
only detectable on left side by stage 40), possibly through preferential development of
spleen precursor cells on that side. In mouse embryos, Nkx2.5 is expressed at E10.5
in two distinct ventral and dorsal domains around the dorsal pancreatic bud, which
overlap Hox-11 expression (Hecksher-Sorensen, Watson et al. 2004).
2.4.6 Pod-1 (capsulin / epicardin)
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Pod-1 is also known as capsulin (Hidai, Bardales et al. 1998; Lu, Richardson et al.
1998) or epicardin (Robb, Mifsud et al. 1998). This transcription factor is expressed
in mesenchymal cells that encapsulate the epithelial primordia of developing viscera,
such as kidney, lung and epicardium (Quaggin, Schwartz et al. 1999; Lu, Chang et al.
2000). Pod-1 is required for splenic development, acting after splenic specification to
control expansion of the splenic anlage (Robb, Mifsud et al. 1998; Quaggin, Schwartz
et al. 1999; Lu, Chang et al. 2000). Pod-1 -/- mice fail to form a spleen, with rapid
apoptosis of the early splenic primordia in these cases and this region is devoid of
cells by El3.5 (Lu, Chang et al. 2000). Pod-1 expression overlaps with other
transcription factors Nkx3.2, Hox-11 and Nkx2.5 in the splenic mesenchyme (Lu,
Richardson et al. 1998; Brendolan, Ferretti et al. 2005).
2.4.7 Nkx2.3
The transcription factor Nkx2.3 is expressed in the gut mesenchyme and spleen of
embryonic and adult mice (Pabst, Zweigerdt et al. 1999). It is essential for normal
development and function of the small intestine and spleen. Nkx2.3 -/- mice have
severe morphological alterations in these organs and die in early postnatal life. Nkx2.3
mutants develop smaller spleens with disorganised white pulp and reduced numbers
of lymphatic cells, whilst some are asplenic.
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2.5 Close developmental relationship between the spleen, pancreas
and stomach
The spleen is known to form from a mesenchymal condensation within the dorsal
mesogastrium (the mesenchymal sheet that attaches the stomach to the dorsal body
wall), adjacent to the dorsal pancreas and stomach during development (Patterson,
Drysdale et al. 2000). The spleen normally displays left-handed asymmetry (Boorman
and Shimeld 2002) and the position of this organ has been used in detecting defects of
laterality, such as situs invertus (Aylsworth 2001). Interestingly, there is no clear
correlation between Left-Right asymmetry and the presence or absence of a spleen, as
shown by a host of papers studying laterality defects in mice and humans. These
report a range of either normally developed spleens, splenic hypoplasia or asplenia
(Yokoyama, Copeland et al. 1993; Roberts, Shutter et al. 1994; Dear, Colledge et al.
1995; Lettice, Purdie et al. 1999; Tribioli and Lufkin 1999; Oh and Li 2002). Also,
asplenia may occur in the absence of laterality defects (Rose, Izukawa et al. 1975;
Waldman, Rosenthal et al. 1977). Taken together, these findings indicate that
mechanisms other than those controlling Left-Right symmetry must be involved in the
control of splenic development (Brendolan, Ferretti et al. 2005).
The spleen shares a very close developmental relationship with the pancreas, with the
splenic mesenchyme budding off from the pancreatic mesenchyme early in
development (Asayesh, Sharpe et al. 2006). This very close developmental
relationship makes it an ideal candidate tissue for further investigation in the search
for a candidate tissue source for future islet neogenesis. Asayesh et al studied this
developmental relationship in Bapxl -/- mice. In normal development, the splenic
mesenchyme initially lies adjacent to the pancreatic endoderm (Hecksher-Sorensen,
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Watson et al. 2004). Shortly after Ell, the spleen forms as a condensation and buds
off from the dorsal pancreas. These tissues are clearly separated by El3.5. However,
no splenic condensation and separation occurs in Bapxl -/- mice and the presumptive
splenic mesenchyme, which still expresses the splenic mesenchymal markers Nkx2.5
and Pod-1 (Brendolan, Ferretti et al. 2005) in these mice, remains as loosely
organised cells lateral to the dorsal pancreas. This tissue can then undergo apoptosis
(shown with a TUNEL assay by Asayesh et aT) or it can go on to form smooth muscle
(indicated by c-kit expression performed by Asayesh et a!) with the adjacent dorsal
pancreatic tissue forming cystic structures which express sonic hedgehog (Shh), a
transcription factor expressed in embryonic gut endoderm and a mediator of gut
endoderm and mesoderm development (Ramalho-Santos, Melton et al. 2000).
This close developmental relationship between the pancreatic mesenchyme and the
spleen has also been observed in other murine studies. In mice with defects in late
pancreatic development, where the pancreatic mesenchyme is unaffected, the spleen
usually survives intact. However, loss of pancreatic mesenchyme is strongly linked
with asplenia (Ahlgren, Jonsson et al. 1996; Apelqvist, Ahlgren et al. 1997; Harrison,
Thaler et al. 1999; Kim, Miletich et al. 2007).
In mice born without an exocrine pancreas, due to a null allele for the protein PTF1-
p48, functional islets are found in the spleen (Krapp, Knofler et al. 1998). The
transcription factor Ptfl directs expression of genes in the exocrine pancreas. Mice
bearing a null mutation die shortly after birth and are found to have a complete
absence of exocrine pancreatic tissue, indicating that protein p48 is required for
differentiation and / or proliferation of the exocrine cell lineage. Interestingly,
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hormone-secreting pancreatic endocrine cell lineages do exist in these mice, in the
mesentery normally harbouring the pancreatic organ, until El6. Subsequently, from
El6 to El8, these cells are no longer found in this location but are now found in the
spleen instead, where they remain functional until neonatal death. It is also interesting
to note that naturally occurring giant splenic islets (devoid of exocrine tissue) are
found in some reptiles, including rattlesnakes and vipers (Hellerstrom and Asplund
1966; Volk and Arquilla 1985; Moscona 1990).
The stomach, pancreas and spleen all share a common splanchnopleural mesodermal
lineage (Matsushita 1995; Kumar, Jordan et al. 2003), as well as common genetic
regulators. Interestingly, Kumar et al showed that the mesoderm underlying the
presumptive pancreatic domain (splanchnic mesoderm between somites 7-9 at the 10
somite stage) in chick embryos was capable of inducing Pdx-1 (Gu, Dubauskaite et al.
2002; Gu, Brown et al. 2003) and other pancreatic gene expression in non-pancreatic
endoderm. This mesoderm was also able to initiate formation of ectopic islet-like
clusters in endoderm that would normally give rise to the stomach (possibly via BMP
/ activin and retinoic acid mesodermal signals).
Expression of the homeobox gene Barx-1 is restricted to stomach mesenchyme during
gut organogenesis (Tissier-Seta, Mucchielli et al. 1995; Kim, Buchner et al. 2005).
However, it is also required for normal formation of the spleen, as studied in mouse
embryos (Kim, Miletich et al. 2007). Barx-1 negative mutants developed normal
lower abdominal organs but the spleen was markedly hypoplastic and embedded
within the dorsal pancreas, rather than in its usual location (apposed to the greater
curvature of the stomach). In addition, the dorsal and ventral pancreatic buds failed to
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fuse (possibly due to absence of stomach rotation) in these embryos. The authors
(Kim et al) report reduced expression of Wtl transcription factor in the mesothelium
of Barx-1 -/- mice, but the expression of other transcription factors known to be
implicated in spleen development were unaffected (Pbx-1, Tlx-1, Nkx2.5, Bapxl,
Pod-1).
2.6 Clinical observations
There is some evidence from the medical literature indicating that splenic preservation
may delay the onset of diabetes in certain illnesses. Firstly, two retrospective reviews
(from two different centres) of patients undergoing surgery for chronic pancreatitis
found a reduced incidence of diabetes after distal pancreatectomy with splenic
preservation compared with distal pancreatectomy with splenectomy (Govil and Imrie
1999; Flutchins, Hart et al. 2002). Secondly, children undergoing splenectomy for
severe thalassaemias have an increased incidence of glucose intolerance (Bannerman,
Keusch et al. 1967; Lee, Tan et al. 1985). Diabetes Mellitus is a well documented
complication ofmultiple transfused thalassaemias (possibly as a result of gradual iron
accumulation), with an estimated overall incidence of 17.5% (Zuppinger, Teuscher et
al. 1975). Although no children in the Lee et al paper were found to be diabetic, those
who had undergone splenectomy had a higher incidence of glucose intolerance. The
authors attribute the lack of diabetes detection in their patient cohort to the relatively
young group of children studied (age range 13 months-13 years) as it is rare for
diabetes to complicate thalassaemia before the age of 10 years, with most reports in
patients in their teens and twenties (Lassman, O'Brien et al. 1974; Saudek, Hemm et
al. 1977). Taken together, these lines of evidence suggest that the spleen may play a
role in delaying or preventing diabetes in pancreatic disease. The mechanism for this
Chapter 2
Page 68
is unclear. The increased incidence of glucose intolerance in children undergoing
splenectomy for severe thalassaemias could simply be a direct effect of increased
haemosiderin deposition. However, one alternative explanation for these reports of
delayed diabetes onset with splenic preservation could be from a possible adult stem
cell population residing in the spleen, which may be recruited to form replacement
islets / beta-cells.
2.7 Advantages of the spleen as a potential tissue source for future
adult stem cell therapeutic strategies
The mature human spleen is an attractive candidate tissue source for future adult stem
cell therapeutic strategies to reverse Diabetes Mellitus. Firstly, the spleen has the
practical advantages of being a surgically very accessible organ. The spleen can be
safely and readily accessed surgically via laparotomy, or via laparoscopy if a
minimally-invasive approach was favoured (Rosen, Brody et al. 2002; Khoursheed,
Al-Sayegh et al. 2004; Pomp, Gagner et al. 2005; Silecchia, Raparelli et al. 2005;
Ruiz-Tovar, Perez-de Oteyza et al. 2007; Makrin, Avital et al. 2008). Splenic tissue
could therefore be readily acquired from the diabetic patient themselves, which may
overcome the difficulties of donor shortages currently limiting allograft
transplantation. It may also alleviate the requirements for immunosuppression when
the tissue is autotransplanted back into the host following in vitro manipulation.
However, it is likely that a concomitant strategy to prevent reactivation of the
autoimmune response would also be required. Reduced immunosuppression
requirements may also make it available to younger recipients such as children, a
group who could gain most benefit from islet transplantation, but who are currently
not routinely offered allograft islet transplants owing to the risks associated with
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lifelong immunosuppression (Coulombe and Gill 2004; Noguchi, Matsumoto et al.
2006). Alternatively, a splenic source of replacement islets could be used for
allotransplantation. It is interesting to note that the spleen is largely discarded at
present during multi-organ retrieval, but could be utilised as an abundant allograft
tissue source, if spleen-derived islet neogenesis is successfully realised.
Secondly, the spleen is advantageous as it is a "non-essential" organ. If a large tissue
mass is required for in vitro manipulation, splenectomy could be considered. The
patient could survive after a full splenectomy if this amount of tissue was required.
However, as mentioned earlier, splenectomy is not without risk of OPS I and so the
appropriate immunisations, longterm antibiotics and patient counselling would be
necessary. Ideally, only a sample of splenic tissue would be required, and then these
cells could be grown and manipulated in an in vitro culture system in order to achieve
the required islet number prior to auto-transplantation. Smaller splenic samples could
be acquired by splenic biopsy, or possibly a partial splenectomy. Splenic biopsy can
safely be achieved percutaneously under radiological guidance (Kang, Kalra et al.
2007; Tarn, Krishnamurthy et al. 2008). Ultrasound-guided biopsy of the spleen has
been reported to be a safe procedure (Civardi, Vallisa et al. 2001; Lieberman, Libson
et al. 2003), including its use in children (Muraca, Chait et al. 2001). The spleen also
has a natural capacity to regenerate after partial splenectomy, making it a very
attractive tissue source to harvest for adult stem cell strategies (Hall, Kurtzberg et al.
2005; Diesen, Zimmerman et al. 2008). It should be noted, however, that despite the
potential advantages of using the spleen as a tissue source, any surgical procedure on
the spleen does carry a risk of bleeding.
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The mature spleen is known to contain an adult stem cell population, capable of
extramedullary haematopoiesis at times of stress (Chadburn 2000). When the bone
marrow's ability to produce blood cells is exceeded, during disease or at times of
stress, the mature spleen can initiate production of any type of blood cell or
component via this haematopoietic stem cell population. Although, the exact
mechanisms behind this extramedullary haematopoiesis phenomenon are not yet
understood, a recent report from mouse model experiments indicates that bone
marrow cells can home to the spleen during acute anaemic stress, where a specialised
population of erythroid progenitors are generated for erythropoiesis, via a BMP4 and
Hedgehog dependent signalling pathway (Perry, Harandi et al. 2008). It is also
interesting to note, given this ability, that the embryological spleen is one of the first
sites of haematopoiesis during development. At around six weeks of gestation, the
developing human spleen produces a full complement of haematopoietic cells. This
actually precedes haematopoiesis by the bone marrow, which begins at five months
gestation, when splenic production decreases (Chadburn 2000). This known
functional adult stem cell population may be a useful potential target for future
therapeutic strategies in islet neogenesis (Kodama, Davis et al. 2005).
The mature spleen also appears to be a favoured site for stem cells to reside. Foetal
cells from offspring have been found at autopsy in humans (decades after pregnancy)
in the mother's spleen (Johnson, Nelson et al. 2001). Foetal cells were found more
frequently in the spleen than in other tissues, such as the pancreas or lymph nodes,
suggesting that the spleen may be a preferential site for foetal cells to be sequestered.
The possible consequences (beneficial or deleterious) of this foetal cell persistence in
maternal tissues is not yet fully understood (Johnson and Bianchi 2004). Furthermore,
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when pancreatic "stem cells" isolated from the adult human donor pancreas are
implanted into immunocompetent mice, these stem cells are subsequently found to
naturally reside in the mouse spleen and remain there for at least two months, in
preference to other sites such as blood or bone marrow (Abraham, Kodama et al.
2004).
Hox-11 (Tlx-1) is known to have widespread expression during embryogenesis (as
previously mentioned in Chapter 2, section 2.4.1). However, Kodama et al found that
a putative mesenchymal stem cell population resides within the spleen of adult mice
(Kodama, Davis et al. 2005). This cell population was Hox-11 +ve, Pdx-1 -ve and
CD45 -ve, the latter indicating that these cells were of non-lymphoid origin. These
cells were localised in the subcapsular region of the spleen in mice. As previously
mentioned (Chapter 2, section 2.4.1), a reservoir ofHox-11 {Tlx-1) positive stem cells
has also recently been found to be uniquely and abundantly expressed throughout
adulthood in the human spleen (Dieguez-Acuna, Gygi et al. 2007; Lonyai, Kodama et
al. 2008). Over 30 normal human post-mortem spleens were analysed (obtained
during harvesting procedures for organ donation) and there was no difference in
expression by gender or age. These cells were located throughout the human adult
spleen (rather than the predominantly subcapsular region in the mouse). Strikingly,
these stem cells displayed autonomous proliferation in tissue culture and were
maintained in culture for at least two months, with persistent Hox-11 {Tlx-1)
expression. The authors also suggest that the abundant expression of this gene means
that these stem cells may not need to be expanded in culture prior to transplantation
(Lonyai, Kodama et al. 2008). Hox-11 expression is already known to play a role in
influencing stem cell behaviour, as the artificial over-expression of Hox-11 in
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embryonic stem cells induces the immortalization of embryonic precursors (Keller,
Wall et al. 1998) . It is also interesting to note that Hox-11 plays an important role in
nature in tissue regeneration within newts, since persistent up-regulation of a Hox-11 -
like gene in this species contributes to the regeneration of entire limbs and the tail
(Simon and Tabin 1993; Beauchemin, Noiseux et al. 1994). Taken together, this
evidence suggests that splenic stem cells are very promising candidates for use in
future therapeutic transplantation strategies.
2.8 NOD mouse model: role of donor splenocytes in reversal of
diabetes?
Non-obese diabetic (NOD) mice are a well-established model for human T1DM.
They exhibit spontaneous autoimmunity which causes diabetes through destruction of
the Islets of Langerhans. Kodama et al have reported permanent reversal of diabetes
in NOD mice (with end-stage disease) through injection with adult mice donor
splenocytes combined with elimination of the autoimmunity using Freund's complete
adjuvant (FCA) (Ryu, Kodama et al. 2001; Kodama, Kuhtreiber et al. 2003). The
return of endogenous insulin secretion and persistent restoration of normoglycaemia
was accompanied by the reappearance of pancreatic beta-cells. Live or irradiated male
adult mouse donor splenocytes were injected into severely diabetic NOD females in
these experiments in order to investigate the origin of the new pancreatic islets
(Kodama, Kuhtreiber et al. 2003). The mice also received a temporary (40 day)
syngeneic islet transplant under the capsule of one kidney to control blood glucose
concentration. Interestingly, when this islet implant was removed, 6 of the 9 mice
(67%) that received live splenocytes remained normoglycaemic, whilst none of the 8
mice that received irradiated splenocytes remained normoglycaemic (they all became
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rapidly and severely hyperglycaemic). In another experiment in this series, the islet
transplant was then maintained for 120 days before removal, to allow a longer period
for islet regeneration. However, in this experiment, the majority of mice remained
normoglycaemic in both the live and irradiated donor splenocyte groups, indicating
that both types of splenocytes could effect disease elimination when a longer period of
normoglycaemia is imposed. In the successfully treated mice, fluorescence in situ
hybridisation (FISH) analysis for detection of the Y chromosome of the male donor
cells showed abundant nuclei positive for the Y chromosome within the islets, but not
the exocrine portion of the pancreas. 29% to 79% of islet cells were of donor origin.
No islets solely of host origin were detected and other organs (such as the brain, liver
and kidneys) were devoid of the donor Y chromosome, indicating that the
incorporation of the donor cells was selective for the diseased pancreas. The absence
of markedly enlarged nuclei or tetraploid nucleoli in the regenerated beta-cells
suggested that new islet cells did not arise by fusion of donor splenocytes with
endogenous islet cells. In addition, the ploidy of the sex chromosomes of regenerated
islet cells was normal, also indicating that the regenerated islets were not the result of
fusion between male and female cells. A final experiment in this series, using a green
fluorescent protein (GFP) marker, examined whether lymphoid (CD45 +ve) or
nonlymphoid / mesenchymal (CD45 -ve) donor splenocytes engaged in islet
regeneration. This experiment found that donor CD45 -ve mesenchymal precursor
cells were reconstituted into functional islets, whilst the donor CD45 +ve splenocytes
did not participate directly in islet regeneration (although they were essential for
disease reversal). Overall, the experiments in this paper showed that the observed
islet regeneration in the pancreas was a combination of regeneration with the donor
spleen cells as well as endogenous regeneration of the treated host (possibly via a
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donor splenocyte contribution to the reversal of autoimmunity, allowing islet
regeneration from endogenous precursor cells). However, it should be noted that
although FCA can abolish autoimmunity in mice, the immune reaction produced is
currently considered too hazardous for use in humans.
In 2006, the Chong research group reported partial recovery of endogenous islet beta-
cell function in streptozotocin-induced diabetic mice, following removal of an 120
day syngeneic islet transplant, through a combination of beta-cell proliferation and
hypertrophy (Yin, Tao et al. 2006). Interestingly, they found that splenic preservation,
or splenocyte infusion following splenectomy, facilitated the restoration of beta-cell
function compared to splenectomised mice. However, they found no evidence of
donor splenocytes differentiating into islet beta-cells in their study. Disappointingly,
three groups (Chong group included) have now been unable to reproduce Kodama et
aVs findings in mice (Chong, Shen et al. 2006; Nishio, Gaglia et al. 2006; Suri,
Calderon et al. 2006). Chong et al used a similar approach to Kodama et al, but used
splenocytes from a transgenic mouse strain in which the mouse insulin promoter
(MIP) drives the expression of GFP, so that GFP is expressed only in their beta-cells
and not in their splenocytes. FCA and splenocytes reversed autoimmunity in 9 / 22
(41%) of the diabetic NOD mice. 14 (63.6%) redeveloped diabetes within 40 days,
and one within 80 days, due to a recurrence of autoimmunity (shown by a second
syngeneic islet transplant given to 6 of these mice, 4 of whom became diabetic again
within 1 week). The majority of these mice remained normoglycaemic after removal
of the islet transplant. Histological pancreas examination showed 5/6 treated mice
had very few hyperplastic islets and one had very few small islets that stained very
weakly or did not stain for insulin (similar finding to Suri et al, 2006). All islets
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within the treated NOD mice were examined for expression of GFP, to determine if
the origin of the new islets were from the host or derived from donor spleen cells. No
beta-cells expressing GFP were detected, nor in the organs outside of the pancreas,
and thus this data does not support a conclusion of beta-cell regeneration from spleen
derived cells. The authors conclude that the therapeutic protocol tested was sufficient
to reverse autoimmune diabetes with restoration of normoglycaemia but via
replication of pre-existing beta-cells, rather than from the donor splenocytes
themselves.
Nishio et al were also unable to reproduce Kodama et aVs findings in the NOD mouse
model. They found islet recovery and reversal of the murine diabetes but an absence
of any infused donor splenocyte contribution to the regenerated beta-cell mass
(Nishio, Gaglia et al. 2006). Single Nucleotide Polymorphism (SNP) analysis was
used to identify donor versus host cells within the regenerated pancreatic islets, which
the authors argue is a more robust test than the FISH analysis used by Kodama et al.
They found that host beta-cells (or possibly seeding and expansion of islet graft-
derived cells), rather than donor splenocytes, contributed to islet regeneration
following muting of the autoimmunity by FCA.
Finally, Suri et al were also unable to reproduce Kodama et al's findings. In this
study, islet regeneration and disease reversal occurred in the treated NOD mice,
through control of the autoimmunity rather than via allogeneic splenocyte-derived
differentiation of new islet beta-cells (Suri, Calderon et al. 2006). GFP expressing
male donor splenocytes were given to female NOD hosts (as per Kodama et aV s
second protocol) but although all treated mice were protected from diabetes and with
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intact islet regeneration, no GFP +ve cells were detected. This showed no evidence
for replacement of islets by the allogeneic spleen cells. The authors conclude that
residual host beta-cells, or host beta-cell precursors, led to disease reversal and
normoglycaemia.
Considerable debate has ensued following the failure of these three separate attempts
to replicate Kodama et aVs original promising results of donor splenocytes forming
new islets (Couzin 2006; Melton 2006). Faustman argues that their cell lineage
tracing technique of Y-chromosome FISH to follow transplanted male cells into
female recipients was more robust than the GFP cell tagging technique used by Chong
et al, which can be difficult to detect if the GFP transgene is expressed inefficiently
(Faustman, Tran et al. 2006). She also argues that it is also possible for the transgene
to be completely silenced in the progeny of GFP-labelled cells (Mezey, Nagy et al.
2003) and that, furthermore, using a non-perfused (frozen) tissue technique could
have technical shortcomings since GFP detection requires perfusion of the tissue with
fixatives (most commonly formaldehyde-based) to prevent diffusion of the marker out
of the cells (Brazelton and Blau 2005). Chong disagrees (in the same publication as
Faustman's comment, page 1243b), arguing that GFP is in fact more robust than Y-
chromosome FISH analysis in testing a transdifferentiation hypothesis, as it is less
prone to artefacts. Chong argues that the Y chromosome FISH analysis can only
detect that the cells are male donor cells and not differentiated beta-cells, whereas the
MIP-GFP technique would robustly show this, if any such cells were present.
However, Faustman's group counter this argument with their use of insulin staining in
the same section as the Y chromosome FISH detection to detect islets containing
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donor splenocytes. Chong goes on to argue that inefficient expression or inadvertent
silencing ofGFP expression has not been reported for the MIP-GFP mouse.
Faustman criticises the sensitivity ofNishio et aV s SNP method, as the sensitivity was
not formally examined and others have reported that this technique cannot be used to
detect low levels of chimerism (Reed and Wittwer 2004). Nishio responded (same
publication, page 1243c) by arguing that they use a different method than the low
sensitivity one cited in the Reed and Wittwer reference and that, more importantly,
Nishio et al have directly evaluated their assay and found it to have the required
sensitivity. They further go on to question the robustness of the Y-chromosome FISH
detection method used by Faustman's group, as Faustman reports a false detection of
the Y chromosome in untreated mice (Faustman, Tran et al. 2006) but Nishio also
additionally criticises inadequate controls (especially an FCA alone control) and poor
imaging quality in the Faustman group's paper.
Faustman argues that Suri et aVs paper showed the lowest rate of islet function
restoration (normoglycaemia), with only 4 out of 22 mice treated successfully. She
suggests that Suri et al may have had a problem with their mice or the tissue, since the
islets of Suri et aV s normoglycaemic mice lacked any lymphocytic infiltration in
addition to the lack of donor splenocytes, in contrast to all the other reports (Kodama,
Kuhtreiber et al. 2003; Chong, Shen et al. 2006; Nishio, Gaglia et al. 2006).
Faustman's group have subsequently further examined their results and found that the
age of the NOD mouse at the start of the disease-reversing treatment influenced the
degree of splenocyte contribution compared with endogenous regrowth of the islet
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(Faustman, Tran et al. 2006). Older mice with more advanced diabetes showed a
higher contribution of splenocytes to regenerating islets and so the extent of
chimerism in transplanted islets may in part depend on the extent of islet destruction
at the time therapy was initiated and the duration of follow-up after therapy. So it is
possible that the other groups may have followed up their animals for shorter time
periods after therapy and used earlier time points, which may explain their
observations of exclusively endogenous islet regeneration.
These seemingly conflicting findings have led to increased scrutiny of the role of the
spleen as a potential future tissue source for islet neogenesis. Therefore, the potential
role of the spleen to derive replacement islets now warrants further investigation,
including an understanding of the molecular mechanisms behind this process and how
this phenomenon might be optimised. This was the focus of the research described in
this thesis.
2.9 Aims and hypothesis of thesis
The general aims of this thesis were therefore:
1. To investigate whether the developing spleen could differentiate into insulin-
producing cells.
2. To investigate the molecular mechanisms behind this iMET process.
3. To investigate how this iMET process could be augmented.
The principal hypothesis addressed in this thesis states that:
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Splenic mesenchyme is able to differentiate into an insulin-producing pancreatic
endocrine cellfate during development
Seven subsequent hypotheses were generated. These are shown in Table 1 and
qualified in their respective chapters.
Table 1 The seven experimental hypotheses generated within this thesis
1. The developing avian spleen is able to differentiate into insulin-producing cells
2. Altering the ratio of splenic mesenchyme to chick pancreatic epithelium in the
recombinants will alter the frequency of observed iMET
3. Altering the overall amount of tissue in the recombinants will alter the frequency
of observed iMET
4. Tlx-1 is down-regulated in the splenic mesenchyme of chimaeric recombinant organs
5. Pdx-1 is up-regulated in the splenic mesenchyme of chimaeric recombinant organs
6. Isl-1 is up-regulated in the splenic mesenchyme of chimaeric recombinant organs
7. iMET within chimaeric recombinant organs can be augmented by addition of a
Wnt agonist to the culture medium
(iMET = islet Mesenchyme-to-Epithelial Transition)
The experimental design used to investigate these aims is outlined in the next chapter.
SECTION TWO
Islet Mesenchyme-to-Epithelial Transition
in the developing avian spleen
Chapter Three





An avian in vitro model of pancreatic organogenesis was used, employing the well-
established chick-quail chimaera system to fate-map tissues within recombinants
during pancreatic development. In these experiments, quail spleens were recombined
with chick pancreatic epithelia. The use of opposing species types for the pancreatic
epithelia and splenic mesenchyme mini-organ recombinants allowed robust fate
mapping during the analysis stage, since Quail not Chick PeriNuclear (QCPN) is
ubiquitously expressed in the nucleoli of all quail tissue.
3.2 Design of in vitro model of pancreatic organogenesis
3.2.1 The use ofan avian model as a model ofhuman development
The avian model is a well-established robust system for investigating the mechanisms
behind human development and disease (Dupin, Ziller et al. 1998; Brown, Hubbard et
al. 2003). It is a powerful system for studying development, since it allows
experimental embryology to be combined with molecular approaches (Streit and Stern
2001). The human and chick genomes show greater preservation of gene order than
between even human and murine genomes (Hillier, Miller et al. 2004). Avian
embryonic tissue is readily available and has the ethical advantage of avoiding the
need to sacrifice the mother (in accordance with current ethical principles regarding
the use of animals in scientific research). The chick genome has 75% homology with
the human genome (ICGSC 2004) and the signalling pathways controlling pancreatic
differentiation are highly conserved between avian and mammalian species (Kim,
Hebrok et al. 1997; Kim, Hebrok et al. 1997; Hebrok 2003; Stafford, Hornbruch et al.
2004; Kume 2005; Kume 2005). Furthermore, there is 68% inter-species homology of
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key transcription factors, such as the pancreatic "master gene" Pdx-1 (Gerrish, Van
Velkinburgh et al. 2004). The amino-acid sequences of avian insulin, glucagon and
somatostatin are identical to, or closely resemble, those in mammals (Epple and Brinn
1987).
Despite the similarities between avian and human pancreatic development, differences
do exist. Firstly, the avian pancreas is compromised of two distinct types of islet: A-
islets, in which pancreatic alpha-cells predominate; and B-islets, in which pancreatic
beta-cells predominate. B-islets are more numerous and A-islets are larger in size.
This results in the avian alpha-cell mass being approximately twice that of the beta-
cell mass in post-natal life. The converse is true in mammals, with the beta-cells
outnumbering the alpha-cells (McClish and Eglitis 1969; Smith 1974). A less
common third islet type exists in the avian pancreas called the "mammalian" islet,
because it contains both alpha-cells and beta-cells (Andrew, Rawdon et al. 1994).
Secondly, avian embryos develop two ventral pancreatic buds compared with a single
ventral bud in mammalian embryos (Rawdon 1998). However, since our avian in vitro
model only uses the dorsal pancreatic bud in construction of recombinants, this
difference should not affect the validity of our model as a surrogate of human
development.
In summary, the avian model is a scientifically valid, ethically sound model with
which to test our hypotheses.
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3.2.2 Chick-quail chimaeric recombinants as a cellfate-mapping tool
During early development, chick and quail embryos share similar morphology and
differentiate into similar structures at similar rates Quail cells transplanted into the
differentiating embryonic chick (in vivo or in vitro) can therefore be considered to
develop in register with the chick tissue at that site (Le Douarin 1969). However,
quail cells differ from chick cells in that they uniquely and ubiquitously express a
quail-specific perinuclear antigen. This allows positive identification of all quail cells
in the chick-quail chimaera by immunocytochemistry, using a monoclonal antibody
raised against the quail-specific perinuclear antigen (QCPN, Quail not Chick
Perinuclear; Selleck and Bronner-Fraser, 1995).
The chick-quail chimaera system provided a highly sensitive and specific cell fate
mapping tool to test the hypotheses. It was chosen because of the following
advantages:
(a) Ubiquitous expression
This technique's ubiquitous expression of the quail-specific perinuclear antigen
ensured that all the splenic cells could be identified within the recombinants, to
optimise the detection of any iMET in the experiments. Other fate mapping
techniques, such as intracellular injection or retroviral transfection of targeted
promoter recombination events, often result in smaller numbers of cells being
labelled and may result in iMET going undetected.
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(b) Uniform intensity ofexpression
The quail-specific perinuclear antigen is expressed with uniform intensity
irrespective of which type of quail tissue is being used or the duration of culture.
This has advantages over other techniques such as the lacZ reporter (Percival and
Slack 1999), which is weakly expressed in mesenchymal tissue and whose
expression intensity may be affected by prolonged duration (and thus may allow
iMET to go undetected).
(c) Permanent expression
The quail-specific perinuclear antigen is a permanent cell marker and the signal is
not diluted by cell division (as may occur with intracellular injected reporter
constructs). It is therefore well suited to modelling the complex and multi-staged
process of organogenesis.
(d) No false positive expression
The quail-specific perinuclear antigen is only expressed by quail cells and avoids
the potential problem of confounding transfer of the cell label to adjacent
unrelated cells, which may occur with fate mapping techniques involving the use
of water-soluble dyes to trace cells.
(e) Excellent resolution




(f) Established and validated model ofpancreatic organogenesis in this
laboratory
This chick-quail chimera model has been successfully used previously to fate map
cells in pancreatic organogenesis in this laboratory (Jayanthi, Rowan-Hull et al.
2005; Teague, Jayanthi et al. 2005; Teague, Rowan-Hull et al. 2006) and lends
itself well to testing our hypotheses.
The chick-quail chimera model does have potential disadvantages:
(a) Requires surgical manipulation
It is important to avoid contamination of quail pancreatic tissue into the chimaeric
recombinant when microdissecting the tissue to be used in constructing the
chimaeric mini-organs, as this could lead to false positive results. Particular care
was taken to address this by using quail spleen controls to test for contamination.
In addition, day 4.5 gestation was specifically chosen to harvest the quail spleens
as the spleen was distinct from the adjacent quail pancreatic mesenchyme at this
stage. Furthermore, meticulous care was taken over the dissection margins when
microdissecting the spleen and a safety cuff of quail spleen was typically left
behind next to the quail pancreatic mesenchyme before discarding this (see
Chapter 4, Table 2).
(b) Possible confounders?
(i) There could theoretically be a possible confounding role of tissue healing after
the surgical manipulation, but it is not known if this occurs or indeed if it has any
confounding effect at all.
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(ii) There could be a possible confounding role of using different species to
construct the mini-organs, but this is unknown.
An alternative equally robust technique for fate mapping the spleen during pancreatic
organogenesis could have been use of a transgenic mouse model (perhaps using GFP
as a cell tracking tool). Time constraints and logistical hurdles precluded their use for
this project (but may form part of future research plans).
3.2.3 Dorsalpancreatic bud development as a model ofpancreatic development
Dorsal pancreatic bud explants have previously been widely used to model pancreatic
development (Le Douarin 1969; Andrew 1975; Apelqvist, Ahlgren et al. 1997;
Rawdon 1998; Kramer, Manning et al. 2002; Chiang and Melton 2003; Hald, Hjorth
et al. 2003). The dorsal and ventral buds are not identical and the dorsal bud
development precedes the ventral, being clearly discernable under the dissecting
microscope at an earlier stage. Additionally, differentiation into insulin-positive beta-
cells (Kramer, Andrew et al. 1987) and glucagon-positive alpha cells (Hald, Hjorth et
al. 2003) precedes that in the ventral buds. Therefore, the preferential use of the
dorsal pancreatic bud permits study of pancreatic organogenesis from an earlier stage.
HH stage 22-23 (Day 4 gestation) was routinely used in our chimaera recombinants
for three reasons; Firstly, the dorsal pancreatic bud is not clearly discernible from
adjacent foregut prior to stage 22 and so is difficult to accurately dissect out.
Secondly, the differentiating pancreatic bud becomes increasingly lobulated at later
developmental stages, which can preclude clean separation of the pancreatic
mesenchyme from its epithelium (Gittes and Galante 1993). Finally, this is the stage
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previously successfully used in this laboratory to model pancreatic organogenesis
(Teague, Jayanthi et al. 2005; Teague, Rowan-Hull et al. 2006). A potential
disadvantage of using pancreatic epithelium, without pancreatic mesenchyme, is that
signals from the mesenchyme could be lost, which may be important for islet
neogenesis.
3.2.4 The avian spleen as a surrogate for pancreatic mesenchyme within the
chimaera
The embryonic spleen was used as a surrogate for pancreatic mesenchyme in the
chimaeric recombinant organs. The use of a surrogate has been validated in previous
studies, for example using stomach mesenchyme (Percival and Slack 1999; Teague,
Jayanthi et al. 2005; Teague, Rowan-Hull et al. 2006). As already discussed in
Chapter 2 section 4, the spleen shares a very close developmental relationship with
the pancreatic mesenchyme, budding off from the pancreatic mesenchyme of the
dorsal bud in early development (Yassine, Fedecka-Bruner et al. 1989). This close
relationship makes it an attractive surrogate tissue to investigate. The spleen is a
mesenchymal structure and therefore lends itself well to use as a mesenchymal
surrogate. This avoids the need for a collagenase step to separate mesenchyme from
epithelium and affords protection against spurious results from contamination of the
mesenchyme by epithelial cells. However, the splenic mesenchyme may have
potential disadvantages compared with stomach mesenchyme; Firstly, it is smaller in
size than the stomach (which may affect the likelihood of observing any iMET), with
the stomach having a thicker mesenchymal investment than the rest of the gut or gut-
derivatives (Roberts, Smith et al. 1998). Secondly, the cell contact and proximity of
mesenchyme to epithelium in normal pancreatic differentiation during development is
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already known to be important (Li, Manna et al. 2004). The stomach lumen
maximises cell-cell contact between the stomach mesenchyme and pancreatic
epithelium by placing the epithelium explant inside the stomach mesenchymal lumen.
Other non-lumenal mesenchyme, such as the splenic mesenchyme, may not benefit
from this very close cell-cell contact.
Although there is a paucity of developing avian embryonic spleen descriptions in the
literature, a chick atlas and previous ontological study of avian embryonic spleens by
Yassine (1989) allowed identification of the spleen during establishment of the model.
The splenic tissue being harvested was also confirmed to be splenic by in situ
hybridisation experiments using Tlx-1 (see Chapter 4, Tables 2 and 3).
3.2.5 Three-dimensional culture system
The three-dimensional culture system is acknowledged to be superior to two-
dimensional systems for studying complex developmental systems (such as the
pancreas), as it more accurately models the three-dimensional niche of the developing
organ (Affolter, Bellusci et al. 2003). In fact, the microgravity conditions afforded by
roller culture is known to enhance pancreatic differentiation and growth during in
vitro culture (Rose, Brown et al. 1999).
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3.3 Validation of in vitro model of pancreatic organogenesis
The three-dimensional roller culture apparatus in this laboratory was already known to
successfully support pancreatic organogenesis from previous experiments
investigating stomach mesenchyme. It was therefore considered to be the optimal
culture system with which to now investigate the role of iMET using splenic
mesenchyme. Non-recombinant splenic mesenchyme atrophied and dissociated when
cultured alone without epithelia. This is a similar finding to that observed in this
laboratory previously using stomach mesenchyme alone (unpublished data).
Therefore, spleen controls were either fixed after one day culture (after overnight
agarose culture step), or fixed straight away after harvesting and microdissecting the
embryos at day zero of culture. Importantly, microdissected control spleens were
always negative for insulin, Pdx-1 and Isl-1 (see Chapter 4, Table 3). This
demonstrated clean dissection margins (with no quail pancreas contamination of the
quail spleens).
3.4 Conclusion
The in vitro model provides a powerful tool for investigating the role of iMET in the









The human spleen may be an ideal source of adult stem cells to use for islet
transplantation to treat Diabetes Mellitus, as discussed in Chapter 2. However, there
has been a great deal of scrutiny over the role of the spleen in achieving this,
following conflicting results in the literature of islet neogenesis from donor
splenocytes in NOD mice (Kodama, Kuhtreiber et al. 2003; Chong, Shen et al. 2006;
Melton 2006; Nishio, Gaglia et al. 2006; Suri, Calderon et al. 2006). Therefore, the
potential role of the spleen to derive replacement islets now warrants further
investigation. Following controversy in the murine model, it is useful to now
investigate splenic iMET in the avian model instead.
I wished to test three hypotheses in the series of experiments described in this chapter:
1. The developing avian spleen is able to differentiate into insulin-producing
cells
2. Altering the ratio ofmesenchyme to epithelium in the recombinants will alter
the frequency of iMET observed
3. Altering the overall amount of tissue in the recombinants will alter the
frequency of iMET observed
4.2 Methods
4.2.1 Tissueprocurement
Fertile chick (Gallus domesticus, hybrid Joice/Hill; Winter Egg Farm, Royston, Herts,
UK) and quail (Coturnix coturnix japonica; Fayre Game, Lytham, UK) eggs were
incubated at 37°C in a humid environment for the required gestation. Developmental
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stage of the embryos was determined according to Hamburger and Hamilton staging
(Hamburger and Hamilton 1951); see Appendix IV. The embryos were removed from
the eggs and placed in chilled (4°C) Leibovitz's L-15 medium (Invitrogen, Paisley,
UK). All embryonic manipulation was performed under sterile conditions and in
accordance with United Kingdom Home Office regulations under the Animals
(Scientific Procedures) Act 1986.
In each experiment, developing embryonic quail spleens E4.5 (Hamburger-Hamilton
(HH) stage 25-29) and chick dorsal pancreatic buds E4 (HH22-24) respectively were
procured, unless otherwise stated (see Figure 6). Previous experiments in this
laboratory, using avian embryonic stomach mesenchyme, have found a window of
competency between stage HH22 and HH28 (inclusive) for the mesenchyme to
undergo iMET, with a diminishing of this competency with increased gestation
(Teague, Rowan-Hull et al. 2006). However, in this thesis, HH25-29 was chosen to
microdissect the spleen, as it is morphologically distinct at this stage from the
adjacent developing dorsal pancreatic bud. HH22-24 was chosen for the chick dorsal
pancreatic buds, as this is the established stage of competency for islet Mesenchyme-
to-Epithelial Transition (iMET) previously used in this laboratory, as discussed in
Chapter 3, section 3.2.3 (Teague, Rowan-Hull et al. 2006). The microdissections were
performed in Leibovitz's L-15 medium using a Leica MZ-16 dissecting microscope
and electronically sharpened tungsten needles.
Figure 6 Microdissection of embryos
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Fig 6 Anatomical boundaries and dissection margins of embryos. Organ blocks were
dissected from HH22-24 chick embryos (A; lateral view) and HH 25-29 quail embryos (B;
ventral view). White lines indicate anatomical boundaries. Red lines indicate the dorsal
pancreatic bud and spleen dissection margins. The dorsal pancreatic bud was taken from chick
embryos and the spleen from quail embryos. Particular care was taken over the quail spleen
dissection margins, leaving behind a cuff of spleen closest to the pancreas, in order to avoid
any quail pancreas contamination.
4.2.2 Separation ofembryonic epithelium and mesenchyme
The embryonic epithelium of each pancreatic bud was microdissected from its
surrounding mesenchymal cortex using chemical digestion with collagenase, as
previously described in the literature (Lear, Jayanthi et al. 2004; Teague, Jayanthi et
al. 2005). The pancreatic buds were treated with freshly prepared 0.1% Type A
Collagenase (Sigma, Dorset, UK) in Leibovitz's L-15 medium at room temperature
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for 8.5 minutes. Following this, the pancreatic buds were transferred into chilled fresh
Leibovitz's L-15 medium (without collagenase) and incubated for 1 hour to allow the
epithelium and mesenchyme to separate. The epithelium was then microdissected off
the mesenchyme. The E4.5 embryonic spleen rudiments required no collagenase
digestion and separation, as this is a mesenchymal structure (without an epithelial
component to remove).
4.2.3 Chick-quail chimaera recombinantmini-organs
To trace cell lineage during pancreatogenesis, the well-established and highly
sensitive chick-quail chimaera model was used. A quail-specific perinuclear antigen is
uniquely and ubiquitously expressed by all quail cells, which allows
immunocytochemical distinction between cells of quail and chick origin (Le Douarin
1969).
Chimaeric chick / quail embryonic recombinants were initially constructed by
recombining one embryonic quail spleen with one chick pancreatic epithelium.
Pancreatic epithelium is known to be an important constituent within the recombinant
in order for iMET to occur, from previous experiments in this laboratory studying
pancreatic mesenchyme (Jayanthi, Rowan-Hull et al. 2005). The amount and ratio of
splenic mesenchyme to chick pancreatic epithelium was subsequently altered (where
indicated in the sub-sections) to investigate the effect of this on any observed iMET.
With regard to species choice within the recombinant chimaeras, quail tissue was used
for the splenic mesenchyme and chick tissue for the pancreatic epithelium because
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previous work in this laboratory recombining stomach mesenchyme with pancreatic
epithelium, or pancreatic mesenchyme with pancreatic epithelium, found an
increased overall incidence of iMET when quail species were used as the
mesenchymal tissue rather than chick species (Lear, Jayanthi et al. 2004). In that
study, a total of 110 recombinants were constructed, recombining pancreatic
mesenchyme with pancreatic epithelium in 70 recombinants and recombining stomach
mesenchyme with pancreatic epithelium in 40 recombinants. Within each of these
groups, half the recombinants used quail mesenchyme and half used chick
mesenchyme, in order to compare any difference between the two species. Overall,
55% of islets were of a mesenchymal origin when quail mesenchyme was used, whilst
only 11% of islets were of a mesenchymal origin when chick mesenchyme was used.
4.2.4 In vitro tissue culture
Each recombinant organ was first incubated overnight in vitro in a "two-dimensional"
("2-D") culture environment using 1% agarose in culture medium, covered with 2mls
culture medium in a humid environment containing 5% carbon dioxide (CO2) and
95% air at 37°C using a Galaxy R CO2 incubator (RS Biotech, Ayr, UK). Unless
stated otherwise, culture medium was always RPMI 1640 medium containing 10%
foetal calf serum, 1% 1-glutamine, and 0.3% penicillin / streptomycin (media and all
additives from PAA Laboratories, Linz, Austria). This overnight 2-D culture step




Further in vitro culture of the recombinants were then performed in a "three-
dimensional" ("3-D") roller culture apparatus (see figure 7) to complete a total culture
period of 7 days (modified after New and Cockroft, 1979). Roller culture permits true
3-D growth in microgravity conditions. Both 3-D growth (Affolter, Bellusci et al.
2003) and microgravity conditions (Spooner, Hardman et al. 1994; Rose, Crisera et al.
1999) have advantages over 2-D culture systems for studying complex tissue
development (such as the complex branching morphogenesis occurring during
pancreatic development). Each recombinant was transferred into its own individual
cylindrical glass bottle within the roller culture apparatus (BTC Engineering, Cambs,
UK). Each cylinder contained 4mls culture medium, which was exchanged for fresh
media every other day. Media were confirmed negative for exogenous insulin (<5.6
picomol/L), glucagon (<5.0 picomol/L) and amylase (<2 IU/L; Department ofClinical
and Laboratory Sciences, University of Oxford, UK) prior to use. The roller culture
apparatus rotated at 30rpm with continuous gas flow (atmospheric conditions as
above).
Figure 7 Roller culture apparatus
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Fig 7 Roller culture apparatus (BTC Engineering). Cylindrical glass containers containing
culture medium are shown mounted on a rotation frame (30rpm). The rotating frame is




Following in vitro culture, tissue was fixed for 2 hours using freshly-thawed
phosphate-buffered 4% paraformaldehyde (PFA) with addition of ethylene glycol
tetra-acetic acid (EGTA) 2mM, before washing in PBS. Tissue intended for
immunocytochemistry on sections was then incubated overnight with 30% sucrose in
PBS before frozen-embedding in Tissue-Tek optimum cutting temperature (OCT)
compound (Sakura Finetek, Thatcham, UK). Frozen tissue was sectioned at 7-10 pm
using a Bright cryostat (specimen temperature -18 °C ; chamber temperature -25 °C)
and placed on polysine-coated microscope slides (vWR International, Leics, UK). The
immunocytochemistry protocol was performed over three (or four) days:
Day One
The frozen sections (on polysine-coated slides) were thawed at room temperature and
rehydrated by incubation in PBS, before rinsing with PBT (Calcium Magnesium Free-
Phosphate Buffered Saline (CMF-PBS) containing 0.1% Triton-X). Slides were then
incubated in blocking buffer for 1 hour at room temperature. Blocking buffer
consisted of CMF-PBS containing 5% heat-inactivated goat serum, 0.5% Triton-X,
0.1% Tween-20 and 0.2% Bovine Serum Albumin. Slides were incubated overnight in
pre-absorbed primary antibody diluted in blocking buffer at 4 °C.
Day Two
The next day, the primary antibody was washed off with PBT washes and then
incubated in blocking buffer for 1 hour before further incubation overnight in




Following overnight secondary antibody incubation, tissues were thoroughly washed
(for up to 24 hours) in PBT before mounting in the nuclear stain 4,6-diamidine-2-
phenylindole dihydrochloride (DAPI; Roche, West Sussex, UK).
Primary antibodies: (1) mouse anti-quail antibody (QCPN 1:5 ; Developmental
Studies Hybridoma Bank [DSHB], IA, USA); (2) guinea-pig anti-insulin (1:2000 ;
Sigma, Dorset, UK); (3) rabbit polyclonal anti-ISL antibody (1:200; Abeam, UK).
The mouse anti-quail antibody, developed by BM and JA Carlson was obtained from
the Developmental Studies Hybridoma Bank (DSHB) developed under the auspices of
the National Institute of Child Health and Human Development (NICHD) and
maintained by The University of Iowa, Department of Biological Sciences, Iowa City,
IA, USA.
Secondary antibodies: (1) Alexa Fluor goat anti-mouse 594 (red) or 350 (blue; 1:1000
or 1:2000 ; Molecular Probes, Invitrogen, Paisley, UK); (2) Alexa Fluor goat anti-
guinea-pig 488 (green; 1:1000 or 1:2000 ; Molecular Probes, Invitrogen, Paisley,
UK); (3) Alexa Fluor goat anti-rabbit 594 (red; 1:1000 or 1:2000 ; Molecular Probes,
Invitrogen, Paisley, UK).
4.2.6 Fluorescence tissue microscopy
High resolution images (1024x1024 pixels) were captured using a Hammamatsu Orca
digital camera on a Zeiss Axioskop fluorescent microscope.
4.2.7 Analysis of insulin-producing cells
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Slides were analysed using fluorescence microscopy for antigen expression and
interpreted together with morphological appearance. Sections were cut at 7-10pm
thickness (approximately one cell thickness), unless stated otherwise. This was
performed in order to attribute antigen expression to the correct cell and also to ensure
that only those cells whose morphology and expression were in the sharpest focus in
any one focal plane were scored with respect to each antigen.
Embryonic origins of splenic insulin-producing cells were determined according to
co-expression of cytoplasmic insulin surrounding a QCPN nucleolus (within a 4,6 -
diaminobenzidine tetrahydrochloride (DAPI) nucleus). The QCPN stains the
nucleolus of all quail cells, and since all quail tissue was splenic in origin in these
experiments, we can identify insulin-producing cells of splenic origin in the
recombinants.
An initial analysis was performed, counting the number of recombinants containing
insulin-producing cells of splenic origin for each recombinant type. A further detailed
analysis was then performed of the number and origin of discrete insulin-producing
cell clusters within the recombinants. The embryonic tissue origins of insulin-
producing cells within all recombinant mini-organs and controls were classified as
epithelial, mesenchymal, or mixed origin. Insulin-producing cell (IPC) clusters of




A statistical analysis of the IPC clusters in each group was performed. The data was
of a binomial distribution. 95% confidence intervals of obtaining the true proportion
of IPC clusters with a mesenchymal contribution in our samples (including purely
mesenchymal origin and mixed origin) were calculated for each group. Following
this, the proportion of IPC clusters with a mesenchymal contribution in each group of
recombinants were compared (two-tailed tests of significance) to test the null
hypothesis that there is no significant difference between the proportion in each
group. Statistical significance was set at the 5% level.
4.3 Controls
An in vitro control for islet cell differentiation was provided by the differentiating
pancreatic epithelium within the recombinants. It was also essential to ensure and
confirm no contamination of the microdissected quail spleens with quail pancreas, in
order to prevent false positive results. This was achieved firstly by taking great care
during the microdissection steps to ensure clean separation (as previously discussed in
Chapter 3, section 3.2.2). In addition, a cuff of splenic tissue was left behind, attached
to the pancreatic mesenchyme, to ensure no pancreatic tissue contaminated the splenic
explants. Control for contamination was performed by removing representative
microdissected chick pancreatic epithelia and quail spleens at day zero. These
underwent overnight culture under the same conditions as the recombinants before
undergoing in situ hybridisation with the Tlx-1 probe (as a splenic marker; see Figure
8) and antibody immunocytochemistry for insulin (as a pancreatic marker). The in situ
hybridisation protocol is described in Chapter 5, section 5.2.7. Microdissected quail
spleens underwent simultaneous sectioning and immunocytochemistry steps with the
recombinants. In addition, the microdissected unused quail pancreas was also
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analysed before discarding this, to give an extra level of confidence over the safety of
the dissection margins. The chick pancreatic epithelium and the discarded quail
pancreatic tissue underwent the same procedure. Table 2 shows that the dissected
control quail spleens were positive for Tlx-1 and negative for insulin, confirming
clean separation, whereas the chick pancreatic epithelium was negative for Tlx-1 and
positive for insulin. Furthermore, the discarded quail pancreas contained a small cuff
of Tlx-1 positive splenic tissue on its distal aspect, giving additional confidence over
the safety of the dissection margins. Table 3 summarises all the splenic control data in
this thesis, using insulin, Tlx-1, Pdx-1 and Isl-1. This demonstrates no quail pancreatic
contamination.
Figure 8 Example of an embryonic quail spleen following Tlx-1 in situ hybridisation
Fig 8 Photograph of a microdissected embryonic quail spleen following wholemount Tlx-1 in
situ hybridisation. The blue indigo colour indicates a positive hybridisation with the Tlx-1
probe, confirming splenic tissue. Original magnification x4.
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Table 2 Tlx-1 in situ hybridisation and insulin antibody immunocytochemistry of controls
demonstrating no contamination of dissection margins, confirming clean separation. The quail
spleens were all negative for insulin, confirming no pancreatic contamination. A small cuff of
quail spleen was also left on the residual quail pancreas before discarding this (Tlx-1 positive
quail pancreas), giving additional confidence over the safety of the dissection margins.








Insulin antibody 0 39
Pdx-1 in situ 0 11
Tlx-1 in situ 17 0
Isl-1 antibody 0 6
Table 3 The number of microdissected quail spleen controls is shown for each
experiment, confirming clean separation. No insulin, Pdx-1 or Isl-1 was detected in




The results are summarised in Table 4. Examples of the insulin-producing cell clusters
of splenic origin seen under fluorescent microscopy are shown in Figures 9 and 10.
4.4.1 One quail spleen to one chick pancreatic epithelium recombinants
Recombining one quail spleen with one chick pancreatic epithelium yielded insulin-
producing cells (IPCs) of splenic origin in 5 of 12 recombinants (42%). A subsequent
detailed analysis revealed that the total number of IPC clusters in this group was 73,
giving an average value of 6 per recombinant. The majority of IPC clusters were of an
epithelial origin (63%), as would be expected from the pancreatic epithelia within the
recombinants. However, 14 (19%) were of a purely splenic origin and 13 (18%) were
of a mixed origin, giving 37% overall with a splenic contribution in this group (95%
confidence interval = 0.37 ± 0.12). This was significantly more than the two quail
spleens to one pancreatic epithelia recombinant group (37% vs 22%; p = 0.036) and
also significantly more than in the two quail spleens to two pancreatic epithelia
recombinant group (37% vs 13%; p = 0.0014).
4.4.2 Two quail spleens to one chick pancreatic epithelium recombinants
Recombining two quail spleens with one chick pancreatic epithelium yielded IPCs of
splenic origin in 3 of 9 recombinants (33%), a similar proportion to that found in the
one quail spleen to one chick pancreatic epithelium recombinant group (see Figure
11). The total number of IPC clusters in this group was 94, giving an average value of
10 per recombinant (see Figure 12). Again, the majority of IPC clusters were of an
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epithelial origin (78%), as expected. 18 (19%) were of a purely splenic origin and 3
(3%) were of a mixed origin, giving 22% overall with a splenic contribution in this
group (95% confidence interval = 0.223 ± 0.09). There was no significant difference
between this value and the 13% found in the two quail spleen to two chick pancreatic
epithelia group (p = 0.139).
4.4.3 Two quail spleens to two chick pancreatic epithelia recombinants
Recombining two quail spleens with two chick pancreatic epithelia yielded IPCs of
splenic origin in 4 of 5 recombinants (80%). This is approximately double the
percentage found in the one quail spleen to one chick pancreatic epithelium
recombinant group (42%). The total number of IPC clusters in this group was 62,
giving an average value of 12 per recombinant. The majority of IPC clusters were
again of an epithelial origin (87%). 3 (5%) were of a purely splenic origin and 5 (8%)
were of a mixed origin, giving 13% overall with a splenic contribution in this group
(95% confidence interval = 0.129 ± 0.092).
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Fig 9 Fluorescent immunocytochemistry of a splenic recombinant showing an example of an
IPC cluster of splenic origin within an islet morphology. A: Splenic quail nucleolar QCPN in
red, B: Cytoplasmic insulin in green, C: Nuclear DAPI in blue, D: Combined image showing
all three channels. This insulin-producing cluster of cells (B) is of splenic origin, as their
nucleoli are positive for QCPN (A). Original magnification x63; section thickness 7-10pm.
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Figure 10 Insulin-producing cell cluster of splenic origin within an islet morphology
(Example 2)
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Fig 10 Fluorescent immunocytochemistry of a splenic recombinant showing an example of
IPCs of splenic origin within an islet morphology. A: Splenic quail nucleolar QCPN in red, B:
Cytoplasmic insulin in green, C: Nuclear DAPI in blue, D: Combined image showing all three
channels. This insulin-producing cluster of cells (B) is of splenic origin, as their nucleoli are
positive for QCPN (A). Original magnification x63; section thickness 7-10pm.
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Figure 11 Bar-chart showing the percentage of recombinants containing IPCs of
splenic origin for each type of recombinant ratio
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Overall, 12 of the total 26 recombinants (46%) contained IPCs of splenic origin,
showing that the developing avian spleen is able to differentiate into insulin
producing cells. Furthermore, it is reasonable to suspect that these discrete IPC
clusters represent avian B-islets. These data support previous findings in this
laboratory that foregut mesenchymal tissue is able to differentiate into islet tissue
(Lear, Jayanthi et al. 2004). The ratio of splenic mesenchyme to chick pancreatic
epithelia does not appear to influence the percentage of recombinants in which this is
observed (42% vs 33%), suggesting that signals from the differentiating pancreatic
epithelium may be a key factor in this iMET process, as this remained the same in
these two groups. However, doubling the amount of each tissue proportionately
increases the percentage of recombinants in which this is observed (42% vs 80%). A
decision was made to construct all subsequent recombinants in this thesis using two
quail spleens to two chick pancreatic epithelia based on this preliminary data, showing
that the frequency of recombinants experiencing iMET increased proportionately.
However, a detailed subsequent analysis of the numbers of discrete IPC clusters
within each recombinant group later revealed that the percentage of IPC clusters with
a splenic origin contribution significantly decreased when either the ratio of
mesenchyme to epithelium, or the amount of tissue in each recombinant, was
increased (37% vs 22% vs 13%; see Figure 12). Therefore, although splenic iMET is
observed in a proportionately higher percentage of recombinants when the amount of
each tissue is increased, the actual percentage of IPC clusters in which iMET is
observed significantly decreases. Therefore, constructing recombinants with two
spleen and two epithelia may not be the optimal combination for future experiments.
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These data show that altering the ratio of mesenchyme to epithelium in the
recombinants alters the frequency of iMET observed, and altering the overall amount
of tissue in the recombinants alters the frequency of iMET observed.
These findings could be attributed to altered signalling between the two tissue types
within these recombinants. When the amount of each tissue is increased per
recombinant, it is reasonable to postulate that with increased tissue mass there are
more signals from the increased amount of pancreatic epithelium, and more splenic
mesenchyme upon which those signals can act. This might explain the increased
chance of iMET occurring in those recombinants (hence iMET observed in 42% vs
80% of recombinants). However, the actual decrease in iMET observed when IPC
clusters are counted suggests that this signalling process is more complex. It is
possible that the pancreatic epithelial signals can only reach a smaller amount of
mesenchyme in the larger sized recombinants, possibly through a reduced interface
between the two tissue types. Alternatively, the pancreatic epithelial signals may have
limited action on tissue that is not in direct contact with it and it is possible that the
contact between the mesenchyme and epithelium may be reduced in the larger
recombinants. It seems unlikely that the decrease in iMET is due to altered culture
conditions (lack of glucose or nutrient availability in the culture media, for example)
when the recombinant size increased, since the average number of IPC clusters
(irrespective of origin) per recombinant proportionately increased (an average of 6,
10, 12 IPC clusters per recombinant respectively). This proportionate increase would
be expected, as the amount of tissue per recombinant in each group is increasing,
although the iMET contribution itself decreases.
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An alternative explanation for these findings could be that some signalling is coming
from residual chick pancreatic mesenchymal tissue within the recombinant, rather
than coming exclusively from the pancreatic epithelia. Although great care was taken
during recombinant construction to cleanly separate chick pancreatic epithelia from
the chick pancreatic mesenchyme, some pancreatic mesenchymal cells may have
remained. Additional control studies would be required to demonstrate clean
separation of these tissues in order to investigate this. A further alternative
explanation to consider for these findings could be that splenic mesenchyme and
pancreatic epithelial cells within the recombinants undergo spontaneous fusion.
However, this is a very rare occurrence both in the chick-quail chimaera system
(Grzeschik 1973) and in mesenchymal beta-cell differentiation (Ianus, Holz et al.
2003), and would not account for the frequency of splenic iMET observed (discussed
further in Chapter 10).
Interestingly, the stomach, pancreas and splenic mesenchyme share a common
splanchnopleural mesodermal lineage (Matsushita 1995; Kumar, Jordan et al. 2003)
as well as common genetic regulators. As a result, the meso-epithelial relationship in
patterning these organs has been an area of intensive investigation for potential
therapeutic strategies. Interestingly, Hox-11 / Tlx-1 knockout mice are born without a
spleen and have a larger stomach and possibly pancreas, suggesting that the splenic
mesodermal cells contribute to these other organs when this gene is absent (Roberts,
Sonder et al. 1995). Recent experiments examining stomach mesenchyme have shown
that splenic rudiments become embedded within the pancreas if Barx-1 (a stomach
mesenchymal transcription factor) is knocked out (Kim, Miletich et al. 2007).
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Furthermore, the pancreatic and splenic mesenchymal marker Bapxl is required for
correct separation of these two organs (Asayesh, Sharpe et al. 2006).
The process of iMET seen in these experiments could be explained by a possible stem
cell population in the mesenchyme common to these tissues, which under particular
microenvironmental conditions is able to reprogram itself and pursue a fate other than
the tissue-specific one. It has also been suggested that non-haematopoietic stem cells
reside in the spleen (Chadburn 2000). Indeed, spleen-derived stromal cells express
osteoblast-specific genes when combined with a proliferating factor (FGF2) and a
differentiating hormone (dexamethasone) in the rat (Derubeis, Mastrogiacomo et al.
2003). The finding by Kodama et al that the spleen of adult mice contains a putative
mesenchymal stem cell population through persistent expression of Hox-11 supports
this theory, whilst providing a possible future role for translational therapeutic
strategies (Kodama, Davis et al. 2005). Hox-11 / Tlx-1 +ve cells possess key stem
cell characteristics by virtue of their capacity to self-renew and also to differentiate
into cells of multiple lineages (references within Lonyai, Kodama et al. 2008). As
previously mentioned (Chapter 2, section 2.4.1), this same group have also recently
published evidence that the adult human spleen uniquely possesses a reservoir of
multi-lineage adult stem cells that abundantly express Hox-11 / Tlx-1 throughout
adulthood (Dieguez-Acuna, Gygi et al. 2007). These may be an attractive cellular
target for future translational research.
Alternatively, the process of iMET from splenic tissue could be attributed to a process
of transdifferentiation. When the spleen is harvested for recombinations in the
experiments described here, progenitor cells have already condensed to make the
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spleen, adjacent to the stomach and dorsal pancreas. These differentiated cells may in
fact transform into the pancreatic endocrine lineage when a specific milieu is created
from recombining these spleens with pancreatic endocrine tissue. As previously
mentioned (Chapter 2, section 2.5), mice bearing a null allele of the PTFl-p48 gene
were born without an exocrine pancreas but harboured functional islets within the
spleen (Krapp, Knofler et al. 1998). Although it is possible these cells were epithelial
derived, one cannot rule out transdifferentiation of the splenic mesenchyme into
endocrine cells as an explanation for their findings.
4.5 Conclusion
In conclusion, these data show that splenic mesenchyme is able to undergo iMET.
This may be attributed to a possible stem cell population within the spleen or the
spleen may be a responsive target for transdifferentiation. However, this iMET
process does not occur in every recombinant and its frequency of occurrence may be
altered by altering the tissue constituents within the recombinant. The molecular
mechanisms behind this iMET process are investigated further in Section Three.
SECTION THREE
Determining the molecular mechanisms
behind islet Mesenchyme-to-Epithelial
Transition in the developing spleen
Chapter Five
Optimisation of an in situ hybridisation
protocol for Tlx-1 and characterisation of





Tlx-1 (previously known as Hox-11) is an essential transcription factor for the
specification of splenic fate during development (see Chapter 2, section 2.4.1), as
shown by gene knockout studies (Dear, Colledge et al. 1995; Roberts, Sonder et al.
1995). Mouse embryo studies have found Tlx-1 expression in the branchial arches,
pharynx, heart, hindbrain, pinna, external auditory meatus and the spleen during
development (Raju, Tang et al. 1993; Roberts, Shutter et al. 1994; Dear, Colledge et
al. 1995; Logan, Wingate et al. 1998). It is known to be expressed in the embryonic
mouse spleen from El 1.5 to E13.5, with weaker expression from E14.5 onwards
(Roberts, Shutter et al. 1994). Logan et al (1998) studied the expression of this gene
in the cranial sensory ganglia and hindbrain in chick embryos and reported that it was
also expressed in similar regions to that previously reported in the mouse, with
prominent expression from stage 20 onwards in the splenic primordium. However,
splenic Tlx-1 expression during normal chick development has not yet been fully
characterised. Expression is known to persist until birth in the mouse, and continues to
be expressed post-natally in the adult mouse spleen (Kanzler and Dear 2001). Also,
there is now evidence for continued expression of this early developmental marker in
CD45 -ve cells of the adult human spleen, as previously mentioned in Chapter 2,
section 2.4.1 (Kodama, Davis et al. 2005; Dieguez-Acuna, Gygi et al. 2007).
It was important at the beginning of this research project to have a splenic marker to
confirm the splenic origin of the tissue being harvested. This gene would also be a
useful splenic marker for the microdissected controls (to assess clean separation; see
Chapter 4, Tables 2 and 3). In addition, it would be interesting to study the expression
of this gene in the splenic mesenchyme when recombined with pancreatic epithelia in
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recombinant chimaeric mini-organs. Firstly, however, the normal expression profile
of Tlx-1 in the avian spleen would need to be characterised before any assessment of
its expression in chimaeric recombinant organs could be made. Therefore, the main
aims of the experiments in this chapter were to: (i) establish a working in situ
hybridisation protocol for Tlx-1, and (ii) characterise the normal avian splenic Tlx-1
expression profile during our developmental period of interest (E4-E11).
5.2 Methods
5.2.1 Solutions and equipment
Solution formulae are shown in Appendix III and / or within the relevant subsections.
Ultrapure distilled water (dFUO) was obtained from a Maxima USF Elga purification
unit (resistivity 18.2 MQ cm; USF Elga, Bucks, UK). To ensure absence of RNase
activity, solutions and equipment used for in situ hybridisation were made up using
RNase-free molecular biology grade water (ddH20) purchased from vWR
International (Leics, UK) and / or autoclaved for 20 minutes at 123°C before use
(Benchtop Compact 40; Priorclave, Gt Lon, UK).
5.2.2 Synthesis ofRNA probesfor in situ hybridisation
The Tlx-1 RNA probe was synthesised from a bluescript DNA plasmid containing the
chick Tlx-1 gene, a generous gift from Dr Cairine Logan, Department ofAnatomy and
Neuroscience Research Group, Faculty of Medicine, University of Calgary, Canada.
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5.2.3 Transformation and amplification ofchemically competent bacteria
Chemically competent, ampicillin resistant One Shot MAX Efficiency DH5a - T1R
Escherichia coli (Invitrogen, Paisley, UK) were transformed with probe plasmids
using a heat shock technique (30secs at 42°C), in accordance with the manufacturer
instructions.
Transformed bacteria were then incubated overnight on Luria-Bertani (LB) agar
plates containing 50mcg/ml 5-bromo-4-chloro-4-indolyl-beta-D-galactopyranoside
(X-Gal) and 0.1 % ampicillin in a humid environment containing 5% CO2 and 95% air
at 37°C. X-Gal is hydrolysed by bacterial beta-galactosidase to form an intense blue
precipitate, allowing blue-white colony selection. The inclusion of ampicillin prevents
incubation of contaminating bacteria. Individual blue colonies harbouring the plasmid
were then selected and amplified by overnight incubations in 5ml and then 1000ml
LB medium containing 0.1% ampicillin, shaking at 37°C.
5.2.4 Plasmid DNA purification and linearization
Amplified bacteria were lysed and the plasmid DNA was purified from the
supernatant using a Plasmid Maxi Kit (QIAGEN, Crawley, UK) according to
manufacturer instructions, available at:
http://wwwl.qiagen.eom/literature/handbooks/PDF/PlasmidDNAPurification/PLS_Plasmid/l
03463 7 HBQIAGENPlasmid_112005.pdf
Purified plasmid DNA was then cleaned and concentrated using a MinElute Reaction






Sequencing of the resultant DNA was performed to confirm correct alignment.
Plasmid DNA nucleotide sequences were obtained from the DNA Sequencing
Facility, Department of Biochemistry, University of Oxford. Alignment was assessed
using the online NCBI nucleotide BLAST engine (http://blast.ncbi.nlm.nih.gov
/Blast.cgi), see Figure 13.
Plasmid DNA was linearised by plasmid-specific restriction enzymatic digestion. Tlx-
1 plasmid DNA was linearised by treatment with Xba-1 restriction enzyme (New
England Biolabs, Herts, UK) buffered by NEBuffer 2 (New England Biolabs, Herts,
UK) for 2 hours at 37°C. Linearised DNA then underwent an additional clean and
concentration step as outlined previously. At the end of this MinElute Reaction Clean
Up Kit protocol, the eluted DNA was re-centrifuged back through the column as an
additional final step, in order to improve the yield.
5.2.5 RNA transcription
Linearised DNA was transcribed for 2 hours using digoxygenin (DIG)-UTP RNA
labelling mix (Roche, West Sussex, UK) and T7 RNA polymerase (Roche, West
Sussex, UK). Following this, the resultant RNA was cleaned and concentrated using
an RNeasy MinElute Cleanup Kit (QIAGEN, Crawley, UK) according to
manufacturer instructions, available at:
http://wwwl.qiagen.com/literature/handbooks/PDF/RNACleanupAndConcentration/RNY_Mi
nElute_Cleanup/l023 760 HBRNYME0303WW.pdf
Figure 13 Sequence alignment of Tlx-1 plasmid
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P'mid 67 CTTTTATTTCTCGTTTCCACATAAATTACACAAGCACTTTATAAAATGAATACACAGAAA 126
I II I I I I I II I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I II I I I I I I I I I
G'nome 24305 CTTTTATTTCTCGTTTCCACATAAATTACACAAGCACTTTATAAAATGAATACACAGAAA 24364
P'mid 127 ACACCTTATAAGTGCATAACTTAAAAAAAAAAAAGCCTTAAAAAAATCTCACTGAAAATA 186
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I II I I I I I I I I I I I I I I I
G'nome 24365 ACACCTTATAAGTGCATAACTTAAAAAAAAAAAAGCCTTAAAAAAATCTCACTGAAAATA 24424
P'mid 187 GGTTTTCTGCTCGCTTGCCTGTACTAGCTGTTTAAACTGGCAGTGCTGTTTTAGATTATA 246
I I I I I I I I I I I I I II I I I I I I I I I I II I I I I I I I I II I I I I I I II I I I I I I I I I I I I II I
G'nome 24425 GGTTTTCTGCTCGCTTGCCTGTACTAGCTGTTTAAACTGGCAGTGCTGTTTTAGATTATA 24484
P'mid 247 AGTAACTGAAAAATATATACTGTATATATAATATCTATATATTCCCGGCGTTTGCTATAG 306
I I I I I I I I I I I I II I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I 1
G'nome 24485 AGTAACTGAAAAATATATACTGTATATATAATATCTATATATTCCCGGCGTTTGCTATAG 24544
P'mid 307 GAAGTGCTTAATTGTGTCTCATTCCCTCAGAACAATTAAAGAAACAACAAAGTCGGAAGT 366
I I I I I I I I I I I I I I I II I I I I II I I I I I I I I I I I I I I I I I I I I II I II I I I I I I I I I I I I
G'nome 24545 GAAGTGCTTAATTGTGTCTCATTCCCTCAGAACAATTAAAGAAACAACAAAGTCGGAAGT 24604
P'mid 367 GAAATCCATTTTCACCCTCGCAAACCTCCTGCCTCATCAAGGGACGCGGGTAGAGCAACC 426
I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I
G'nome 24605 GAAATCCATTTTCACCCTCGCAAACCTCCTGCCTCATCAAGGGACGCGGGTAGAGCAACC 24664
P'mid 427 CGTGGGGCCGCGCTTTGCAAATGATATGGAAATAACCCATGGAACGGAGCAGCAGCACCC 486
I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
G'nome 24665 CGTGGGGCCGCGCTTTGCAAATGATATGGAAATAACCCATGGAACGGAGCAGCAGCACCC 24724
P'mid 487 CTGCCCAGCGCCGCCGGGCTCTCCTGGTTATTAAAGCTCGGGCTGATCGGCGCCGTGGCG 546
I I I I I I I I I I I I I I III I I I I I I I I I I I III I II I I I I I I I I I I I I II I II I I I III I I I
G'nome 24725 CTGCCCAGCGCCGCCGGGCTCTCCTGGTTATTAAAGCTCGGGCTGATCGGCGCCGTGGCG 24784
P'mid 547 GCCGGGGACAGTTTGGGCTCTTCGTGCAATTGAGATATCACATTTACCGTCCTCAGGAGG 606
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I II I I I I I I I I
G'nome 24785 GCCGGGGACAGTTTGGGCTCTTCGTGCAATTGAGATATCACATTTACCGTCCTCAGGAGG 24844
P'mid 607 CTGTCAGTTCCTTCGCTGCTTCCCCCCTCGCAGGAAAAAA-TTAATGAAAAAGGGGAGGA 665
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I
G'nome 24845 CTGTCAGTTCCTTCGCTGCTTCCCCCCTCGCAGGAAAAAAATTAATGAAAAAGGGGAGGA 24904
P'mid 666 GACGCCGCTAGGTGAGGTCCGAAGGGCTGCCTGCTGCCGCCAGCACAAATTGCTGCTGGG 725
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
G'nome 24905 GACGCCGCTAGGTGAGGTCCGAAGGGCTGCCTGCTGCCGCCAGCACAAATTGCTGCTGGG 24964
P'mid 726 AGGCCAAGAGACGGGTGGCTTTCTCCATGTGTTGCGTCCCCAAACGTCTCCAGCGCCAAG 785
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I
G'nome 24965 AGGCCAAGAGACGGGTGGCTTTCTCCATGTGTTGCGTCCCCAAACGTCTCCAGCGCCAAG 25024
P'mid 786 GGCCCGGCGCGGTGCCTGGCTGCACAAACACGCTTCC-AAGGAGCCGTGTCCTTTTGTTC 844
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
G'nome 25025 GGCCCGGCGCGGTGCCTGGCTGCACAAACACGCTTCCCAAGGAGCCGCGTCCTTTTGTTC 25084
P'mid 845 CGATCAGTCCAAAGCGCGTACCGATAGACGCGCGTTATATATACATACAGTCCTACGGGG 904
I I I I I I I I I I I III I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I II I I I I I
G'nome 25085 CGATCAGTCCAAAGCGCGTACCGATAGACGCGCGTTATATATACATACAGTCCTACGGGG 25144
P'mid 905 TGCCTCCAGCCCTGCAG 921
G'nome 25145
I I I I I I I I I I I I I I I I I
TGCCTCCAGCCCTGCAG 25161
Fig 13 Tlx-1 plasmid sequence alignment against the Gallus gallus chick genome, using the
online NCBI nucleotide BLAST engine. The Tlx-1 probe was a kind gift from Cairine Logan
(1998, Journal of Neuroscience; 18:5389-5402), and consisted of an -800 base pair sequence
entirely contained within the 3' untranslated region of the gene (chromosome 6;
NW_001471720). Alignment against the genome confirmed Tlx-1 identity, with 99%
homology to this region (identities= 854 / 857, GenBank accession number AF071874).P'mid
= plasmid sequence, G'nome = untranslated region of Tlx-1 from Gallus gallus genome.
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5.2.6 Avian embryonic tissue procurement and dissection
Fertile chick (Gallus domesticus, hybrid Joice/Hill; Winter Egg Farm, Royston, Herts,
UK) eggs were incubated at 37°C in a humid environment for the required gestation.
Developmental stage of the embryos was determined according to Hamburger and
Hamilton staging (Hamburger and Hamilton 1951) ; see also Appendix IV). The
embryos were removed from the eggs and placed in chilled (4°C) Leibovitz's L-15
medium (Invitrogen, Paisley, UK). Intact abdominal organ blocks were then
microdissected from the embryo, using a Leica MZ-16 dissecting microscope and
electronically sharpened tungsten needles. All embryonic manipulation was
performed under sterile conditions and in accordance with United Kingdom Home
Office regulations under the Animals (Scientific Procedures) Act 1986. Abdominal
organ blocks typically included the stomach, liver, pancreas, kidneys, spleen and
foregut. These organ blocks were fixed for at least 2 hours using freshly-thawed
phosphate-buffered 4% paraformaldehyde (PFA), with addition of EGTA 2mM. The
fixed tissue was then washed in PBS before slowly dehydrating the tissue down a
methanol series (25%, 50%, 75%, 100%) diluted in CMF-PBS, and stored at -20°C
overnight, or until later required for in situ hybridisation
5.2.7 Whole-mount in situ hybridisation
Hybridisation was performed with digoxigenen (DIG) - labelled riboprobes (modified
after Nieto et al., 1996). Details of solutions are given in Appendix III: Supplemental
solution information. Hybridisation experiments included positive and negative
controls. Strict RNase-free conditions (gloves, RNase-free solutions etc) were
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observed during the in situ hybridisation, especially on Day One of the protocol. The
in situ hybridisation protocol was performed over a three (or four) day period:
Day One
The tissue stored in 100% methanol at -20°C were rehydrated back down the
methanol series and washed twice in PBT (10 minutes for each wash). The tissues
were prepared for hybridisation with 20 minutes incubation in lOpg/ml proteinase K
in PBT, followed by two PBT washes (5minutes each). The tissue was subsequently
fixed in 4% PFA with 0.2% glutaraldehyde for 20 minutes and washed twice in PBT
(10 minutes each). The tissue was then washed for 10 minutes in prehybridisation
buffer at 70 °C, before incubating in prehybridisation buffer for 2 hours at 70 °C.
Following this, the tissue was incubated overnight in 1 pg / ml digoxigenen (DIG)
labelled mRNA probe at 70 °C.
Day Two
Following overnight hybridisation, tissues were washed the next day at 70 °C in the
following solutions (5 minutes for each wash): 100% Solution 1, then 75% Solution 1
: 25% 2x SSC (3M sodium chloride, 300mM tri-sodium citrate dihydrate), then 50%
Solution 1 : 50% 2x SSC, then 25% Solution 1 : 75% 2x SSC. Following this, two 30
minute washes were carried out at 70°C in 2x SSC + 0.1% CHAPS (3-[(3-
Cholamidopropyl) dimethylammonio]-l-propanesulfonate) followed by two 30
minute washes at 70°C in 0.2x SSC + 0.1% CHAPS. Two 10 minute washes in TBTx
at room temperature were performed followed by incubation in blocking solution for
2-3 hours (10% sheep serum, 2% Bovine Serum Albumin, in TBTx), before
Chapter 5
Page 125
incubating overnight in sheep anti-DIG alkaline phosphatase-conjugated antibody
(1:200; Roche, West Sussex, UK) at 4°C.
Day Three
Following overnight incubation, the antibody was thoroughly washed off for at least
ten washes (30 minutes each) at room temperature in TBTx containing 0.1% Bovine
Serum Albumin. The tissue could optionally undergo further overnight washes in
TBTx and 0.1% BSA (at 4°C), as additional washing off of the antibody helps to
reduce "background" staining during the colour reaction. The tissue was then washed
three times in AP buffer before incubating in the dark in a colour reaction solution
containing NBT (nitro blue tetrazolium chloride) and BCIP (5-bromo-4-chloro-3-
indolyl phosphate , toluidine salt). When the colour had developed (dark blue/indigo
t
colour), colour visualisation was enhanced by transferring into fresh PBT, before
fixation in fresh phosphate-buffered 4%PFA.
5.2.8 Bright-field microscopy
High-resolution (2560x1920 pixels) interpolated RGB images were captured using a
Micropublisher 5MP RT digital camera mounted on a Zeiss Axioskop microscope
5.2.9 Tlx-1 expression during normalforegut development
Materials and methods were all as previously described. Chick embryos were
harvested for embryonic days 4 to 11 (Hamburger-Hamilton stages 23 to 37) and Tlx-
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1 in situ hybridisations were performed on their abdominal organ blocks. Following
this, abdominal organ blocks were sectioned (12pm) for each developmental day.
Figure 14 Chemical structure of EGTA
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5.3 Optimisation of a protocol for Tlx-1 in situ hybridisation
The successful in situ hybridisation protocol described in section 5.2.7 is a modified
protocol from that previously used in this laboratory. The previous unmodified
laboratory protocol had successfully been used with other probes (Shh, Barxl, Pdxl)
and so was also initially performed for the Tlx-1 probe on E3-E8 chick and quail
embryos. However, although expression in other Tlx-1 expressing regions was present
(pharyngeal arches, heart etc.), splenic expression was very weak and variable.
Initially this was thought to be due to poor penetration of the probe through the body
wall to reach the spleen. This was addressed by dissecting out the abdominal organ
block from the embryo and performing the in situ hybridisation on this excised tissue.
However, splenic expression remained poor and so the in situ was repeated using
freshly re-transcribed Tlx-1 (transcribed RNA was confirmed adequate using gel
electrophoresis and measuring the Optical Density using spectrophotometry) and
using freshly made solutions, but again with only weak expression and only on the
periphery of the spleen, but strong gut endodermal Shh positive control expression
(Apelqvist, Ahlgren et al. 1997). Therefore, transformation of new DH5 competent
cells with the Tlx-1 plasmid was undertaken, followed by amplification and
linearization to produce fresh Tlx-1 DNA, before transcribing fresh Tlx-1 RNA probe
(DNA or RNA produced at each stage was again confirmed adequate by gel
electrophoresis and spectrophotometry). The Tlx-1 plasmid sequence was correctly
aligned, confirming that this was the correct sequence for Tlx-1 (see Figure 13).
However, repeat in situ hybridisation with this probe was again very poor, but strong
distinct positive control expression in the stomach was seen using the stomach
mesenchymal marker Barx-1 (Kim, Buchner et al. 2005).
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The in situ hybridisation protocol itself was then modified, incorporating additional
steps from in situ hybridisation protocols in the literature (Wilkinson 1992; Streit and
Stem 2001; Hargrave, Bowles et al. 2006). This produced excellent distinct splenic
staining, indicating that the degree of success with this probe was dependent on the
type of protocol used. This modified protocol involved the ubiquitous addition of
Ethylene Glycol Tetra-acetic Acid (EGTA; see Figure 14) to all 4% PFA fixative
used. In addition, 0.2% glutaraldehyde was also added to the fixative used on Day
One. 5% Poly Vinyl Alcohol (PVA) was initially also added to the AP buffer on Day
Three of the protocol. However, the in situ worked as clearly without PVA as it did
with, and so this was subsequently omitted from the final modified in situ
hybridisation protocol. Different post-harvesting fixation periods were also finally
compared (1 hour, 2 hours, 6 hours and 24 hours), as this has been reported as a
crucial factor for the quality of the final in situ hybridisation signal (Streit and Stem
2001). However, no difference was observed with different fixation times, with either
Tlx-1 or Barx-1 in situ hybridisations (all in situ's performed equally well with
different fixation periods).
This new successful modified in situ hybridisation protocol is detailed in the previous
section (Section 5.2.7). This protocol also worked very well with other probes used in
our laboratory for in situ hybridisation reactions (including Pdx-1 and Barx-1) and is
now the preferred protocol for in situ hybridisations in our laboratory.
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5.4 Tlx-1 expression during normal avian foregut development
Tlx-1 was expressed in the spleen of all abdominal organ blocks at each
developmental stage analysed (see Table 5 and Figure 15). It was only expressed in
the spleen, with no expression observed in other abdominal viscera or surrounding
tissues. Interestingly, the spleen begins in a caudal position in relation to the stomach
until E6 but then gradually assumes an increasingly rostral position relative to the
stomach, until it achieves a position cranial to the stomach by E9.









4 23/24 5 +
5 27 4 +
6 28/29 8 +
7 30 6 +
8 34 6 +
9 35 9 +
10 36 8 +
11 37 6 +
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Left panels (black background):
Dorsal whole-mount view of
inicrodissected chick embryo
abdominal organ blocks after
Tlx-1 in situ hybridisation on the
indicated days of development.
The spleen is stained in blue in
each image (also identified by
arrow), in close proximity to
adjacent stomach (st).
Scale bars 1mm.
Right panels (light background):
Cross-sections (12pm) through
chick embryo abdominal organ
blocks after Tlx-1 in situ
hybridisation for each indicated
day of development; the spleen






The Tlx-1 in situ hybridisation protocol was successfully optimised through two
combined protocol modifications; the ubiquitous addition of EGTA to the fixative and
addition of glutaraldehyde to the fixative on Day One of the protocol.
EGTA is a calcium chelator which specifically binds Ca 2+ ions. This is in comparison
to another chelator Ethylene Diamine Tetraacetic Acid (EDTA), which chelates a
wide range of divalent cations but with less affinity specifically for calcium. EGTA
also stabilises the pH. Historically, EGTA has been widely used in fixatives as it was
thought to help cytoskeletal stabilisation. The cytoskeleton is very dynamic and
sensitive to changes in the chemical and mechanical environment. EGTA helps to
inhibit enzymes and so halts cellular activity, thus preserving the cellular structure and
so optimising the in situ hybridisation signal. EGTA's enzyme-inhibiting effect may
also inhibit RNase activity, thus improving the in situ hybridisation signal.
Interestingly, EGTA has previously been reported to inhibit nucleases (Wang and
Gegenheimer 1990) and there has been a report that RNase activity is Ca2+ dependent
(Gbenle and Akinrimisi 1984). Decalcification has also been previously reported to
improve the sensitivity of fluorescent in situ hybridisation techniques using EDTA
(Brown, Edwards et al. 2002; Martinez-Ramirez, Cigudosa et al. 2004; Korac, Jones
et al. 2005), through preservation of the DNA (Brown, Edwards et al. 2002). An
alternative explanation for the improved in situ hybridisation signal could be that
removing calcium from the cell membrane permits increased pore size formation
(during the Proteinase-K step), thus improving probe access to the mRNA. However,
EGTA may have some detrimental effects when used to fix certain plant tissues
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(Wang, Liu et al. 2005), which may partly explain why it has not continued to be so
widely used for in situ protocols.
Glutaraldehyde is a fixative which helps to preserve the cell structure. It forms cross¬
links with proteins in close proximity to help protect the mRNA. It has been reported
to improve detection of gene expression when used in the fixation step (Ma, Rogers et
al. 2002), and has been used as a fixative in past in situ hybridisation protocols in the
literature (Godard and Jones 1980; Paeratakul, De Stasio et al. 1988; White and
Gorovsky 1988). However, its use may have declined owing to its potentially harmful
toxic properties.
Optimal tissue fixation is known to be important in gene expression studies and
results can vary according to variations in the fixative type, temperature and duration
of fixation (Streit and Stern 2001; Ma, Rogers et al. 2002). Interestingly, no difference
was observed in the quality of the final in situ hybridisation signal with different
fixation times in these experiments.
PVA has been reported to enhance the detection of low abundance transcripts in quail
embryos during in situ hybridisation reactions (Barth and Ivarie 1994). However, we
found the addition of this to be unnecessary, as we discovered that the protocol
continued to work excellently when this agent was omitted.
Tlx-1 is normally expressed within the developing chick spleen throughout the
developmental period studied (E4-E11). This is in keeping with a previous study in
the literature describing its expression in the mouse (Dear, Colledge et al. 1995;
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Kanzler and Dear 2001). It is also known to be expressed in other regions of the
embryo, such as the branchial arches, pharynx, heart, hindbrain, pinna and external
auditory meatus (references in Chapter 2, section 2.4.1). However, there is no
expression in other abdominal viscera or surrounding tissues, and this is confirmed in
this study. This makes it a very useful spleen-specific developmental marker for use
in this thesis. Now that Tlx-1 expression has been characterised during normal splenic
development, the regulation of this gene can be studied in the splenic mesenchyme of
chimaeric recombinant organs, together with genes responsible for islet development.
5.6 Conclusions
The Tlx-1 in situ hybridisation reaction was successfully optimised through
modifications to the protocol. This involved the ubiquitous addition of EGTA to all
fixative used, plus addition of glutaraldehyde to the fixative on Day One of the in situ
protocol.
Tlx-1 is normally expressed within the developing chick spleen throughout the
developmental period studied (E4-E11). There is no expression in other abdominal
viscera or surrounding tissues, making it a very useful spleen-specific developmental
marker for use in this thesis. Now that splenic Tlx-1 expression has been characterised
during normal development, the regulation of this gene can be studied in the splenic
mesenchyme of chimaeric recombinant organs, together with genes responsible for
islet development. This is investigated in the following chapters.
Chapter Six






An understanding of the molecular mechanisms underlying islet MET in the spleen
would be of scientific interest on its own merit, but is clearly crucial if the potential
for use in future therapeutic strategies for Diabetes Mellitus is to be harnessed. It is
becoming increasingly evident that in order to persuade pluripotent cells to undergo
islet cell differentiation, carefully coordinated provision of islet developmental cues
are required (Miyazaki, Yamato et al. 2004; Brolen, Heins et al. 2005; Santana,
Ensenat-Waser et al. 2006; Treff, Vincent et al. 2006; Roche, Ensenat-Waser et al.
2007; Saitoh, Yamato et al. 2007; Vaca, Berna et al. 2008). To inform the design of
future differentiation strategies, the aim of this chapter (and subsequent chapters) was
to examine the molecular mechanisms behind iMET. This was also important in
understanding why splenic insulin expression was not observed in all recombinants,
but whether there might be a spectrum of splenic tissue reprogramming, with insulin
expression only being observed when the tissue had been fully reprogrammed.
The aim of this chapter was to investigate whether the key splenic transcription factor
Tlx-1 (see Chapter 5) continued to be expressed by the splenic mesenchyme within
chimaeric recombinant organs, or whether the splenic mesenchyme was
reprogrammed when recombined with pancreatic epithelium. The following
hypothesis was generated: Tlx-1 is down-regulated in the splenic mesenchyme of
chimaeric recombinant organs. Interest in this idea arose from previous investigation
into avian pancreatogenesis in this laboratory, which found a down-regulation of the
stomach mesenchymal transcription factor Barx-1 when stomach mesenchyme was
recombined with pancreatic epithelium (unpublished). In addition, previous attempts
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to recapitulate renal MET have shown that mesenchymal stem cells are only
competent to differentiate into renal epithelium when reprogrammed by signals from
the differentiating epithelial ureteric bud (Yokoo, Ohashi et al. 2005).
6.2 Methods
Recombinants were generated as detailed previously (2 quail spleens recombined with
2 chick pancreatic epithelia) and cultured for 7 days before fixation. Microdissected
quail spleen controls were fixed either at day 0 or day 1 of in vitro culture, since
previous experience had found that mesenchymal cells cultured alone (in the absence
of epithelium) do not tolerate in vitro conditions well (and certainly not surviving
much beyond one day).
Following in vitro culture, wholemount in situ hybridisation for Tlx-1 was performed
as previously described, but with the addition of a 30 minute incubation of the tissue
in 6% Hydrogen Peroxide in PBT, followed by two 5 minute washes in PBT, before
the proteinase K step (on Day One of the protocol). This step was added to quench
endogenous peroxidase activity.
Following the in situ hybridisation, the tissue underwent further fixation (limited to
one hour). Fixative was washed off with PBS before incubating overnight with 30%
sucrose in PBS. The tissue was then frozen in Tissue-Tek OCT compound (Sakura
Finetek, Thatcham, UK), sectioned (10 microns thickness) and placed on polysine-
coated microscope slides (vWR International, Feics, UK) ready for
immunocytochemistry with a QCPN peroxidase reaction. Controls also underwent
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wholemount in situ hybridisation for Tlx-J before further fixation, sectioning and
analysis. Since the splenic tissue was all quail in origin, it was not necessary to
routinely perform QCPN peroxidase reactions on these.
6.2.1 QCPNperoxidase reaction protocol
Following sectioning, the slides were washed in PBS then PBT before incubation in
blocking buffer (as described previously) for 60 minutes. The slides were then
incubated in QCPN primary antibody in blocking buffer (1:5) overnight. The antibody
was washed off the next day. After this, a modified VECTASTAIN Elite Mouse IgG
ABC kit protocol (Vector Laboratories, Peterborough, UK) was used: The primary
antibody was washed off with PBS and then the slides were incubated in diluted
biotinylated secondary antibody solution for 30 minutes. The secondary antibody was
washed off in PBS multiple times before incubating for a further 30 minutes in
VECTASTAIN Elite ABC reagent. The slides then underwent multiple washes in
PBS before using a DAB (3,3-diaminobenzidine) Substrate Kit for Peroxidase (Vector
Laboratories, Peterborough, UK) to perform the peroxidase substrate solution
incubation. Only approximately 10 seconds peroxidase incubation were required for
the brown stain intensity to occur. The peroxidase solution was then promptly washed
off in tap water (as it contains nickel, which improves the stain). Slides were mounted
in DPX (distyrene plasticiser xylene mixture) mountant before inspecting under a
bright-field microscope.
All chimaeric recombinant mini-organs and controls were analysed using bright-field
microscopy for antigen expression, interpreted together with morphological criteria.
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Tlx-1 expression was analysed by recording whether the QCPN +ve regions (brown)
had Tlx-1 +ve expression (blue) or not, and QCPN regions could then be classified as
either Tlxl +ve or -ve, or a "mixed" region if there was mixture of Tlx-1 +ve and Tlx-
1 -ve areas within the QCPN +ve region.
6.3 Tlx-1 is down-regulated in splenic mesenchyme during iMET
Nine spleen recombinants were produced (two quail spleens recombined with two
chick pancreatic epithelia) and eleven quail spleen controls (six were fixed at day 0 in
vitro culture and five underwent 1 day culture before fixation). All the controls were
positive for Tlx-1 (see Figures 16(b) and 16(c)). In addition, 8 quail abdominal organ
blocks underwent simultaneous Tlx-1 in situ hybridisation (as a positive and negative
control) and showed distinct positive splenic expression, with negative expression in
all other regions of the abdominal organ block. No Tlx-1 expression was detected in
any of the recombinants (see Table 6), showing that the splenic mesenchyme in the




Figure 16 Comparison of Tlx-1 expression in a splenic recombinant and spleen
controls
Fig 16(a)
Fig 16(a) No blue Tlx-1 expression seen in the splenic mesenchyme within a recombinant.
M = brown QCPN nucleoli (splenic tissue); E = pancreatic epithelium; the super-imposed
dashed line delineates the boundary between epithelium and mesenchyme in this section;
10pm section thickness, scale bar 10pm.
Figl6(b)
Fig 16(b) An example of combined Tlx-1 and QCPN expression in a splenic mesenchyme
control (high power magnification). Tlx-1 in situ hybridisation is shown in blue and QCPN in
brown. The in situ hybridisation was performed alongside the recombinant in situ




Fig 16(c) Tlx-1 expression seen in a splenic mesenchyme control. The splenic tissue was all
of quail origin and so a QCPN peroxidase step was not routinely required in the controls. This
image shows a positive control for the Tlx-1 in situ hybridisation and was performed
alongside the recombinant in situ hybridisation reaction. 10pm section thickness, scale bar
10pm.






with some Tlxl +
area ("mixed")
1 + - -
2 + - -
3 + - -
4 + _ _
5 +
6 + - -
7 + - -
8 + - -
9 + - -
Table 6 showing which splenic recombinants had regions of combined Tlx-1 +ve and QCPN
+ve expression. No combined expression was detected, demonstrating dramatic down-




There was dramatic down-regulation (100%) of Tlx-1 in all the recombinants in this
series. We would normally expect splenic mesenchyme to express Tlx-1 at this stage
of gestation in vivo (Ell; see Chapter 5, Figure 15). Therefore, the complete down-
regulation of this transcription factor is due to recombining the mesenchyme with the
pancreatic epithelium and is most likely to be mediated via signals received from the
differentiating pancreatic epithelium. It is unlikely to be an epiphenomenon arising
from tissue manipulation or culture conditions, although recombination of splenic
mesenchyme with non-pancreatic epithelia would need to be performed to confidently
exclude this. It would also be helpful to perform a viability assay on the recombinant
tissue following the roller culture as a further additional control study to ensure the
apparent 100% down-regulation was not due to the cells being damaged during the
culture period. However, this would seem unlikely given that insulin, pdx-1 and isl-l
were all seen to be expressed by the cells at the end of the same culture period (see
Chapters 4, 7 and 8). It is interesting to note that previous experiments in this
laboratory studying Barx-1 down-regulation in stomach mesenchyme, when
recombined with either pancreatic epithelia or stomach epithelia, have shown that the
mesenchyme is reprogrammed specifically through recombination with pancreatic
epithelia (unpublished data). It is very likely that the same principle applies with
splenic mesenchyme and that recombination of the splenic mesenchyme with another
tissue (in this case pancreatic epithelium) is required to re-program the mesenchyme
to no longer express the splenic transcription factor Tlx-1.
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Tlx-1 gene knockout studies show that expression of this gene is essential for splenic
development, possibly via increased proliferation of mesenchymal cells or reduced
apoptosis (see Chapter 2, section 2.4.1). The role of Tlx-1 in proliferation is consistent
with reports that Hox-11 +ve human acute lymphoblastic leukaemia (ALL) is caused
by a translocation on chromosome 10. This translation breaks-off Hox-11 from
upstream regulation, resulting in uncontrolled proliferation of Hox-11 target genes
(Dube, Kamel-Reid et al. 1991; Hatano, Roberts et al. 1991; Kennedy, Gonzalez -
Sarmiento et al. 1991). Taken together, this evidence suggests that Tlx-1 has a
proliferative role (Lonyai, Kodama et al. 2008). This stem-cell like property may
mean that cells expressing this gene are amenable to manipulation for regenerative
cellular therapies. As previously mentioned (Chapter 2, section 2.4.1), there is also
evidence for continued expression of this early developmental marker in CD45 -ve
cells of the normal adult human spleen (Kodama, Davis et al. 2005; Dieguez-Acuna,
Gygi et al. 2007), which may be useful in future therapeutic strategies if such a cell
source can be manipulated using human splenic tissue. A promising and ethical future
strategy might be to use mature Tlx-\ expressing splenic tissue from the diabetic
patient for autologous transplant (following in vitro manipulation into islets) to treat
their diabetes, which may limit or reduce the need for immunosuppression currently
required for an allograft (Kodama, Davis et al. 2005; Robertson, Rowan-Hull et al.
2008). This would need to be balanced against any potential safety risks with this
gene, given its association with ALL. However, Tlx-1 is known to be expressed in
normal adult human spleens and the tumorigenesis in ALL is due to translocation
from its upstream regulatory genes. Furthermore, the experiments in this chapter





The results suggest that Tlx-1 is down-regulated in splenic mesenchyme when
recombined with pancreatic epithelia. This is a complete down-regulation (100%) and
indicates that the splenic mesenchyme is being genetically reprogrammed into an
alternative non-splenic fate. The next two chapters investigate whether the pancreatic
transcription factors Pdx-1 and IsI-J are up-regulated in this tissue.
Chapter Seven






The aim of this chapter was to investigate whether the homeodomain transcription
factor Pdx-1 was expressed by the splenic tissue within chimaeric recombinant
organs. Pdx-1 expression is extremely important for pancreatic organogenesis and is
considered the pancreatic "master gene". It is expressed by all pancreatic epithelial
precursors and null expression results in a failure of pancreatic development in mice
(Jonsson, Carlsson et al. 1994). During mouse development, Pdx-1 expression begins
at E8 (Ohlsson, Karlsson et al. 1993; Guz, Montminy et al. 1995; Li, Arber et al.
1999), before the onset of pancreatic bud formation and islet hormone gene
expression. Pdx-1 is initially expressed broadly in the primitive posterior foregut, with
pancreas development being initiated only in a restricted region of Pdx-1 expressing
posterior foregut in which endodermal Shh expression is repressed. Interestingly,
when Shh is artificially inhibited with a Shh blocker, pancreatic expansion is
promoted but also with ectopic pancreatic endocrine and exocrine structures
developing in regions adjacent to the pancreas, such as the stomach and duodenum
(Kim and Melton 1998). Once the pancreas has differentiated, Pdx-1 expression is
restricted to beta-cells, where it transactivates the insulin promoter (Ohlsson, Karlsson
et al. 1993). Pdx-1 is not expressed in foregut mesenchyme (Ahlgren, Jonsson et al.
1996). It was therefore important to determine whether the splenic mesenchyme was
being reprogrammed to express this pancreatic gene in our chimaeric recombinants.
This chapter addresses the hypothesis that Pdx-1 is up-regulated in the splenic




Recombinants were generated as detailed previously (2 quail spleens recombined with
2 chick pancreatic epithelia) and cultured for 7 days before fixation. The previously
described wholemount in situ hybridisation was performed using a Pdx-1 probe, with
the addition of a 30 minute incubation of the tissue in 6% Hydrogen Peroxide in PBT,
followed by two 5 minute washes in PBT, before the proteinase K step (on Day One
of the protocol). This step was added to quench endogenous peroxidase activity. The
Pdx-1 RNA probe was synthesised from a bluescript DNA plasmid containing the
chick Pdx-1 gene, a generous gift from Dr A. Grapin-Botton, Swiss Institute for
Experimental Cancer Research (ISERC), Lausanne, Switzerland. The methodology
was the same as that detailed previously, with the following exceptions during the
generation of the Pdx-1 probe; (i) The Pdx-1 plasmid DNA was linearised by
treatment with Hindlll restriction enzyme (New England Biolabs, Herts, UK)
buffered by NEBuffer 2 (New England Biolabs, Herts, UK) for 2 hours at 37°C; (ii)
During RNA transcription, linearised DNA was transcribed for 2 hours using
digoxygenin (DIG)-UTP RNA labelling mix (Roche, West Sussex, UK) with T3
(rather than the T7 used for Tlx-1).
Following the in situ hybridisation, the tissue underwent further fixation (limited to
one hour). Fixative was washed off with PBS before incubating overnight with 30%
sucrose in PBS. The tissue was frozen in Tissue-Tek OCT compound (Sakura Finetek,
Thatcham, UK), sectioned (10 microns thickness) and placed on polysine-coated
microscope slides (vWR International, Leics, UK) ready for immunocytochemistry
with a QCPN peroxidase reaction. The QCPN peroxidase reaction was performed as
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previously described. Controls also underwent wholemount in situ hybridisation for
Pdx-1 before further fixation, sectioning and analysis.
All chimaeric recombinant mini-organs and controls were analysed using bright-field
microscopy for antigen expression, interpreted together with morphological criteria.
The expression of Pdx-1 was analysed by recording the blue Pdx-1 positive regions
within each recombinant and also whether there was co-expression of QCPN within
the patch. The Pdx-1 regions could then be classified as either QCPN +ve or QCPN -
ve, or "mixed" if there was some epithelial and some QCPN +ve contribution to that
Pdx-1 region.
7.3 Pdx-1 is up-regulated in splenic mesenchyme during iMET
5/9 (56%) spleen recombinants had regions of co-localisation of QCPN and Pdx-1
indicating up-regulation of Pdx-1 in splenic mesenchyme in these recombinants (see
Figure 17 and Table 7). Nearly all the recombinants (8 / 9) had regions of QCPN
negative Pdx-1 positive expression, as would be expected from the pancreatic
epithelium in the recombinant. Eleven quail spleen controls were analysed for Pdx-1
(five were fixed at day 0 in vitro culture and six underwent 1 day culture before
fixation). All these quail spleen controls were negative for Pdx-1, confirming clean
separation (no quail pancreas contamination). In addition, 8 quail abdominal organ
blocks also underwent simultaneous Pdx-1 in situ hybridisation (as a positive and
negative control) and showed distinct positive pancreatic expression, with negative
expression in all other regions of the abdominal organ block (see Figure 18 showing
pancreatic Pdx-1 expression in a wholemount E10 organ block control).
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Figure 17 Sectioned image showing an example of a combined QCPN +ve
Pdx-1 +ve region in a splenic recombinant
Fig 17 showing an area of splenic mesenchyme (shown by the brown QCPN nucleoli)
expressing Pdx-1 (in blue); 10pm section thickness, 10pm scale bar.
Figure 18 Chick pancreatic Pdx-1 expression during normal development
Fig 18 Pdx-1 expression in the pancreas at day 10 of normal gestation (HH36). Distinct blue
Pdx-1 expressing Islets of Langerhans can be seen within the pancreas. Scale bar 100pm; P =
pancreas, D = duodenum.
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Table 7 Pdx-1 expression in each splenic recombinant
"Mixed"
QCPN -ve contribution (Pdx-1 QCPN +ve
Recombinant (epithelial) +ve region with (splenic)
Pdx-1 +ve some QCPN +ve Pdx-1 +ve
areas)
1 + (D + (D + (2)
2 - + (2)
3 + (1) + (1) -
4 + (2) + 0) -
5 + d) - -
6 + d) - -
7 + (2) + (D -
8 + (2) -
9 + (3) - -
Table 7 This table shows which splenic recombinants had combined Pdx-1 +ve and QCPN
+ve regions (number of regions indicated in brackets). Nearly all recombinants had Pdx-1 +ve
QCPN -ve regions, as expected from the pancreatic epithelia. However, 5/9 recombinants
displayed regions of combined Pdx-1 +ve QCPN +ve regions (including Pdx-1 regions that
were purely QCPN +ve, or of a "mixed" contribution with some QCPN +ve areas within it).




These results show that Pdx-1 is up-regulated in the splenic mesenchyme when
recombined with pancreatic epithelia and this was observed in over a half of cases
(56%). Table 7 shows that in these 5 recombinants, there was a Pdx-1 region of
"mixed" origin (with some QCPN +ve splenic contribution) in at least 3 recombinants
whilst two recombinants contained Pdx-1 regions of completely splenic origin (QCPN
+ve, Pdx-1 +ve). 8/9 recombinants contained Pdx-1 regions of epithelial origin, as we
would expect from the chick pancreatic epithelia. However, one recombinant
contained no epithelial contribution, but only splenic Pdx-1 regions (recombinant 2).
The Pdx-1 -ve splenic controls give additional confidence over the safety of the
dissection margins in this thesis. Whilst insulin is a useful indicator of pancreatic
tissue, Pdx-1 is more widely expressed by pancreatic tissue during early development
and is expressed from an earlier gestation.
These distinct confluent Pdx-1 +ve regions seen in the splenic mesenchyme of the
recombinants (see Figure 17) presumably represent B-islets at this stage of gestation.
Although the pancreatic epithelia is now day 11 gestation at the end of the in vitro
culture period, it is difficult to accurately assess which day of pancreatic gestation the
splenic tissue might be, as they were initially developing down a splenic fate (at day 4
gestation) until recombined with pancreatic epithelia. However, we know from the
insulin studies (Chapter 4) that distinct insulin-expressing clusters, with islet
morphology, have developed in the splenic mesenchymal tissue by this same stage,
and so it is reasonable to suspect that these Pdx-1 regions are islets too. As already
mentioned, Pdx-1 is expressed by all pancreatic epithelial precursors (Jonsson,
Carlsson et al. 1994) and is later restricted to beta-cells (Ohlsson, Karlsson et al.
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1993). Therefore, the Pdx-1 up-regulation in the splenic mesenchyme at this stage
indicates that this tissue is being reprogrammed into a pancreatic epithelial endocrine
fate (ie: islet Mesenchyme-to-Epithelial Transition).
This finding of Pdx-1 expression during splenic iMET is important because Pdx-1
expression is known to continue in mature adult beta-cells (Ohlsson, Karlsson et al.
1993) and is essential for their function (Ahlgren, Jonsson et al. 1998; Holland, Hale
et al. 2002). Loss ofPdx-1 expression in mature beta-cells causes a dramatic decrease
in their expression of insulin, Nkx6.1 and the glucose transporter GLUT2 (glucose
transporter type 2, which is a marker ofmature beta-cells) (Pang, Mukonoweshuro et
al. 1994; Ahlgren, Jonsson et al. 1998). Furthermore, mice heterozygous for a Pdx-1
deficiency are glucose-intolerant (Ahlgren, Jonsson et al. 1998), consistent with the
finding that humans carrying dominant Pdx-1 mutations are predisposed to "maturity-
onset diabetes of the young" (MODY), a form of T2DM (Staffers, Ferrer et al. 1997;
Macfarlane, Frayling et al. 2000).
7.5 Conclusions
These results show that Pdx-1 is up-regulated in the splenic mesenchyme when
recombined with pancreatic epithelia and this was observed in over a half of cases
(56%). Pdx-1 up-regulation in the splenic mesenchyme indicates that this tissue can
be reprogrammed into a pancreatic epithelial endocrine fate in vitro when recombined
with pancreatic epithelium. The next chapter investigates whether Isl-1 is also up-
regulated in the splenic mesenchyme of recombinants.
Chapter Eight






The aim of this chapter was to investigate whether the pancreatic transcription factor
Isl-1 (islet-1) was expressed by the splenic mesenchyme within chimaeric
recombinant organs. This gene is expressed in developing pancreatic islets (Karlsson,
Thor et al. 1990; Ahlgren, Pfaff et al. 1997). The Isl-1 gene encodes a transcription
factor of the LIM homeodomain family, a class of proteins that control cell-fate
decisions (Way and Chalfie 1988). Early expression is first seen in the pancreas of
mouse embryos at E9, both in the dorsal pancreatic mesenchyme (DPM) and
epithelium (DPE) (Ahlgren, Pfaff et al. 1997). Although Isl-1 is not expressed in the
ventral pancreatic mesenchyme (VPM), ventral pancreatic epithelial (VPE) Isl-1
expression is first detected at Ell, consistent with the one to two day delay in islet
cell genesis in the ventral pancreatic bud (Herrera, Huarte et al. 1991; Ahlgren, Pfaff
et al. 1997). Analysis of pancreatic epithelial endocrine cells (between E9.5-E13)
shows Isl-1 expression after their final mitotic division but before the onset of
hormone-gene expression (Ahlgren, Pfaff et al. 1997). DPM expression is transient
but is essential for its development and also for the generation of glucagon-expressing
cells in the DPE. Isl-1 expression in pancreatic epithelium is required for
differentiation of islet cells, since pancreatic explants generated from Isl-1(-/-) mice
are absent of insulin, glucagon and somatostatin expression (Ahlgren, Pfaff et al.
1997). Foregut Isl-1 expression becomes more restricted during development, with
expression in stomach mesenchyme, pancreatic mesenchyme and pancreatic
epithelium at El 1.5 in mice embryos, but then only in pancreatic epithelial precursors
by E13.5 (Kim, Hebrok et al. 2000). Isl-1 is also found in islet beta-cell progenitors
and co-localises with insulin in differentiated beta-cells to maintain insulin production
(Karlsson, Thor et al. 1990; Habener, Kemp et al. 2005). It is expressed in alpha,
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beta, delta and pancreatic polypeptide cells of the adult islet (Dong, Asa et al. 1991;
Thor, Ericson et al. 1991).
Previous study in this laboratory has shown up-regulation of Isl-1 in stomach
mesenchyme when recombined with pancreatic epithelia (Rowan-Hull, Rao et al. In
Press). We were now interested to know whether this gene was also up-regulated in
splenic mesenchyme, when recombined with pancreatic epithelia. This chapter
addresses the hypothesis that Isl-1 is up-regulated in the splenic mesenchyme of
chimaeric recombinant organs.
8.2 Methods
Recombinants were generated as detailed previously (2 quail spleens recombined with
2 chick pancreatic epithelia) and cultured for 7 days before fixation and cryo-
sectioning (7- 10pm). Immunocytochemistry for QCPN and Isl-1 was performed, as
detailed previously (Chapter 4, section 4.2.5). Slides were mounted in DAPI and
analysed using fluorescence microscopy for antigen expression. Embryonic origins of
splenic Isl-1 positive cells were determined according to co-expression of nuclear Isl-
1 surrounding a QCPN nucleolus. Microdissected quail spleen controls were fixed
either at day zero or after overnight culture. Controls underwent Isl-1
immunocytochemistry and analysis as above.
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8.3 Isl-l is up-regulated in splenic mesenchyme during iMET
3/9 (33%) spleen recombinants had co-localisation of QCPN and Isl-1, indicating
that Isl-1 is up-regulated in splenic mesenchyme when recombined with pancreatic
epithelia (see Table 8). All 9 recombinants had epithelial Isl-1 expression, as expected
from the pancreatic epithelia within the recombinant.
Interestingly, the Isl-1 expression in the splenic mesenchyme did not appear to depend
upon its proximity to epithelial pancreatic tissue in these experiments, since Isl-1
positive cells of splenic origin were seen in their own separate clusters away from any
neighbouring epithelia in 2 of 3 recombinants (see Figure 20B). The third
recombinant showed Isl-1 positive clusters of mixed origin but also isolated splenic
mesenchymal cells showing Isl-1 expression (see Figure 21).
In addition, a quantitative analysis of Isl-1 expression was also performed. Within the
three recombinants that demonstrated iMET, the mean number of all Isl-1 +ve cells
(regardless of origin) was 375 ± 150, and the mean number of splenic mesenchymal
cells expressing Isl-1 was 52 ± 38 (see Figure 19).
Six quail spleen controls were analysed for Isl-1 expression (3 cultured overnight in
normal RPMI, and 3 using RPMI with BIO; see Chapter 9: A Preliminary Study of the
Effect of a Wnt Agonist on islet Mesenchyme-to-Epithelial Transition in the
Developing Spleen) and were all negative, confirming clean separation.
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Isl-1 +ve QCPN +ve Isl-1 +ve
contribution)
1 + - +
+ +2 -
3 + - -
4 + - -
5 + - -
6 + - -
7 + - -
8 + + +
9 + - -
Table 8 Cell clusters of QCPN -ve lsl-1+vc expression were seen in all recombinants, as
expected from the pancreatic epithelium. However, cell clusters of QCPN+ve Isl-l+ve
expression were seen in 3 / 9 recombinants, demonstrating up-regulation of this gene in the
splenic mesenchyme.
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Fig 19 Bar-chart showing number of Isl-1 positive cells of epithelial origin (in blue) and
number of Isl-1 positive cells of splenic origin (in red) for each recombinant
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Figure 20 Expression pattern of Isl-l+ve cells of splenic origin
f
m* •
Fig 20 Splenic mesenchymal cells undergo iMET to express the pancreatic epithelial marker
lsl-1 in the absence of directly neighbouring pancreatic epithelial cells. Bl: The splenic
mesenchymal Isl-1 +ve cells appeared in two recombinants in isolated clusters. B2: The same
Isl-1 clusters as Bl, combined with red and blue channels. Examples of splenic cells
expressing Isl-1 are indicated by super-imposed white arrows. Al: An epithelial Isl-1 cluster
is shown for reference. A2: The same Isl-1 cluster as Al, combined with red and blue
channels (note the absence of QCPN positive nucleoli in the Isl-1 positive cells). QCPN (red)
identifies cells of splenic origin. DAPI (blue) labels the nucleus of all cells. Nuclear Isl-1
expression is shown in green. Original magnification x63; section thickness 7- 10pm.
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Fig 21 Splenic mesenchymal cells undergo iMET to express the pancreatic epithelial marker
Isl-l in the absence of neighbouring pancreatic epithelial cells. CI: The mesenchymal Isl-1
+ve cells in one recombinant appeared as isolated cells. C2: The same Isl-1 +ve cells
(indicated by super-imposed white arrows), with red and blue channels shown. Dl: Another
example of isolated mesenchymal Isl-1 +ve cells. D2: The same Isl-1 +ve cells (indicated by
white arrows), with red and blue channels shown. QCPN (red) identifies cells of splenic
origin. DAPI (blue) labels the nucleus of all cells. Nuclear Isl-1 expression is shown in




Isl-1 was expressed in the splenic mesenchyme in a third of recombinants, confirming
the hypothesis that Isl-1 is up-regulated in the splenic mesenchyme when recombined
with pancreatic epithelia. This further demonstrates that the cells within splenic
mesenchyme are able to adopt a pancreatic fate in vitro when recombined with
pancreatic epithelium. These results also indicate that splenic mesenchyme can
transdifferentiate into an endocrine epithelial fate, similar to the Pdx-1 up-regulation
findings in Chapter 7. Again, this presumably occurs under the influence of
developmental signalling from the differentiating pancreatic epithelium. This might
explain why Isl-1 up-regulation was only seen in a third of cases, perhaps with some
mesenchyme receiving more of these signals than others. A pancreas-specific
epithelial signalling pathway could be confirmed by recombining splenic
mesenchyme with non-pancreatic epithelium (stomach epithelium, for example) as a
negative control.
In normal development, splenic mesenchyme does not express this homeobox gene
(Ahlgren, Pfaff et al. 1997; Kim, Hebrok et al. 2000), and spleen controls in this
experiment were also negative for Isl-1. The negative spleen controls also confirm
clean separation and give additional confidence over the safety of dissection margins
in this thesis.
Original studies of Isl-1 gene expression suggested that it was restricted to cells of the
endocrine pancreas (Karlsson, Thor et al. 1990). However, Isl-1 expression is now
known to be more widespread. Expression in the adult rat is not restricted to
pancreatic islets, but has also been detected in extra-pancreatic locations, including
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the nervous system (central and peripheral) and distal tubules of the kidney, but not in
the spleen (Dong, Asa et al. 1991; Thor, Ericson et al. 1991). Mammalian Isl-1 coding
sequences, and their expression in non neuroendocrine lineages, are conserved
between rat, hamster and human species (Wang and Drucker 1994). There are also
reports of extra-pancreatic expression of Isl-1 during development in stomach
mesenchyme, forebrain, hypothalamus, pituitary and the pineal gland (Kim, Hebrok et
al. 2000; Liu, Liu et al. 2005; Zhang, Liu et al. 2006; Elshatory and Gan 2008).
Therefore, although Isl-1 up-regulation in the splenic mesenchyme of our
recombinants is most likely due to pancreatic islet reprogramming, an alternative fate
cannot be entirely excluded; such as stomach mesenchyme, alternative endocrine
(pituitary, pineal), neural (forebrain, hypothalamus) or inner ear. However, when
interpreting the Isl-1 expression in light of recombination with pancreatic epithelia,
along with the findings of Pdx-1 up-regulation and insulin expression in the splenic
mesenchyme, the argument for pancreatic islet reprogramming is compelling.
Isl- 1 expression in foregut mesenchyme is poorly understood. Although the role of
the mesenchyme in the regionalisation of both the gut endoderm / epithelium (Yasugi
and Mizuno 2008) and the pancreas (Kumar, Jordan et al. 2003) have been examined,
there is little evidence of the regulation of mesenchymal differentiation by the
epithelium. However, it is interesting to note that patterning of the radial axis of the
gut mesenchyme in the chick has been shown to be controlled by the epithelium
(Fukuda, Tanigawa et al. 1998; Sukegawa, Narita et al. 2000).
Previous results from our laboratory demonstrate that stomach mesenchymal cells up-
regulate Isl-1 when recombined with pancreatic epithelium, but can also co-express
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insulin (Rowan-Hull, Rao et al. In Press). It would be interesting to test this property
in Isl-l+ve splenic mesenchyme cells. Our current understanding of iMET from
experiments involving stomach mesenchyme / pancreatic epithelium recombinants is
that signals from the pancreatic epithelium result in mesenchyme transition into an
endocrine progenitor. In the splenic recombinants in this thesis, Isl-1 was expressed
both within large cellular clusters of splenic mesenchyme and also as isolated cells.
This occurred in the absence of adjacent or neighbouring pancreatic epithelium,
suggesting that splenic tissue may be able to transdifferentiate with greater
independence from close epithelial-mesenchyme interactions. Theoretically, this may
occur under the influence of soluble factors from the pancreatic epithelium, rather
than direct cell-to-cell interactions. The observation of isolated cells expressing Isl-1
may be explained by these cells receiving inadequate FGF2 signals from the
pancreatic epithelium, which are required for clustering to occur (Hardikar, Marcus-
Samuels et al. 2003).
The ability of the splenic mesenchyme to transdifferentiate may be due to the very
close relationship shared between the spleen and pancreas during normal development
(see Chapter 2, section 2.5). Interestingly, previous study of stomach mesenchyme /
pancreatic epithelia recombinants found separate Barx-1 and Isl-1 regions in the
mesenchyme with no combined expression, indicating that Barx-1 must be down-
regulated in the mesenchyme before this same tissue undergoes Isl-1 up-regulation
(unpublished data, using Barx-1 in situ hybridisation, QCPN peroxidase reaction and
Isl-1 antibody immunohistochemistry). It would be interesting to investigate this same
property in splenic mesenchyme / pancreatic epithelia recombinants, to see whether
Tlx-1 must be down-regulated before Isl-1 is up-regulated. However, given the
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dramatic and complete down-regulation of Tlx-1 in the splenic mesenchyme (Chapter
6), it seems likely that a similar reprogramming sequence occurs, where the splenic
identity is lost before the new pancreatic identity is achieved.
8.5 Conclusions
Isl-1 was expressed in the splenic mesenchyme in a third of recombinants, showing
that Isl-1 is up-regulated in the splenic mesenchyme when recombined with pancreatic
epithelia. Taken together with the previous Pdx-1 up-regulation and insulin
expression data, this result supports the finding that cells within splenic mesenchyme
can be reprogrammed to adopt a pancreatic endocrine epithelial fate in vitro when
recombined with pancreatic epithelium.
Chapter Nine
A preliminary study of the effect of a Wnt
agonist on islet Mesenchyme-to-Epithelial




The aim of this chapter was to begin a preliminary investigation into whether the
addition of a Wnt (wingless-type) agonist to the culture medium would augment
iMET. The hypothesis generated was that iMETwithin chimaeric recombinant organs
can be augmented by addition of a Wnt agonist to the culture medium. This
preliminary study analysed the number of splenic Isl-1 expressing cells, in
recombinants cultured with or without a Wnt agonist. Many studies have suggested
that canonical Wnt signals play an important role in pancreas development. For
example, a direct Wnt target, Cdx4 (caudal type homeobox 4), acts to pattern the
foregut endoderm (Kinkel, Eames et al. 2008). Furthermore, Wnt signalling is both
necessary and sufficient for beta-cell proliferation (Rulifson, Karnik et al. 2007).
Interestingly, Wnt signals also function in mesenchyme-to-epithelial transition in the
developing metanephric kidney during nephron tubule formation (Kispert, Vainio et
al. 1998).
Wnt molecules are a family of structurally-related secreted glycoproteins which are
largely conserved in mammals (Piters, Boudin et al. 2008). They signal through
binding Frizzled (Fz) receptor family members, which induces one of three known
signalling pathways, including the canonical pathway studied here. This pathway
depends on the translocation of a cytoplasmic complex, p-catenin, to the nucleus,
where it binds lymphoid-enhancer binding factor / T-cell specific transcription factors
(Lef / Tcfs), to control gene transcription (Eisenmann 2005). In the absence of Wnt
signals, P-catenin is targeted for proteasomal degradation, through phosphorylation
with the molecule Glycogen Synthase Kinase 3-P (GSK3P). The binding of a Wnt-
ligand to an Fz receptor inactivates GSK3P, crippling the destruction complex, and
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allowing (3-catenin to translocate to the nucleus (see Figure 22). This study uses a
GSK3P inhibitor, known as "Bio", as a Wnt agonist.
Figure 22 Flow-chart illustrating canonical Wnt signalling pathway
Wnt ligand No Wnt ligand
Wnt + Fz
TCytoplasm T
B catenin + GSK3B
1 ™











Fig 22 Flow-chart to illustrate canonical Wnt pathway. Absence of Wnt favours B-catenin
destruction (via GSK3P). The presence of Wnt results in this molecule binding to Fz
(.Frizzled) receptor, inactivating GSK3p and hence preventing B-catenin destruction. B-
catenin can then enter the nucleus, where it binds with Lef/ Tcfs (lymphoid-enhancer binding





The materials and methods used in this section were identical to those used in Chapter
9, with the exception that Bio (Sigma, Dorset, UK), which is a GSK3p-inhibiting Wnt
agonist, was added at a concentration of lpM to the RPM1 culture medium, where
indicated. This included the RPMI used in the overnight agarose step and all RPMI
used in the roller culture. A working concentration of lpM was chosen following a
study of the literature, which found working concentrations previously used in similar
kinds of experiments ranging from 5nm to 2.5 pM (Heller, Klein et al. 2003; Naito,
Shiojima et al. 2006; Slack, Lin et al. 2008; Ullmann, Gilles et al. 2008).
9.3 Results
Three splenic recombinants were successfully cultured in the presence of Bio. All
three produced epithelial Isl-l +ve cell expression but only one recombinant (1/3,
33%) contained Isl-l+ve cells of a mesenchymal origin. Interestingly, this was only




Figure 23 Expression pattern of Isl-1 positive splenic mesenchymal cells following
culture with Wnt agonist
Fig 23 Expression pattern of Isl-l+ve splenic mesenchymal cells in a recombinant cultured in
the presence of Bio. When recombined with chick pancreatic epithelium, quail splenic
mesenchymal cells (A) undergo iMET to express the pancreatic epithelial marker Isl-1 (B).
This occurs in the absence of directly neighbouring pancreatic epithelial cells. The splenic
mesenchymal cells also appear in isolated clusters (A) when Bio is added to the culture
medium. A: Splenic quail QCPN in red, B: Nuclear Isl-1 in green, C: Nuclear DAPI in blue,
D: Combined image showing all three channels. Cluster of Isl-l+ve splenic mesenchymal




The conclusions that can be drawn from this initial study of adding a Wnt agonist are
limited, owing to the low number of recombinants. The experiment should be
repeated during future work with a larger number of recombinants, before definite
trends can be elucidated. Future work should also study the effect of adding a Wnt
agonist on other pancreatic markers within the splenic mesenchyme of recombinants,
such as insulin and Pdx-1. This study showed that 33% of recombinants contained Isl-
7+ve cells of a splenic origin when cultured with Bio, the same percentage as that
found without Bio (Chapter 8, section 8.3). Therefore, these preliminary results of
three recombinant analysed for Isl-l suggest that there may be no increase in Isl-1
expression observed in splenic mesenchyme when recombined with pancreatic
epithelium in the presence ofa Wnt agonist, but further work is required.
Several studies implicate Wnt signals in pancreas development (Heiser, Lau et al.
2006; Jonckheere, Mayes et al. 2008). The addition of a Wnt agonist at this
developmental stage may have been too late to produce a measurable effect using Isl-
1 in this experiment. For example, a recent study found that ectopic stabilisation of P-
catenin in vivo within mouse pancreatic epithelium has divergent effects on organ
growth and differentiation (Heiser, Lau et al. 2006). Early stabilisation of B-catenin
resulted in a reduced pancreatic mass. Conversely, stabilisation later in pancreatic
development resulted in enhanced proliferation and increased pancreatic mass. The
apparent hinge point in that study occurred at mouse El2.5 (chick E3.75; just before
the gestation that eggs are harvested in this thesis). Similar bi-phasic and stage-
specific effects of Wnt signalling have been reported in the development of other
organs, such as cardiomyogenesis and haematopoiesis (Naito, Shiojima et al. 2006).
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Further characterisation of Writ signalling during iMET would be useful, possibly
through the addition of the Wnt agonist at differing time-points during iMET.
These preliminary results do not preclude the possibility that Wnt stimulation may be
augmenting the expression of earlier pancreatic markers through an expansion of the
endocrine progenitor pool. Analysis of other early pancreatic transcription factors,
such as Pdx-1 or Ngn-3, may help to clarify this.
If future tests are unable to demonstrate measurable differences in iMET, it may
reflect either an inability of either or both the recombinant tissues to respond to Wnt
signals in the culture medium, or perhaps a level of competition between these two
tissues preventing a significant change in either one.
Since the pancreatic epithelium is known to be required for iMET to occur within the
mesenchyme, it is reasonable to attribute fFnt-unresponsiveness to the epithelium.
Some populations of fully-differentiated beta-cells that tolerate in vivo P-catenin
stabilisation have been identified (Heiser, Lau et al. 2006). These fully differentiated
cells display low nuclear and high cytoplasmic P-catenin levels, with no change in
insulin expression. Some populations of fully differentiated beta-cells may express
mechanisms which prevent stabilised P-catenin from entering the nucleus, rendering
them unresponsive to increased canonical Wnt signals. Since Bio is a P-catenin
stabiliser, this may also be the case in the experiments in this chapter.
Moreover, an eventual inability to demonstrate a significant change in iMET in
response to Wnt may reflect a limitation of the experimental model. The pancreatic
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mesenchyme that surrounds the developing pancreatic epithelium was replaced with
splenic mesenchyme, which could render the pancreatic epithelium portion
unresponsive to Wnt signals. Interestingly, a recent report has demonstrated that
mPygo2 (pygopus; an essential component of the nuclear complex necessary for
canonical Wnt signalling) plays a role during the onset of endocrine development after
mouse E12.5 (chick E3.75) (Jonckheere, Mayes et al. 2008). Pancreatic hypoplasia
and decreased insulin expression in germ-line mPygo2 mutants were reported and
these defects were attributed to decreased proliferation of undifferentiated progenitors
after mouse E13 (chick E4.75). However, the pancreas develops normally with
epithelium-specific mutations, suggesting that I!«/-responsiveness in the endocrine
pancreatic epithelium is an exclusive property of the surrounding pancreatic
mesenchyme. The dependence of mPygo2 upon Wnt signalling was confirmed, and
canonical Wnt activity was demonstrated in the pancreatic mesenchyme when
mPygo2 mutant mice first show defects. The avian model in this thesis assesses
endocrine differentiation at the equivalent developmental window. Therefore,
separation of the pancreatic epithelium from its surrounding (f>?/-responsive
pancreatic mesenchyme during the recombinant chimaera construction may impair its
ability to respond.
However, epithelial IPCs have already been observed in the microdissected pancreatic
epithelium in this thesis at the time of pancreatic mesenchyme removal (see Chapter
4, Table 2). It is therefore likely that the pancreatic epithelial progenitors have already
received the initial signals from the pancreatic mesenchyme at the time of dissection.
In this case, the addition of our Wnt agonist may be too late to exert a noticeable
effect in the absence of the pancreatic mesenchyme. Therefore, removal of the
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pancreatic mesenchyme to create the recombinant tissue at this stage would not
preclude initial Wnt signals being received from the pancreatic mesenchyme, but may
preclude attempts to later augment them in the pancreatic epithelium.
9.5 Conclusions
The conclusions that can be drawn from this preliminary study of adding a Wnt
agonist are limited, owing to the low number of surviving recombinants. The
experiment therefore needs to be repeated during future work before definite trends
can be elucidated. However, these preliminary results of three recombinants analysed
for lsl-1 suggest that there may be no increase in Isl-1 expression observed in splenic
mesenchyme when recombined with pancreatic epithelium in the presence of a Wnt
agonist.
SECTION FOUR
Conclusions and Future Research
Chapter Ten
Conclusions and Future Research
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10.1 Summary of main results
The key findings in this thesis are summarised in Figure 24. Chapter 4 has outlined
initial "proof of principle" experiments testing the first three experimental hypotheses
(see Chapter 2, section 2.9, Table 1, hypotheses 1 to 3). The key findings show that
the developing avian spleen is able to differentiate into insulin-producing cells (in
almost a half of recombinants overall), and in an islet morphology, showing the first
hypothesis to be true. The ratio of splenic mesenchyme to chick pancreatic epithelia
does not appear to influence the percentage of recombinants in which iMET is
observed (42% vs 33%), suggesting that signals from the differentiating pancreatic
epithelium may be a key factor in this iMET process. However, doubling the amount
of each tissue proportionately increases the percentage of recombinants in which this
is observed (42% vs 80%). Although splenic iMET is observed in a proportionately
higher percentage of recombinants when the amount of each tissue is increased, the
actual percentage of IPC clusters in which iMET is observed significantly decreases
when either the ratio of mesenchyme to epithelium, or the amount of tissue in each
recombinant, was increased (37% vs 22% vs 13% respectively: see Chapter 4, Figure
12). Therefore, altering the ratio of splenic mesenchyme to chick pancreatic
epithelium in the recombinants, or altering the overall amount of tissue in the
recombinants, does alter the frequency of observed iMET, showing the second and
third hypotheses to be true. These findings could be attributed to altered signalling
between the two tissue types within the recombinants.
Section 3 outlines experiments investigating the molecular mechanisms behind
splenic iMET, to test the final four experimental hypotheses (see Chapter 2, section
2.9, table 1, hypotheses 4 to 7). Experiments in Chapter 5 show how the Tlx-1 in situ
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hybridisation reaction was optimised through modifications to the protocol. This
involved the ubiquitous addition of EGTA to all fixative used, plus addition of
glutaraldehyde to the fixative on Day One of the in situ protocol. Experiments in
Chapter 5 then describe the characterisation of the splenic expression profile of Tlx-1
during normal chick development during the developmental period in question (E4 to
El 1 inclusive). Tlx-1 was found to be expressed in the spleen throughout this period,
with no expression observed in other abdominal organs or surrounding tissues.
Experiments in Chapter 6 show that the splenic mesenchyme is reprogrammed when
recombined with pancreatic epithelia, through the dramatic down-regulation of Tlx-1,
showing hypothesis 4 to be true. Experiments in Chapters 7 and 8 show the pancreatic
endocrine transcription factors Pdx-1 and Isl-1 are up-regulated in the splenic
mesenchyme when recombined with pancreatic epithelia, showing hypotheses 5 and 6
to be true. Finally, in Chapter 9, an attempt to augment iMET was made through the
addition of a Wnt agonist to the culture medium. Preliminary data suggests that there
may be no augmentation of Isl-1 up-regulation. However, this experiment needs to be
repeated as part of future work before hypothesis 7 can be accurately answered, along
with a study of its effect on insulin-producing cells of splenic origin and Pdx-1
regulation.
One potential weakness of the methodology used in this thesis is the risk of quail
pancreatic contamination of the quail spleen during the microdissection steps of
recombinant construction, as this might lead to false positives. However, no
contamination was detected in any of the controls throughout the project, giving a
very high level of confidence over the safety of the dissection margins (see Chapter 4,
Table 3). Furthermore, a range of different pancreatic markers and a splenic marker
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were used giving additional confidence, as well as great care being taken over the
dissection, with a safety cuff of quail spleen (closest to the quail pancreas) being left
behind during the dissection.
Taken together, these findings show that splenic mesenchyme is able to differentiate
into an insulin-producing pancreatic endocrine cell fate during development, thus
showing the principal hypothesis to be true.
Figure 24 Summary of key MD findings
1. The developing avian spleen is able to differentiate into insulin-producing
cells and in an islet morphology
2. Altering the ratio of splenic mesenchyme to pancreatic epithelium in the
recombinants alters the frequency of observed iMET
3. Altering the overall amount of tissue in the recombinants alters the frequency
of observed iMET
4. The Tlx-1 in situ hybridisation reaction can be optimised through protocol
modifications
5. Tlx-1 is expressed in the spleen during normal chick development throughout
the developmental period studied (day 4 to day 11 gestation) and in no other
abdominal viscera
6. The splenic mesenchyme is reprogrammed when recombined with pancreatic
epithelia, as shown by dramatic down-regulation of Tlx-1
7. Pdx-1 is up-regulated in the splenic mesenchyme of chimaeric recombinant
organs
8. Isl-1 is up-regulated in the splenic mesenchyme of chimaeric recombinant
organs
9. Further work is required to confirm the effect on iMET of adding a Writ
agonist to the culture medium (although preliminary data suggests that there
may be no augmentation of Isl-1 up-regulation)
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10.2 Putative model of islet Mesenchyme-to-Epithelial Transition in
the developing spleen
10.2.1 Isletmesenchyme-to-epithelial transition in the developing spleen : a new
pathwayfor isletformation?
The finding that splenic mesenchyme is able to differentiate into an insulin-producing
pancreatic endocrine cell fate during development is striking, as it offers a potential
alternative pathway for islet differentiation through islet Mesenchyme-to-Epithelial
Transition. It challenges the previously widely held dogma that islets are derived
exclusively from endoderm (Percival and Slack 1999; Gu, Dubauskaite et al. 2002;
Kawaguchi, Cooper et al. 2002). This finding also supports previous findings of
iMET observed in both stomach and pancreatic mesenchyme in this model of
pancreatic organogenesis (Lear, Jayanthi et al. 2004; Jayanthi, Rowan-Hull et al.
2005; Teague, Rowan-Hull et al. 2006). Islet MET from foregut mesenchyme may be
a previously unrecognised pathway of normal islet development. Alternative
pathways for islet neogenesis may exist in order to provide a survival advantage at
times of stress or disease, for example. In addition, perhaps such pathways may also
play a role in the "honeymoon" period observed during the onset of T1DM, where
preservation of beta-cell function and reduced insulin requirements can initially be
observed for a period after diagnosis (Heinze and Thon 1983; Abdul-Rasoul, Habib et
al. 2006).
Until recently, islet differentiation was considered to be limited exclusively to
differentiation of TVgni-positive cells derived from Pdx-1 expressing endoderm (Gu,
Dubauskaite et al. 2002). However, a recent human genetic analysis has challenged
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this dogma, finding beta-cell development in humans with homozygous mutations of
the Ngn-3 gene (Wang, Cortina et al. 2006). This is surprising, given that all
endodermal islet precursors are iVgni-positive (Gu, Dubauskaite et al. 2002). This
finding may indicate a pathway for beta-cell formation that is independent of
endodermal Ngn3 precursors and iMET may be one such source. As already
mentioned in Chapter 2, it is interesting to recall that in vivo ectopic islet
differentiation within the spleen has previously been observed in nature. This has been
observed naturally in some reptiles (Volk and Arquilla 1985) and also experimentally
in mice lacking an exocrine pancreas (Krapp, Knofler et al. 1998). Together with the
data in this thesis, these observations suggest that islet MET in the spleen may be able
to occur naturally in vivo. Alternatively, the specific in vitro culture conditions and
tissue manipulation within this model may alter the embryonic niche and provide
signalling cues that allow islet MET to occur.
A possible alternative explanation to consider for our findings could be that splenic
mesenchymal and pancreatic epithelial cells within the recombinants undergo
spontaneous fusion. However, this is a very rare occurrence both in the chick-quail
chimaera system (Grzeschik 1973) and in mesenchymal beta-cell differentiation
(Ianus, Holz et al. 2003), and would not account for the frequency of splenic iMET
observed in this thesis. Furthermore, it would seem unlikely that such a rare
occurrence would also account for the accumulative body of evidence for iMET
observed in other experiments (Kodama, Kuhtreiber et al. 2003; Lear, Jayanthi et al.
2004; Jayanthi, Rowan-Hull et al. 2005; Teague, Rowan-Hull et al. 2006).
Chapter 10
Page 179
The evidence supporting splenic iMET presented in this thesis may helpfully
contribute to the debate over the role that adult mouse donor splenocytes may play in
forming replacement islets to reverse diabetes in NOD mice (Kodama, Kuhtreiber et
al. 2003; Chong, Shen et al. 2006; Couzin 2006; Faustman, Tran et al. 2006; Melton
2006; Nishio, Gaglia et al. 2006; Suri, Calderon et al. 2006). Although the evidence
here is from an avian embryonic model, and not adult donor splenocytes, the ability of
the developing avian embryonic spleen to be reprogrammed into an insulin-expressing
pancreatic endocrine fate is noteworthy.
10.2.2 Hypothetical signallingpathways and molecular mechanisms behind islet
Mesenchyme-to-Epithelial Transition in the developing spleen
The attempts in Section 3 to elucidate some of the molecular mechanisms behind this
iMET process may also prove helpful in future islet neogenesis strategies using
pluripotent cells. The presence of pancreatic epithelium was required for the splenic
mesenchyme to be reprogrammed and undergo iMET and this reprogramming process
presumably occurred under the influence of signalling by the differentiating
pancreatic epithelium. However, it is important to remember that initial islet
development has already occurred in the developing pancreatic tissue being harvested
for recombinant construction (E4). Indeed, insulin expression was observed in the
control chick pancreatic epithelia at the time of initial recombinant construction (see
page 104 , Table 2). It is therefore unclear how the presence of the pancreatic
epithelium within the recombinants could be influencing the splenic mesenchyme in
my experiments, and which candidate signals from the differentiating pancreatic
epithelium might be playing a role in the observed splenic iMET. Further work is
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necessary to investigate this. However, expression of the very early pancreatic
transcription factor Pdx-1 is known to continue into adult life, and so it is feasible that
early pancreatic factors such as these could continue to influence splenic mesenchyme
within the recombinant during the culture period (Ohlsson, Karlsson et al. 1993).
The importance of differentiating pancreatic epithelium for MET is similar to a
previous finding in this laboratory examining pancreatic mesenchyme (Jayanthi,
Rowan-Hull et al. 2005). I postulate that these signals are responsible for the down-
regulation of Tlx-1 and up-regulation of Pdx-1 and lsl-l in the splenic mesenchyme.
The splenic mesenchyme appears very competent to be reprogrammed, as evidenced
by the dramatic 100% down-regulation of 77x-l (Chapter 6). However, a range of
pancreatic fate re-programming appears to occur, with Pdx-1 being up-regulated in
just over a half of recombinants (Chapter 7), Isl-l in a third of recombinants
(Chapter 8) and differentiation into insulin-producing cells of splenic origin in
approximately half of recombinants overall (Chapter 4), but in up to 80% of
recombinants when two spleens are recombined with two pancreatic epithelia. This
range of re-programming may be due to a range of pancreatic signalling being
experienced by the splenic mesenchyme, from the pancreatic epithelia within the
recombinants. As discussed, the role of increased Wnt signalling on splenic iMET is
still unknown and requires further investigation. Therefore, a summarised
hypothetical signalling pathway for splenic iMET is shown in Figure 25.
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Fig 25 Hypothetical model of splenic iMET, based on the findings in this thesis. The splenic
mesenchyme undergoes iMET under the influence of signals provided by the differentiating
pancreatic epithelium; splenic mesenchyme in blue, pancreatic epithelium in white, pancreatic
epithelial signalling on splenic mesenchyme shown in black arrows, sm = splenic




10.3 Potential future applications of this research in treating
patients with Diabetes Mellitus
The data presented in this thesis indicates that the spleen may be a suitable tissue
source from which replacement islets could potentially be derived. However, further
work is needed to investigate splenic iMET, in particular further characterisation of
the mechanisms controlling this (especially the required temporal pancreatic
signalling cues) and whether the mature human spleen is capable of undergoing this
iMET process (see section 10.4: Future Research). A desirable future islet phenotype
derived from pluripotent cells would be safe and stable, capable of physiological
insulin secretion kinetics, capable of maintaining euglycaemia and reversing Diabetes
Mellitus.
A possible future treatment model could be envisaged, whereby a splenic biopsy is
taken from the patient themselves shortly after diagnosis, either percutaneously (under
radiological guidance) or surgically (via laparoscopy or laparotomy). This could be
manipulated in vitro to produce the required islet phenotype and then transplanted
back into the patient, via the portal vein for example (the route currently commonly
utilised for allograft islet transplantation). Candidates for such a treatment would
initially be T1DM patients, and T2DM patients requiring insulin. However, this
treatment could eventually be made available to all patients with Diabetes Mellitus, if
it provided euglycaemia and disease reversal, was low risk, and could be undertaken
in a minimally-invasive manner.
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If the new islets are susceptible to the same autoimmune attack as the native islets,
they may require shielding from this (through concomitant immunosuppression, or
perhaps via an immunomodulatory strategy or immunoisolation encapsulation) and
"top-up" islet transfusions may even be required. Although islet regeneration offers
the potential to reverse the disease, ameliorating the autoimmunity in T1DM will
probably still be required to truly "cure" this disease.
In addition to autotranplantation, a splenic source of replacement islets could also be
used for allotransplantation. Splenic tissue is readily available during multi-organ
retrieval, but is generally not utilised. Therefore, this could be an abundant allograft
tissue source in the future, if spleen-derived islet neogenesis is successfully realised.
10,4 Future research
Future work should involve further characterisation of the splenic IPC clusters
produced via iMET. This would be useful to establish whether other islet cell types
can also be produced and this could initially be undertaken using glucagon
immunochemistry to detect alpha-cells (Teague, Rowan-Hull et al. 2007). In addition,
it would be interesting to study whether these IPC clusters expressed the glucose
transporter protein Glut2, which is a marker of mature beta-cells (Pang,
Mukonoweshuro et al. 1994).
Further characterisation of the molecular mechanisms behind the splenic iMET
observed in this thesis should be performed. Future research should initially further
investigate the effect of adding a Wnt agonist to the culture medium on Isl-l
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expression, but also on insulin and Pdx-1 expression. Other extrapolation studies to
augment or inhibit candidate signals should also be considered. The temporal
pancreatic signalling cues need to be characterised. This might be achieved through
using gene Micro-arrays or Real Time-Polymerase Chain Reaction techniques.
Alternatively, differentiation protocols previously used to produce insulin-secreting
islet-like clusters from human embryonic stem cells (Jiang, Au et al. 2007) could be
adapted and applied to microdissected embryonic quail spleens.
Functional studies of the spleen-derived IPC clusters produced from splenic iMET
should be performed to assess physiological islet hormone release (including insulin
and glucagon). This could be performed through functional tests to measure insulin
secretion upon glucose stimulation (using C-peptide enzyme-linked immunosorbent
assay (ELISA), for example). The role of donor adult splenocytes to reverse diabetes
in experimental models could also be re-addressed, following the conflicting results in
NOD mice models (see Chapter 2, section 2.8).
Translational strategies should also be considered. This work has so far focussed on
iMET in embryonic spleens, but future studies could investigate the adult spleen,
initially using avian adult splenic tissue recombined with differentiating pancreatic
epithelium. If adult splenocytes are unresponsive to such signalling cues, they may
need to be dedifferentiated before becoming responsive to differentiating signals and
this could be investigated in a similar approach to that used recently with human skin
fibroblasts (Tateishi, He et al. 2008).
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The findings in this thesis, together with the recent discovery that the mature human
spleen continues to express TIx-1 throughout adulthood, may be a useful target for
future bench-to-bedside translation strategies for this work (Dieguez-Acuna, Gygi et
al. 2007; Lonyai, Kodama et al. 2008). The Tlx-1 positive cell population in the
mature human spleen could be manipulated in vitro, using an understanding of the
molecular mechanisms behind splenic iMET outlined in this thesis, together with the
future research detailed above. Together, these studies will help inform the design of
novel future splenic iMET differentiation strategies to produce replacement islets for
the treatment of T1DM.
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Appendix I: Refereed publications
To date, the following refereed articles and abstracts have been published from the
work presented in this thesis:
• Robertson SA, Rowan-Hull AM, Johnson PRV. The spleen- a potential source
of new islets for transplantation? Journal Pediatric Surgery. 2008;43:274 -278.
• Initial characterisation of the molecular mechanisms behind splenic islet
mesenchyme-to-epithelial transition. Stuart Robertson, Autumn Rowan-Hull,
Paul Johnson. British Association of Paediatric Surgeons international meeting,
Salamanca, Spain, 2nd-5th July 2008 (abstract)




Presentations given at scientific meetings from work presented in this thesis:
Oral presentations:
• The lowly spleen - a potential source of new islets for transplantation?
Robertson SA, Rowan-Hull AM, Johnson PRV. Academic Paediatric Surgery
Group national meeting. Alder-Hey Hospital, Liverpool, UK. Nov 9th 2006
• The Spleen - a potential source of new islets for transplantation?
Robertson SA, Rowan-Hull AM, Johnson PRV. Prize-winning oral
presentation in the Peter Paul Rickham prize competition at the British
Association of Paediatric Surgeons international meeting, Edinburgh 17-20th
July 2007
• Islet mesenchyme-to-epithelial transition in the developing avian spleen
Oral presentation at the Academic Paediatric Surgeons Group national
meeting, Oxford, 17th January 2008
Poster presentations:
• Initial characterisation of the molecular mechanisms behind splenic islet
mesenchyme-to-epithelial transition. Stuart Robertson, Autumn Rowan-
Hull, Paul Johnson. British Association of Paediatric Surgeons international
meeting, Salamanca, Spain, 2nd-5th July 2008
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Appendix III: Supplemental solution information
Stock solutions
20x CMF-PBS (pH7.4) : 3M NaCl, 160mM Na2P04, 340mM NaH2P04 in molecular
biology grade water (ddH20); stored at room temperature (RT).
4% Phosphate-buffered paraformaldehyde (PFA) with EGTA: For 400mls:
dissolve 16g PFA in 360mls ddH20. Heat to dissolve with 5 drops 1M NaOH (takes
approximately 20 minutes). Filter into measuring cylinder. Add 40mls lOx PBS. Add
1600 pi 0.5M EGTA (=2mM).
RNA probe synthesis solutions
Luria-Bertani (LB) medium: lOg bacto-tryptone, 5g yeast extract, lOg NaCl in 1L
dH20 in conical flask; autoclaved for 20 minutes, then stored at RT.
LB Agar: lOg bacto-tryptone, 5g yeast extract, lOg NaCl, 15g agar in 1L dH20 with
pH adjustment to 7.5 through additional NaOH titration; stored at RT and liquefied
through microwave heating prior to use.
Plasmid DNA linearization reaction solution: added to eppendorf in following
order; 6 pi ddH20, 2 pi buffer, 10 pi DNA plasmid, 2 pi restriction enzyme. Enzymes
and buffers stored at -20°C. Buffer chosen in accordance with NEBuffer chart
(http://www. neb.com/nebecomm/tech_reference/restriction enzymes/buffer activity restrictio
n enzymes.asp). For example, NEBuffer chart recommended "Buffer 2" for Tlx-1
plasmid linearization, with addition of 0.2 pi Bovine Serum Albumin.
RNA transcription reaction solution: added to eppendorf in following order; 9 pi
ddH20, 2 pi lOx transcription buffer; 2 pi digoxygenin (DIG), 5 pi linearised DNA, 1
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pi RNase inhibitor, 1 pi of either T7 or T3 polymerase enzyme (depending on which
linearised plasmid was being transcribed).
In situ hybridisation solutions and formulae
Prehybridisation solution (50mls): 25mls 50% formamide (Fluka), 12.5mls 5x
SSC, lg 2x Boehringer blocking powder, 50pl 0.1% Triton-X, 2.5mls 0.5% CHAPS
(Sigma C3023) ,125pl 50pg / ml yeast RNA (sigma R6625), 500pl 5mM EDTA,
125pl 50pl/ml heparin; make up to 50 mis with ddH20. Heated to 70°C to dissolve
blocking powder.
2 x SSC + 0.1% CHAPS solution (50mls): 5mls 20x SSC, 0.5mls 10% CHAPS;
made up to 50 mis with ddH20.
0.2 x SSC + 0.1% CHAPS solution (50mls): 0.5mls 20x SSC, 0.5mls 10% CHAPS;
made up to 50mls with ddH20.
TBTx solution: 50mM Tris 7.4, 0.1% TritonX-100, 150mM NaCl; required volume
of ddH20 added.
Pre-absorption of antibody solution (lOmls): 1ml 10% sheep serum, 0.2g 2%
Bovine Serum Albumin, 9mls TBTx, 15mg Embryo powder, 5pi Anti-DIG Fab
fragment. Rocked at 4°C for 3 hours. Centrifuged for 10 minutes to remove embryo
powder debris at end.
Embryo powder (should match species eg: chick / quail): Embryos homogenised
ranging from day 4 to day 6 gestation (half chick, half quail) in minimal volume PBS
(RNase free). 4x volume of ice-cold acetone added. Mixed and incubated on ice for
30 minutes. Centrifuged at 10,000g for 10 minutes (in eppendorfs). Supernatant
removed and discarded. Pellet washed with ice-cold acetone and centrifuged at 8,000g
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for 10 minutes. Pellet spread out and ground into fine powder on filter paper. Allowed
to air dry. Stored in air-tight tube at 4°C.
Solution 1 (50mls): 25mls Formamide, 12.5mls 20x SSC, 50pl TritonX-100, 2.5mls
10% CHAPS; make up to 50 mis with ddH20.
AP buffer (50mls): 5mls 1M Tris pH 9.5, 1ml 5M NaCl, 500pl Tween2o, 1.25mls
2M MgCl; make up to 50 mis with ddH20.
Colour reaction solution (1ml): 1ml AP buffer, 3.5pl BCIP (100% DMF 50mg/ml),
4.5pl NBT (70% DMF 75mg/ml).
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Appendix IV: Hamburger Hamilton chick staging chart
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